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Osteoarthritis (OA), a chronic degenerative condition of the diarthrodial joints is 
most predominant amongst the middle aged and elderly population, where it is 
associated with progressive disability and deformity of the joints.  Whilst the exact 
mechanism of OA pathogenesis is currently unknown, chondrocyte death by 
apoptosis is seen as one of the main contributors to the disease process.  It is 
increasingly recognised that the overproduction of mediators such as Nitric Oxide 
(NO) in Osteoarthritic cartilage contributes to the disease pathology partly by 
inducing chondrocyte apoptosis.  Therefore, agents, which protect against NO-
induced mitochondrial injury, may have therapeutic potential in Osteoarthritis. 
The CRF related peptide, Urocortin I (UCNI), has been shown to protect the 
human chondrocyte cell line, C-20/A4, from SNAP/NO induced apoptotic death, 
but little is yet known about its mechanism of action.  Therefore the aim of this 
project is to investigate the potential mechanism through which UCNI exerts its 
observed protective effects.  The studies documented here, have demonstrated 
the endogenous expression of this cytoprotective peptide, UCNI, by C-20/A4 
chondrocytes and have shown that treatment of chondrocytes with SNAP (a NO 
donor) resulted in a significant increase in apoptosis which was abrogated by the 
addition of exogenous UCNI.  Therefore, an investigation into the potential 
mechanism for UCNI mediated protection against apoptosis in chondrocytes (i.e. 
chondroprotection) detected the mRNA expression of both CRFR1 and CRFR2 
receptors specifically the CRFR1α and CRFR2β  splice variants by the C-20/A4 
chondrocytes.  However the CRFR antagonist, α−helical CRH failed to induce 
apoptosis or abrogate the protective effects of UCNI against SNAP/NO induced 
apoptosis.  RT-PCR studies have also demonstrated C-20/A4 mRNA expression 
of the Kir6.1, Kir6.2, SUR1 and SUR2B subunits of the KATP channels suggesting 
that functional KATP channels are also present in these cells, which represent a 
further putative mechanism of action for UCNI.   
Quantitative PCR studies were performed to determine regulation of CRFR and 
Kir6.1 expression by UCNI.  These studies showed that treatment of chondrocytes 
with UCNI and SNAP alone and concurrently resulted in no significant change in 
mRNA expression of either CRF receptors or kir6.1 (the pore forming subunit of 
the mitochondrial KATP channel).  Treatment of chondrocytes with Diazoxide, a 
mitochondrial KATP channel opener, resulted in a reduction in SNAP induced 
apoptosis, mimicking that seen for UCNI, suggesting a similar protective role for 
these channels in chondrocytes, to that proposed in other cell types and 
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1 INTRODUCTION	  
1.1 Chondrocyte	  and	  the	  Articular	  cartilage	  environment	  
The diarthrodial (synovial) joints are freely movable joints within the skeletal 
system that permit repetitive movement that is smooth, pain-free and frictionless 
(Roach et al, 2007).  These properties are attributed to a thin, whitish layer of 
connective tissue derived from a hyaline cartilage temple, which covers the 
interosseous surface known as articular cartilage (figure 1.1A). 
Articular cartilage is a connective tissue, devoid of neuronal connections and has 
no blood or lymphatic vessels (Roach et al, 2007; Poole, 1997); it therefore 
essentially relies on solutes diffusing through the synovial fluid and to and from the 
underlying subchondral bone for its source of nutrients and oxygen supply, as well 
as waste exchange(Chubinskaya and Kuettner, 2003; Coimbra et al, 2004).   
It is composed of a single highly differentiated mesenchymal cell type, the 
chondrocyte, which is found, embedded in matrix cavities or spaces called lacunae 
and surrounded by an extensive extracellular matrix (ECM) (Poole, 1997; Lin et al, 
2006).  The nature of these cartilage specific cells and their surrounding ECM, 
divide the articular cartilage horizontally into four well defined layers or zones 
namely: tangential (or superficial), transitional (middle or intermediate), radial (or 
deep), and calcified (Poole, 1997; Chi et al, 2004) (figure 1.1B-C). 
 
In each layer, the chondrocytes differ in morphology, distribution, metabolic activity, 
expression of genes and responsiveness to stimuli (Chi et al, 2004; Chubinskaya 
and Kuettner, 2003).  For instance, the chondrocytes located in the tangential 
layer are flat, disc-shaped cells that are arranged with their long axis parallel to the 
articular cartilage surface.  In the transitional, radial and calcified layers, the 
chondrocytes are rounded.  The cells located in the transitional layer are randomly 
distributed throughout the ECM.  The Deep layer constitutes about 30% of the total 
cartilage thickness and contains chondrocytes, which are arranged in columns that 
are oriented perpendicular to the “tidemark” – a demarcation that segregates the 
upper three cartilage layers (the tangential, transitional and radial) from the 
calcified layer (figure 1.1.C and D) (Hayes et al, 2003; Buckwalter and Mankin, 
1998; Poole, 1997).   
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Figure 1.1: A schematic representation of the articular cartilage structure 
A: shows the location of the articular cartilage within the knee joint.  B: A Haemotxylin and Eosin 
(H&E) staining showing the histology of articular cartilage with its four defined zones.  C: A 
diagrammatic representation of the structure of the articular cartilage and the subchondral bone as 
depicted in the previous H&E satin (C).  D: The articular cartilage cell and collagen organisation 
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In addition to its horizontal subdivisions, the articular cartilage matrix can be 
divided circumferentially to the chondrocyte where three layers are described 
based on its structure and morphology; the pericellular, territorial (or capsular) and 
interterritorial matrices (Chubinskaya and Kuettner, 2003; Poole, 1997) (see figure 
1.2).  The chondrocyte is encircled by the pericellular matrix, which, in conjunction 
with the cell is referred to as a chondron.  These chondrons are the basic 
functional units of the cartilage and may contain a single, two or multiple 
chondrocytes, which are surrounded by collagen fibrils (the territorial matrix).  
Finally, the ECM environment is composed of many of these territories enclosed in 
the interterritorial matrix, which represents the largest portion of the cartilage 
matrix constituting about 90% of the cartilage volume (Poole, 1997; Chubinskaya 
and Kuettner, 2003; Chi et al, 2004).  The chondrons of the tangential and 
transitional layers contain a single chondrocyte, whilst the radial zone is composed 




Figure 1.2: The three layers of the ECM the Pericellular matrix, Territorial matrix and 
Interterritorial matrix. 
The diagram shows the chondrocyte (C) encapsulated in the pericellular matrix (PC) to form the 
chondron, surrounding the chondron is the territorial matrix (TM) with its extending collagen fibrils 
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The ECM is chiefly composed of water (75%), proteoglycans (mostly aggrecan) 
(20%) and type II collagen fibres (5%) (Ruiz-Romero et al, 2005; Chubinskaya and 
Kuettner, 2003).  Other ECM macromolecules include: type VI, IX, X, and XI 
collagen fibres, non-collagenous proteins (such as fibronectin, and cartilage 
intermediate layer protein (CLIP)) and lipids (Goldring, 2000; Aigner et al, 2006; 
Roughley, 2001).  The proteoglycans characterize the elastic properties of the 
tissue endowing the cartilage with its compressive strength, whilst the collagen 
fibres confer its tensile strength; collectively, they disperse mechanical pressure 
imposed on localised joint areas to avoid damage to the cartilage tissue (Roach et 
al, 2007; Aigner et al, 2006).   
Chondrocytes in the superficial layer synthesize large amounts of densely packed 
thin collagen fibres (hence the capacity of the cartilage to resist tension) but low 
amounts of proteoglycans.  The presence of abundant collagen in this zone gives 
the cartilage its characteristic opaque appearance (Chi et al, 2004; Hayes et al, 
2003; Poole, 1997).  In the transitional layer, chondrocytes increase their 
proteoglycan production (Poole, 1997; Hayes et al, 2003).  The deep zone 
contains the highest proteoglycan content in contrast to the calcified layer, which 
lacks proteoglycans.  The calcified layer separates the hyaline cartilage from the 
underlying subchondral bone and serves to anchor the articular cartilage to the 
subchondral bone.  The small population of hypertrophic chondrocytes in the 
calcified layer are embedded in uncalcified lacunae (Poole, 1997; Martel-Pelletier 
et al, 2008). 
The chondrocytes are sparsely distributed throughout the ECM of the cartilage and 
although they constitute only approximately 5-10% of its total volume, they ensure 
that the structural integrity and functionality of the tissue is regulated and 
maintained.  The roles of the chondrocyte include: synthesis, secretion, 
organization and degradation of the distinct repertoire of ECM macromolecules 
such as proteoglycans, collagen, non-collagenous and membrane protein 
synthesis, the production of cartilage metabolic enzymes and maintenance of 
cartilage tissue homeostasis (Goldring, 2000; Chubinskaya and Kuettner, 2003; 
Poole, 1997; Ruiz-Romero et al, 2005).  
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Generally, the chondrocytes sustain cartilage homeostasis by maintaining a state 
of equilibrium between the production of the ECM macromolecules (anabolic 
activities) and their subsequent degradation and loss (catabolic activities) via 
interaction with the pericellular matrix (Aigner et al, 2006; Chubinskaya and 
Kuettner, 2003; Lin et al, 2006; Magne et al, 2005).   
The anabolic program is initiated in response to matrix degradation and involves: 
secretion of cytokines that are antagonists of catabolism, synthesis of ECM 
components and protease inhibitors, and chondrocyte replication.  The cytokines 
involved in this process include: Bone Morphogenetic proteins (BMPs), Insulin-like 
Growth Factor (IGF) and Transforming Growth Factor beta  (TGFβ), (Aigner et al, 
2006; Chubinskaya and Kuettner, 2003; Ruiz-Romero et al, 2005; Goldring, 2000). 
Conversely, the catabolic phenotype may be induced by stimuli such as 
proinflammatory cytokines and involves: suppression of ECM synthesis, promotion 
of the production of proteases, oxidants and other catabolic mediators, inhibition of 
cell proliferation and the induction of chondrocyte apoptosis.  Such cytokines 
include: interleukin-1β (IL-1β), tumour necrosis factor alpha (TNFα), and 
interleukin-17 (IL-17), which are responsible for maintaining the catabolic 
phenotype of the cartilage (Abramson and Yazici, 2006; Ruiz-Romero et al, 2005; 
Lotz et al, 1995).  A diagrammatic representation of this balance in cartilage 
metabolism is shown in figure 1.3. 
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Figure 1.3: A diagrammatic representation of the cytokines involved in balancing the 
anabolic and catabolic activities in articular cartilage 
IL-1 =Interleukin-1, IL-17 =Interleukin-17, LIF= Leukaemia Inhibitory Factor, OSM= Oncostatin M, 
sTNF-R= soluble Tumour Necrosis Factor Receptor, GDF-5= Growth Differentiation Factor, IL-1ra 
= Interleukin-1 receptor antagonist, TGFβ=Transforming Growth Factor β, FGF=Fibroblast Growth 
Factors, PGE2= Prostaglandin E2.  The anabolic cytokines promote matrix synthesis, whilst the 
catabolic cytokines promote matrix degradation.  The inhibitory cytokines inhibit the catabolic 
cytokines, which cause matrix degradation for e.g. IL-4 and IL-10 promote chondroprotection in 
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Consequently, in normal, healthy tissue the chondrocytes maintain the 
composition and structural integrity of articular cartilage to provide a substance 
which functions synergistically as a biomechanical shock absorber which 
dissipates compressive and shearing forces evenly over the joint surface to reduce 
stress on the joint, a lubricant reducing friction and wearing of the cartilage 
surfaces and a load bearing surface that essential for smooth and free joint 
movements (Chubinskaya and Kuettner, 2003; Poole, 1997). 
Numerous studies have attested that the ECM environment is a rich source of 
information in which cell-matrix interactions are vital in controlling biological 
processes such as: chondrocyte growth, migration, differentiation and survival 
(Loeser et al, 2000; Lin et al, 2006; Lukashev and Werb, 1998).  In particular, the 
interaction between the chondrocyte and its’ pericellular matrix have been shown 
to be of great importance in regulating the biochemical, biophysical and 
biomechanical transduction mechanisms of the chondrocyte response to 
mechanical stimuli.  Essentially, normal loading of the joints coupled with 
enzymatic activity degrades ECM components, which are compensated for by an 
increased synthesis of matrix components to maintain the homeostatic balance of 
the matrix (Lin et al, 2006; Aigner et al, 2006). 
Whilst articular cartilage is a resilient substance, a number of mechanical and 
biological events can disturb the normal homeostatic processes within the tissue 
resulting in an imbalance in the anabolic and catabolic events in favour of 
catabolism, as the cell-ECM interaction is misregulated and metabolic responses 
are altered.  Consequently, the increased catabolic processes result in matrix 
degradation and ultimately, tissue damage (Lin et al, 2006; Aigner et al, 2006; 
Lukashev and Werb, 1998).  This degeneration of the cartilage tissue is referred to 
as Osteoarthritis (OA) (Aigner et al, 2006). 
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Osteoarthritis (OA) is a chronic degenerative condition characterised by cartilage 
degradation leading to joint dysfunction.  The disease is prevalent in older 
individuals worldwide (affecting >50% of the population over 60 yrs) and is 
frequently associated with significant pain, deformity and disability, especially of 
the hips and knees (Haq et al, 2003; Felson et al, 2000; Poole et al, 2002).  
There is currently no preventative treatment or cure available for OA.  In the early 
stages, treatment is currently limited to analgesics (such as paracetamol and non-
steroidal anti-inflammatory drugs, NSAID’s) and intra-articular injections of 
hyaluronic acid and corticosteroids, which provide symptomatic relief.  In the latter 
stages surgical intervention by endoprosthetic surgery is the only treatment and 
thus this disease and its’ treatment carries huge socio-economic burden 
(Abramson and Yazici, 2006; Roach et al, 2007).  The current treatment options 
available for OA treatment are shown in figure 1.4.   
The clinical features of swelling, stiffness and loss of joint function are a result of 
the metabolic and biochemical changes which occur in the articular cartilage of the 
affected joints in the course of the disease process (Poole et al, 2002; Birchfield, 
2001). 
Whilst the exact pathology of OA is not fully understood, it seems likely that 
disease progression is multi–factorial and may occur as a consequence of a 
complex system of interacting factors including: abnormal biomechanical forces, 
environmental and biochemical factors (Goldring, 2000; Haq et al, 2003) and 
genetic predisposition (Haq et al, 2003; Fernandez-Moreno et al, 2008).  These 
factors continue to result in an alteration in the normal functioning of the 
chondrocytes with the resulting abnormalities leading to the clinical features 
observed, of which joint pain is the cardinal feature (figure1.5) (Goldring, 2000; 
Martel-Pelletier et al, 2008; Haq et al, 2003). 
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Figure 1.4: A representation of the current treatment strategies available for the treatment of 
OA patients 
As the severity of the disease process increases so does the treatment.  Supervision of treatment 
begins at simple non-surgical interventions however, before this stage treatment is largely 
unsupervised by a medical practitioner.  Adapted from (Dieppe and Lohmander, 2005). 
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Figure 1.5: A schematic presentation of the interaction between environmental and 
endogenous risk factors for joint damage, OA development, joint pain and their 
consequences.  Adapted from (Dieppe and Lohmander, 2005).	  
 
There is evidence to suggest that during the early stages of OA the chondrocytes 
up-regulate their anabolic events producing chondrons and synthesising ECM 
molecules such as proteoglycans and collagen, in an attempt to repair the 
cartilage and regain tissue homeostasis following the increased production of the 
catabolic cytokines and degrading enzymes.  Increased synthesis and deposition 
of the CLIP protein into the interterritorial matrix has also been observed.  
However, with time, the catabolic activities increase and the chondrocyte lose their 
ability to sustain the anabolic activities necessary for maintaining matrix repair and 
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Ultimately, the imbalance between the anabolic and catabolic activities in the 
articular cartilage in favour of catabolism results in the degradation of collagen 
fibres and proteoglycans from the matrix.  This final pathway culminates in 
articular cartilage degradation characterised by reduced ECM water content and 
pericellular matrix volume and loss of cartilage tensile strength (Aigner et al, 2006; 
Goldring, 2000; Chubinskaya and Kuettner, 2003; Lorenzo et al, 1998). 
Some of the key factors proposed are the overproduction of chemokines and 
proinflammatory cytokines such as TNFα and IL-1β, stimulated by the increased 
catabolic program, which in turn promotes the increased synthesis of proteinases 
such as: matrix metalloproteinases (MMPs), aggrecanases, plasmogen activators 
(PA) and cathepsins.  Activity of these proteases, along with Nitric Oxide (NO) and 
other catabolic mediators, results in the degradation of cartilage and promotion of 
chondrocyte death by apoptosis (Abramson and Yazici, 2006; Goldring, 2000; 
Ruiz-Romero et al, 2005).  Thus, understanding the balance between the anabolic 
and catabolic phenotype of the chondrocytes are crucial for developing treatment 
strategies for OA as potential therapeutic interventions can target at, for instance, 
delaying or inhibiting the catabolic process which culminates in chondrocyte 
apoptosis and cartilage destruction (Aigner et al, 2006).  
Chondrocyte death results in a reduced number of active cells in the articular 
cartilage and therefore a reduction in the capacity of the cartilage cells to repair 
existing cartilage and/or generate new cartilage components.  The end results of 
such events are the progressive destruction of the articular cartilage matrix and 
formation of cysts.  Osteophyte formation and subsequent remodelling and 
sclerosis of the subchondral bone are also pathological manifestations, (Sandell 
and Aigner, 2001; Buckwalter and Martin, 2006) that are considered to occur as a 
consequence of a compensation mechanism for lack of cartilage (Haq et al, 2003).   
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1.3 Cell	  Death	  
1.3.1 Apoptosis	  
Apoptosis is the term used to describe the innate, genetically controlled 
morphological and biochemical processes by which a cell responds to various 
stimuli to systematically inactivate, dissemble and degrade its’ structural and 
functional constituents in order to complete its own demise (Kim and Blanco, 2007; 
Majno and Joris, 1995). 
The word “apoptosis” is of Greek origin and was first used as an analogy to 
explain the “falling off” of the leaves from trees or the petals from flowers by Kerr 
et al, in 1972; emphasising that though this process of cellular destruction 
occurred in a very complicated but orderly fashion, it is an essential part of a living 
organisms life cycle (Gewies, 2003; McHugh and Turina, 2006).   
In contrast to other forms of cell death, apoptosis occurs through cellular, chemical 
and molecular processes, which are controlled and regulated by cellular signalling 
systems (Kim and Blanco, 2007; Kuhn et al, 2004; Gewies, 2003).  Thus, apoptotic 
cell death is a non-accidental programmed process in which the cells are actively 
involved and for this reason apoptosis is sometimes referred to as “cell suicide” 
(Majno and Joris, 1995). 
Apoptosis can be considered as a universally critical event as it occurs in both 
physiological and pathological scenarios (Kim and Blanco, 2007; McHugh and 
Turina, 2006).  With regards to its physiological benefits, apoptosis is essential for 
the normal development of multicellular organisms and for regulating and 
maintaining cell populations of adult tissues (Gewies, 2003; Kim and Blanco, 2007; 
Kuhn et al, 2004).  Apoptosis is a fundamental part of many biological events 
including development and morphogenesis, proliferation and homeostasis, 
regulation and function of the immune system, and the elimination of harmful and 
damaged cells that would otherwise pose a threat to the organism (Kim and 
Blanco, 2007; Schultz and Harrington, 2003; Gewies, 2003).  Apoptosis and 
Programmed Cell Death (PCD), are used interchangeably to refer to apoptosis; 
reflecting that the death of cells follows a sequential program of cellular, 
biochemical and molecular events (Kim and Blanco, 2007; Majno and Joris, 1995). 
Chapter	  1:	  Introduction	  	  
	   13	  
 
In relation to apoptosis as a pathological event, dysfunction or dysregulation of 
apoptosis has been implicated in many diseases.  For example, inadequate levels 
of apoptosis have resulted in pathological conditions such as cancer, and 
autoimmune diseases (e.g. systemic lupus erythematosus (SLE) and rheumatoid 
arthritis); whilst excessive apoptosis promotes the initiation and development of 
neurodegenerative diseases (e.g. alzheimer’s disease, spinal muscular atrophy, 
parkinson’s disease), ischaemic disease (e.g. congestive heart failure and stroke), 
severe immunodeficiency syndrome and acquired immune deficiency syndrome  
(AIDS) (Kim and Blanco, 2007; Gewies, 2003). 
Typically, the apoptotic process is divided into three stages and is characterised 
by a range of distinctive morphological changes.  Thus, apoptosis can be divided 
into a commitment or initiation phase, an execution phase and a clearance phase 
with the structural changes associated with apoptotic cell death occurring in the 
execution phase (Kruidering and Evan, 2000; Kim and Blanco, 2007).  In addition, 
apoptosis can be distinguished by the following: cell shrinkage, chromatin 
condensation and margination to the perimeter of the nuclear membrane, 
cytoplasmic condensation, externalisation of phosphatidylserine phospholipids 
from the inner to the outer membrane envelope, plasma membrane blebbing or 
budding and finally the formation of apoptotic bodies containing cell remnants 
(coalescent chromatin in well defined masses, organelles and cytosol) encircled by 
a cytoplasmic membrane.  Clearance of the apoptotic bodies from the tissues is 
achieved by phagocytosis involving dendritic cells and macrophages.  This 
process ensures that no inflammatory mediators are released to initiate an 
inflammatory response within the tissue, which is vital to maintain normal 
functioning of the tissues and immune system and the health of organisms during 
development (Kim and Blanco, 2007; Gewies, 2003; Kruidering and Evan, 2000; 
McHugh and Turina, 2006).   
Apoptosis can occur through two distinct pathways extrinsic and intrinsic.  These 
two pathways differ in their initiation and signalling mechanisms but eventually 
activate the same mechanisms signals resulting in the characteristic features 
associated with apoptotic cell death (Kim and Blanco, 2007; Gewies, 2003). 
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The intrinsic or mitochondrial pathway of apoptosis may be initiated by stimuli such 
as DNA damage, cellular stress (e.g. from exposure to ultraviolet irradiation, X-
irradiation, viral infection or chemotherapeutic agents), growth factor deprivation 
and oxidative stress following free radical generation (Schultz and Harrington, 
2003; Gewies, 2003; McHugh and Turina, 2006).   
Following cellular damage, the pro-apoptotic members of the B cell leukaemia/ 
lymphoma 2 (Bcl-2) family, Bax and Bak, normally localised in the cytosol are 
relocated to the mitochondria where they integrate into the outer mitochondrial 
membrane and contribute to the formation of pores referred to as Permeability 
Transition pore (PT pore).  Consequently, cytochrome C (Cyt C) and other pro-
apoptotic factors (e.g. Smac/DIABLO and apoptosis-inducing factor (AIF)), located 
within the mitochondrial intermembrane space are released into the cytoplasm via 
the PT pore.  In the cytosol, cytochrome C interacts with the adaptor protein, Apaf-
1 (apoptotic protease activating factor-1) and subsequently recruits procaspase-9.  
These three proteins, along with deoxyadenosine triphosphate (dATP) form the 
Apoptosome complex, which activates procaspase-9 to its active form caspase-9, 
the initiator caspase of the intrinsic pathway.  The released Smac/DIABLO inhibits 
IAP (Inhibitor of Apoptosis Protein), an anti-apoptotic protein that functions to block 
caspase activity and activation, permitting the activated caspase-9 to initiate the 
rest of the caspase cascade in which the effector caspases-3, -6 and -7 are 
activated (see figure 1.6) ultimately resulting in apoptosis (Gewies, 2003; Schultz 
and Harrington, 2003; Kim and Blanco, 2007). 
The release of Cyt C and other pro-apoptotic mediators from the mitochondria is 
normally prevented by the anti-apoptotic proteins Bcl-2 and Bcl-XL, which are 
localised to the outer membrane of the mitochondria (see figure 1.6.).  The Bcl-2 
and Bcl-XL anti-apoptotic proteins, like Bax and Bak are members of the Bcl-2 
family and function as inhibitors apoptosis by via blocking the formation of the PT 
pore.  Consequently, an excess of Bcl-2 and Bcl-XL proteins at the mitochondria 
renders the cell less sensitive to apoptosis (McHugh and Turnia, 2006, Schultz 
and Harrington, 2003). 
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Conversely, the extrinsic pathway is defined by cell surface transmembrane 
receptors, which collectively are referred to as Death Receptors (DRs) and they 
transmit apoptotic signals following activation resulting from the binding of specific 
ligands.   
Currently, six types of DRs are recognised:  
• Fas (also known as CD95 or APO-1) 
• TNF receptor 1 (TNFR1) also known as p55 or CD120a 
• TNF-related apoptosis-inducing ligand receptor-1 (TRAIL-R1) also known 
as Death receptor 4 (DR4)  
• TNF-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) also known 
as Death receptor 5 (DR5) 
• Death receptor 3 (DR3) also known as APO-3or TNF-receptor-related 
apoptosis mediated protein (TRAMP) 
• Death receptor 6 (DR6).   
These DRs are members of the Tumour Necrosis Factor Receptor (TNF-R) 
superfamily and so their ligands are chiefly Tumour Necrosis Factor (TNF), TRAIL 
and Fas Ligand (Fas-L/CD95L) (Kruidering and Evan, 2000; Schulze-Osthoff et al, 
1998; Schultz and Harrington, 2003). 
Activation of the extrinsic apoptotic pathway is achieved by ligation of Death 
Receptors with their cognate ligands (e.g. Fas-L binding to the Fas receptor). 
Interaction of the death receptor with its’ ligand results in the recruitment of 
adaptor proteins by the cytoplasmic death domains (DD) of the death receptor.  
These recruited adaptor proteins (e.g. Fas associated Death Domain (FADD) in 
the case of the Fas-FasL interaction) also contain a DD and a protein-protein 
interaction domain referred to “Death Effector Domain (DED”).  Once recruited, the 
DD of the adaptor protein interacts with the DD of the death receptor resulting in 
recruitment of procaspase -8 and binding of the DED of the adaptor protein with 
the DED of procaspase 8.  The resulting receptor signalling complex consisting of 
the DD of the death receptor, adaptor protein and procaspase-8 is referred to as 
the “Death Inducing Signalling Complex”- DISC.   
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Following association of the DISC, procaspase -8 is activated to caspase 8, the 
initiator caspase of the extrinsic pathway.  Capsase 8, in turn causes subsequent 
cleavage and activation of the effector procaspases -3, -6 and -7 to their active 
forms (caspase -3, -6 and -7), which execute apoptosis via cleavage of their 
substrates (e.g. structural and regulatory intracellular proteins) resulting in the 
biochemical and morphological features characteristic of apoptotic cell death 
(Gewies, 2003; Kuhn et al, 2004; Kim and Blanco, 2007; Schultz and Harrington, 
2003). 
In addition, apoptosis via the extrinsic pathway involving the Fas or TNFR1 death 
receptors can be mediated through a mitochondrial dependent apoptotic pathway. 
This cross talk between the intrinsic and extrinsic pathways of apoptosis is 
facilitated by the pro-apoptotic Bcl-2 family member, Bid.  Initiation of this 
mitochondrial apoptotic pathway is said to be activated in response to low 
concentrations of procaspase -8 at the DISC.  Subsequently, caspase -8 cleaves 
and activates Bid to its’ truncated form termed “tBid” (truncated Bid).  tBid is then 
translocated to the mitochondria where in concert with Bax and Bak results in the 
release of Cyt C, Smac/DIABLO and downstream activation of the effector 
caspases of the intrinsic apoptotic pathway.  The Bid protein can also be inhibited 
by Bcl-2 and Bcl-XL (see figure 1.6) (Schultz and Harrington, 2003; Gewies, 2003; 
Scaffidi et al, 1998; Antonsson and Martinou, 2000). 
More recently, a third apoptotic pathway involving the Endoplasmic Reticulum (ER) 
has also been implicated.  Though its’ exact downstream signalling pathways are 
not fully known, Caspase 12, localised to the Endoplasmic Reticulum is believed to 
be the initiator caspase for this intrinsic apoptotic pathway.  Activation of caspase 
12 may result from Endoplasmic Reticulum stress such as calcium homeostasis 
dysregulation and excess misfolded protein accumulation in the ER (Kim and 
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Figure 1.6: An overview of the extrinsic (death receptor mediated) and intrinsic 
(mitochondria and endoplasmic reticulum) pathways of apoptosis. 
DD= death domains, DED= death effector domain, Cyt C= cytochrome C, IAP= inhibitor of 
apoptosis protein, Smac/DIABLO= Second mitochondria-derived activator of caspases, TNF-
tumour necrosis factor, ER= endoplasmic reticulum, Apaf-1= apoptotic protease activating factor -1. 
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1.3.2 The	  Bcl-­‐2	  Family	  of	  Proteins	  
	  
The Bcl-2 family members are essential signalling components, which play a 
central role in regulating apoptosis.  These Bcl-2 proteins have been localised to 
the cytosol, outer nuclear envelop, endoplasmic reticulum and mitochondrial 
membranes and are regulated by cytokines and other death-survival signals at 
different stages of the apoptotic pathway (Antonsson and Martinou, 2000; Adams 
and Cory, 2001; Schultz and Harrington, 2003).  Members of the Bcl-2 family 
share a very low homology in their amino acid sequence; however these proteins 
share homology in specific regions designated the Bcl-2 Homology (BH) domains 
of which there are four: BH1, BH2, BH3, and BH4.   
The Bcl-2 proteins mediate protein interactions through these domains to exert 
their effects (Schultz and Harrington, 2003; Antonsson and Martinou, 2000). 
Consequently, the Bcl-2 family can be divided into two groups, those that are “anti-
apoptotic” inhibiting apoptosis and “pro-apoptotic “promoting apoptosis and the 
survival or death of a cell is partly determined by the balance between the pro-
apoptotic and anti-apoptotic Bcl-2 proteins.  Additionally, mammalian cells contain 
at least 15 Bcl-2 proteins and they can be characterised based on their function 
and BH domain organisation as shown in table 1.1 (Schultz and Harrington, 2003; 
Gross et al, 1999). 
 
 
Table 1.1: The mammalian Bcl-2 family of anti-apoptotic and pro-apoptotic members.  The 
Bcl-2 family members can be grouped according to their function to inhibit or promote apoptosis as 
well as their BH homology.  The Bcl-2 subfamily proteins all bear resemblance to the first identified 
protein, Bcl-2 and have 4 conserved BH domains.  The BH3 subfamily shares homology only in 
their BH3 domain.  The Bax sub family constitutes the Bcl-2 family proteins with 3 domains BH1, 
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Necrosis is generally regarded as “accidental cell death or non-programmed” as it 
occurs unintentionally without the activation of a sequential program of intracellular 
signalling cascades (such as activation of caspases) (Kim and Blanco, 2007; Kuhn 
et al, 2004).  Though apoptosis occurs in both physiological and pathological 
conditions, necrosis is predominantly seen in disease processes (Ziegler and 
Groscurth, 2004)and cells normally undergo necrosis following depletion of ATP 
(approximately  20-25% of baseline) (McHugh and Turina, 2006).  Necrotic cell 
death can be induced by viruses (e.g. HIV), bacteria (e.g. Mycobacterium avium), 
defence components of the immune system (e.g. complement), heat stress, 
bacterial toxins, physical trauma and metabolic poisons as well as diseases such 
as Alzheimer’s and Epilepsy (Proskuryakov et al, 2003).   
Many of the agents which trigger the apoptotic pathway have also been shown to 
initiate necrotic cell death, these include: cytokines released from affected tissues, 
which ligate TNF, Fas and TRAIL death receptors, increased production of 
reactive oxygen species and DNA damage (Proskuryakov et al, 2003).  However, 
apoptosis can be distinguished from apoptosis by a variety of characteristic 
features (table 1.2). 
Secondary necrosis is the mechanism by which the remnants of the apoptotic 
bodies that are not phagocytosed, undergo degradation similar to necrosis in 
which the cell swells and ruptures releasing their contents leading to inflammation 
and localised tissue damage (McHugh and Turina, 2006; Ziegler and Groscurth, 
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Table 1.2: The key distinguishing features between Apoptosis and Necrosis mechanisms of 
cell death. 
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1.3.4 Osteoarthritis	  (OA)	  and	  Apoptosis	  
 
For many years, there has been much debate concerning which of the underlying 
mechanisms of cell death is responsible for hypocelluarity in OA.  Over the last 
decade however, several studies have documented apoptotic cell death as the 
main cause of cell depletion in OA (Blanco et al, 1998; Hashimoto et al, 1998; Kim 
et al, 2000; Lotz et al, 1999; Kim and Blanco, 2007).  Heraud et al, in 2000, 
investigated the occurrence of apoptosis in OA cartilage compared to normal 
cartilage.  Following quantification of chondrocytes isolated from OA and normal 
cartilage or chondrocytes present in situ in frozen cartilage sections, Heraud et al 
reported that approximately 18-21% of chondrocytes in osteoarthritic cartilage 
displayed apoptotic characteristics such as externalisation of phosphatidylserine 
phospholipids, compared with only 2-5% in healthy cartilage.  This suggests that 
apoptosis increases in OA as compared to in normal cartilage (Heraud et al, 2000).  
There is also evidence to suggest that chondrocyte apoptosis increases with age, 
a factor that has also seen to contribute OA pathogenesis as a result of prolonged 
mechanical wear and tear causing alterations in the cartilage matrix components 
(Lorenz and Richter, 2006; Aigner et al, 2007). 
Matrix degradation as a consequence of chondrocyte apoptosis has also been 
implicated as a major mechanism in the pathogenesis of OA (Kim and Blanco, 
2007).  The Fas death receptor and its ligand FasL has been implicated in 
promoting chondrocyte apoptosis in OA (Cheng et al, 2004; Goggs et al, 2003) 
and this pathway of apoptosis may possibly promote chondrocyte death in early 
OA as its expression was predominant in the superficial and transitional cartilage 
layer, where cartilage degeneration begins (Lotz et al, 1999; Hashimoto et al, 
1997).  
One of the main inducers of cell death in OA is the inflammatory mediator nitric 
oxide (NO) (Martel-Pelletier et al, 2008; Haq et al, 2003).  NO can be generated in 
response to stimuli such as the pro-inflammatory cytokines IL-1β and TNFα and 
human chondrocytes were observed to produce large amounts of NO following 
stimulation with these cytokines (Goggs et al, 2003; Lotz et al, 1999; Abramson, 
2008).  
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An increase in NO was observed in OA cartilage and it has been demonstrated to 
inhibit matrix synthesis, promote matrix catabolism and chondrocyte apoptosis 
(Martel-Pelletier et al, 2008; Heraud et al, 2000).  Research by Intekhab-Alam in 
2006, has also reported that apoptosis and not necrosis is the predominant cause 
of cell death in a human chondrocyte cell line, C-20/A4, following stimulation of 
cells with various pro-apoptotic stimuli: IL-1β, TNFα and a NO donor-SNAP 
(Intekhab-Alam, 2006).  The duration of apoptosis in cells occurs rapidly, within 
minutes to hours, although the duration of chondrocyte apoptosis in cartilage is 
unknown (Heraud et al, 2000). 
It is now widely accepted that chondrocyte death contributes to the pathogenesis 
of OA via cartilage degeneration.  These cells maintain the integrity and 
functionality of the cartilage matrix and thus their loss ultimately results in matrix 
degeneration.  If chondrocyte apoptosis is a major contributing factor to the 
development of OA, then reduction and/or prevention of this cell death would 
represent a possible target for therapeutic intervention in OA.   
Intekhab-Alam, (2006) has also demonstrated that C-20/A4 chondrocytes express 
a Corticotropin releasing factor (CRF) family peptide, Urocortin I (UCNI), that is 
upregulated when the cells are subjected to stressors such as nitric oxide donors 
(SNAP) and pro-inflammatory cytokines previously mentioned.  Selective depletion 
of endogenous Urocortin I by the addition of anti-UCNI antibody to C-20/A4 
chondrocyte culture medium, or the addition of the competitive CRF antagonist, 
alpha helical corticotrophin releasing hormone (9-41) (αhCRH(9-41)), resulted in an 
increased level of chondrocyte death even in the absence of pro-apoptotic stimuli.  
Conversely, addition of exogenous Urocortin I reduces the level of both NO and 
TNFα induced apoptosis indicating a possible ‘chondroprotective’ role for Urocortin 
I (Intekhab-Alam, 2006; Petsa, 2007).  Since recent studies have suggested that 
UCNI exerts a greater degree of chondroprotection than other members of the 
Urocortin family, Urocortin II (UCNII) and Urocortin III (UCNIII) (Petsa, 2007), this 
research will focus on UCNI only. 
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1.4 Urocortin	  I	  (UCNI)	  and	  the	  CRF	  family	  of	  peptides	  
	  
To date, the Corticotropin Releasing Factor (CRF) family of peptides consists of 
six members, namely: Corticotropin Releasing Factor (CRF), Urotensin I (Uro I), 
Sauvagine (Svg), and the Urocortin family comprised of Urocortin I (UCNI), 
Urocortin II (UCNII) or Stresscopin related peptide (SRP), and Urocortin III (UCNIII) 
or Stresscopin (SCP) (table 1.3) (Vale et al, 1997; Lederis et al, 1982; Okawara et 
al, 1988; Montecucchi and Henschen, 1981; Stenzel-Poore et al, 1992). These 
peptides are classified as the CRF family due to their structural and 
pharmacological homology to CRF, the first documented member (a hypothalamic 
peptide) isolated and characterised in 1981 by Vale et al (Vale et al, 1981; Kuizon 
et al, 2009).   
 
 
Table 1.3:The mammalian and non-mammalian members of the CRF related peptide family.  The 
non-mammalian CRF like peptides are: Sauvagine and Urotensin I, whilst the mammalian CRF like 
peptides are: CRF, UCNI, UCNII (SRP) and UCNIII (SCP).  Adapted from: (Dautzenberg and 
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1.4.1 Urocortin	  I	  (UCNI)	  
	  
Urocortin I (UCNI), the second member of this family to be identified, is a 40 amino 
acid peptide that was initially discovered by Vaughan et al, in 1995 following 
screening of a rat midbrain cDNA library with fish Urotensin I specific probe to 
isolate the cDNA which codes for the UCNI precursor (Cepoi et al, 1999; Vaughan 
et al, 1995; Fekete and Zorrilla, 2007).  Shortly after, in 1996, the human gene for 
UCNI was isolated from a genomic library constructed from human placenta by 
Donaldson et al, (Takahashi et al, 1998; Donaldson et al, 1996).  The human and 
rat UCNI shares a 95% amino acid sequence homology (Takahashi et al, 1998; 
Okosi et al, 1998) and since its discovery in rat and human the gene has also 
been identified in several other species including mouse, sheep, rhesus monkey 
and frog where the sequence remains highly conserved (Fekete and Zorrilla, 
2007). 
The human gene that encodes UCNI was localised to chromosome 2 (2p23-p21) 
and consists of two exons and one intron, with the mRNA sequence encoding the 
122-124 amino acids precursor peptide residing in exon 2, analogous to the CRF 
peptide (Fekete and Zorrilla, 2007; Gysling et al, 2004; Huang et al, 2004).  In 
addition to the mRNA coding region, also of importance on the UCNI gene are the 
multiple transcription factor binding sites in the UCNI promoter, some of which 
have been shown to regulate UCNI transcription.  Such sites include: the TATA-
like box, cyclic adenosine monophosphate (cAMP) responsive element (CRE) and 
GATA and CCAAT enhancer-binding protein (C/EBP) transcription factor-binding 
site (Fekete and Zorrilla, 2007; Zhao et al, 1998).  For instance, augumented 
levels of cAMP are observed to stimulate UCNI production, which is facilitated via 
CRE binding sites on the promoter region of the UCNI gene increasing UCNI 
mRNA expression (Hauger et al, 2006; Slominski et al, 2001). 
The UCNI peptide was originally known simply as Urocortin (UCN) and the name 
was derived from the fact that it displays a 63% amino acid sequence homology to 
fish Urotensin I (thus “Uro”) and a 45% homology to mammalian Corticotropin 
Releasing Factor (thus “cort”)(Koob and Heinrichs, 1999).   
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However, searching of the public human genome databases in 2001 identified two 
new members of the CRF family, the human homologues designated Stresscopin 
related peptide (SRP) and Stresscopin (SCP) and in mice are these are Urocortin 
II (UCN II) or Urocortin III (UCN III), both of which are composed of 38 amino acids 
(table 1.3) (Lewis et al, 2001; Reyes et al, 2001; Hsu and Hsueh, 2001; Suda et al, 
2004; Chanalaris et al, 2003).  UCN was consequently re-designated as UCNI by 
the International Union of Pharmacology so that it can be distinguished from UCNII 
and UCNIII (Suda et al, 2004; Hauger et al, 2003).   
UCNII and UCNIII were noted to share sequence identity to CRF and UCNI, but 
were designated “Urocortins”, as they predominantly bind to the Corticotropin 
Releasing Factor Receptor type 2 (CRFR2)(Fekete and Zorrilla, 2007).  The 
human UCNII peptide shares a 31% homology to human UCNI whilst a 26% 
identity exists between human UCNIII and human UCNI.  Moreover, a 37-40% 
sequence homology exists between UCNII and UCNIII (Takahashi et al, 2004; 
Imperatore et al, 2006; Hsu and Hsueh, 2001). 
The UCNI mRNA is ubiquitously expressed in several tissues, notably, the skin 
and the reproductive, immune, digestive, cardiovascular and central nervous 
systems where it has a number of diverse physiological roles (Oki and Sasano, 
2004; Slominski et al, 2000; Fekete and Zorrilla, 2007).  In the cardiovascular 
system, UCNI production was observed to have a variety of physiological effects 
on cardiac function where a dose dependent administration resulted in an increase 
in heart rate, cardiac output and coronary blood plus a decrease in blood pressure 
in conscious rats (Parkes et al, 2001; Latchman, 2002). UCNI also exerted 
cardioprotective effects against cell death induced by hypoxia and UCNI mRNA 
levels were elevated following thermal injury in cultured cardiac cells (Okosi et al, 
1998; Parkes et al, 2001).  Furthermore, UCNI demonstrated protection against 
cell death following ischaemia/reperfusion injury in both cultured cardiac myocytes 
and the intact rat heart (Brar et al, 1999; Brar et al, 2000; Latchman, 2002).  
However, in the heart UCNI also appears to induce, and be involved in, cardiac 
hypertrophy (Latchman, 2002; Nishikimi et al, 2000; Chanalaris et al, 2005). 
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UCNI expression was also detected in the gastrointestinal tract and tissues of the 
immune system where expression was increased in diseases such as Gastritis 
and Rheumatoid arthritis; suggesting that UCNI may be involved in regulating 
immune responses(Oki and Sasano, 2004).  Such roles of UCNI in the heart and 
gastrointestinal tract are postulated to be mediated via the GATA transcription 
factors which bind to the GATA regions of the UCNI promoter mediating UCNI 
expression therein (Zhao et al, 1998). 
In relation to the Nervous system, UCNI expression was identified in many regions 
of the brain including the Edinger-Westphal nucleus, lateral superior olive, 
supraoptic nucleus, hypothalamus, and pituitary (Skelton et al, 2000; Zhao et al, 
1998; Oki and Sasano, 2004).  UCNI was reported to suppress appetite and 
regulate fluid homeostasis in rats (Oki and Sasano, 2004; Parkes et al, 2001; 
Spina et al, 1996).  Studies by Zhao et al, 1998 demonstrated that the UCNI 
promoter region contains binding sites for the C/EBP transcription factor and it is 
suggested that the effects of UCNI in appetite suppression may potentially be 
mediated through activation of C/EBP transcription factors, which increase UCNI 
expression (Zhao et al, 1998).  Other possible roles for UCNI in the CNS include 
the regulation of anxiety and activity (Oki and Sasano, 2004; Spina et al, 1996; 
Latchman, 2002).  
UCNI expression in the reproductive system, notably the placenta implies a role 
for UCNI in labour, maintaining placenta function and regulation of sex hormone 
synthesis in the ovaries (Hillhouse and Grammatopoulos, 2002; Oki and Sasano, 
2004).  There is also increasing evidence suggesting that UCNI may play a role in 
regulating carcinogenesis.  Several studies have identified UCNI expression in 
various cancers, for instance in pituitary adenoma, prostatic and endometrial 
carcinoma where it exerts numerous anti-cancer effects that are primarily 
mediated via activation of their receptors (Wang and Li 2007).  UCNI inhibited the 
growth of tumour cells in a human neuroblastoma cell line (Schoeffter et al, 1999) 
as well as the proliferation of melanoma cells both in vitro and in vivo, these 
effects of UCNI were mediated through CRFR1 receptors (Carlson et al, 2001; 
Wang and Li, 2007).   
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Although UCNI has been identified in several different tissues, its’ cytoprotective 
properties against cell death have thus far only been reported in cardiac myocytes, 
nerves cell and chondrocytes (Petsa, 2007; Brar et al, 1999; Abuirmeileh et al, 
2007; Intekhab-Alam, 2006).   
UCNI and other peptides of the CRF family are believed to exert their physiological 
actions primarily via two different types of stimulatory G-protein (Gs) coupled, 
seven transmembrane domain receptors: Corticotropin Releasing Factor Receptor 
1 (CRFR1) and Corticotropin Releasing Factor Receptor 2 (CRFR2) 
(Grammatopoulos and Chrousos, 2002; Koob and Heinrichs, 1999).   
 
1.5 The	  Corticotropin	  Releasing	  Factor	  Receptors	  (CRFR)	  
	  
The Corticotropin Releasing Factor Receptors: CRFR1 and CRFR2, are members 
of the class II/ B1 subtype group of the G protein-coupled receptor (GPCR) 
superfamily, other members of which include the glucagon, calcitonin and 
parathyroid hormone (PTH) receptors (Bale and Vale, 2004; Grammatopoulos and 
Chrousos, 2002; Hauger et al, 2006; Perrin et al, 2006).  The CRFR1 and CRFR2 
receptors share a 70% sequence homology at the amino acid level (Bale and Vale, 
2004; Fekete and Zorrilla, 2007; Grammatopoulos and Chrousos, 2002; Catalano 
et al, 2003).  The genes which encode the CRFR1 and CRFR2 receptors are 
however located on different chromosomes (17 and 7 respectively) with each 
having several splice variants which are differentially expressed in the CNS and 
peripheral tissues (Grammatopoulos and Chrousos, 2002; Bale and Vale, 2004; 
Kuizon et al, 2009). 
The existence of CRFR1 and CRFR2 splice variants can be attributed to the fact 
that class II GPCR superfamily genes exhibit extron-intron organisation whereas 
other GPCR classes are devoid of introns, especially in their protein coding 
regions.  This unique characteristic of the class II GPCR genes allows extensive 
alternative splicing resulting in a variety of receptor subtypes with alternative 
domains from one gene, which can exhibit differential ligand binding, specificity 
and G-protein coupling (Catalano et al, 2003; Gentles and Karlin, 1999; Hillhouse 
and Grammatopoulos, 2006). 
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In this respect, the CRFR1 and CRFR2 receptors have been shown to vary in their 
pharmacological ligand binding profile (Takahashi, 2001; Bale and Vale, 2004; 
Fekete and Zorrilla, 2007; Grammatopoulos and Chrousos, 2002).  For instance, 
the CRFR1 receptor binds CRF, UCNI, Urotensin I and Sauvagine whilst CRFR2 
predominantly binds UCNI, UCNII, UCNIII, Sauvagine and Urotensin 
I(Grammatopoulos and Chrousos, 2002).  As UCNI binds to CRFR2 with a higher 
affinity than other CRF related peptides, and UCNII and UCNIII only bind to 
CRFR2, it has therefore been proposed that the Urocortins are the likely 
endogenous agonists for CRFR2 receptors (Koob and Heinrichs, 1999; Fekete 
and Zorrilla, 2007; Catalano et al, 2003).  The differential tissue distribution and 
pharmacology of the CRFR1 and CRFR2 receptors implies that they perform 
diverse physiological roles (Fekete and Zorrilla, 2007; Catalano et al, 2003). 
CRFR receptors are predominantly, but not exclusively, coupled to a GS protein 
signalling pathway activating adenylate cyclase and increasing cAMP levels, 
culminating in activation of Protein Kinase A (PKA) dependent mechanisms such 
as, the activation of L-type calcium channels and P42/44 Mitogen Activated 
Protein Kinase (MAPK) pathways (Grammatopoulos and Chrousos, 2002; Perrin 
et al, 2006; Fekete and Zorrilla, 2007).  These receptors have also been shown to 
couple with Gq proteins resulting in Phospholipase C (PLC) activation and 
subsequent hydrolysis of phosphatidylinositol 4,5, bisphosphate (PIP2) to generate 
diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3).  The produced inositol-
1,4,5-triphosphate (IP3) increases intracellular calcium levels via release of 
calcium from the endoplasmic reticulum, whilst DAG activates Protein Kinase C 
(PKC) dependent MAPK mediated responses(Grammatopoulos and Chrousos, 
2002; Perrin et al, 2006; Chen et al, 2005; Fekete and Zorrilla, 2007). 
A third CRF receptor subtype was identified by Arai et al (2001) in the brain of 
catfish species, termed catfish CRFR3 (cfCRFR3); but this receptor appears to be 
unique to the catfish and shares a high degree of homology with the catfish 
CRFR1 receptor – approximately 85% amino acid homology (Dautzenberg and 
Hauger, 2002; Fekete and Zorrilla, 2007; Arai et al, 2001).  Figure 1.7 illustrates 
the principal CRFR signalling pathways. 
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Figure 1.7: A schematic representation of the principal CRF receptor signalling pathways 
following interaction of CRF family peptides ligands (e.g. UCNI, CRF) to the CRF receptor. 
PKA=Protein Kinase A, PKC= Protein Kinase C, AC= adenylate cyclase, PLC= phospholipase C, 
GC= guanylate cyclase, GTP= guanosine triphosphate, GDP= guanosine diphosphate, MAPK= 
mitogen activated protein kinase, GPCR= G-protein coupled receptor, CRF= corticotropin releasing 
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factor ! (TNF!) and interleukin (IL-1)
! concentrations, possibly via homologous
downregulation by increased production of Ucn.
Impaired CRH-R2 function during systemic
inflammation might diminish the adaptive
cardiovascular response that ccurs in this state.
Signaling properties of CRH receptors
G-protein coupling and second messengers
In most, but not all, tissues, stimulation of either
CRH-R1 or CRH-R2 by CRH and CRH-related
peptides triggers activation of adenylyl cyclase and
increases cAMP levels [38,39]. In studies using
receptor overexpression in transfection systems, it
has been confirmed that CRH receptors are primarily
coupled to the Gs–adenylyl cyclase signaling pathway.
However, in certain tissues, CRH is unable to activate
this pathway, although it can activate alternative
signaling cascades [40,41]. For example, in some
tissues, activated CRH receptors stimulate
phosphoinositol hydrolysis.
Accumulating evidence [38,40,41] suggests that
even in the presence of identical CRH receptors, there
is tissue-specific G-protein coupling and activation of
alternative signaling cascades. This apparent tissue-
specific effect of CRH and CRH-like peptides is one of
the most intriguing areas of CRH receptor research.
However, at present, the factors determining
CRH-receptor–G-protein coupling are unknown.
Several studies investigating the CRH receptor
transfected in in vitro expression systems have
dem nstrated multiple G-protein activation, with an
order of potency Gs"Go>Gq/11>Gi1/2>Gz. By contrast, 
in native cells, the pattern of G-protein activation by
endogenous CRH receptors appears to be unique for
each tissue [21,41–43] and is controlled by as yet
undefined mechanisms. Such differential G-protein
activation would predict modulation of distinct
signaling cascades, suggesting that CRH and
CRH-like peptides can generate different responses
in target tissues (Fig. 3). Indeed, CRH receptors
modulate a plethora of intracellular protein kinases
(PKs), such as protein kinase A (PKA), protein
kinase C (PKC), protein kinase B (PKB)/Akt, and
the p42/p44 and p38 mitogen-activated protein
kinases (MAPKs), as well as other important
signaling molecules, such as Ca2+, nitric oxide
synthase (NOS), guanylyl cyclase, Fas and Fas
ligand [44–48].
The exact mechanism regulating the ability of
CRH receptors to switch between signaling cascades
has yet to be elucidated. However, it is tempting to
p42/p44 MAPK
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characteristics of the CRH
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1.5.1 Corticotropin	  Releasing	  Factor	  Receptor	  1-­‐(CRFR1)	  
In 1993, the first Corticotropin Releasing Factor Receptor denoted, CRFR1, was 
discovered by Chen et al (Chen et al, 1993).  The human CRFR1 gene has been 
localised to the long arm of chromosome 17 (17q12-q22) and consists of 14 exons 
and 13 introns (figure1.8), which span approximately 20kb (Zmijewski and 
Slominski, 2010; Hauger et al, 2006; Hillhouse and Grammatopoulos, 2006). 
 
Figure 1.8: A diagrammatic representation of the CRFR1 receptor exon organisation 
containing all 14 exons. 
The 7 transmembrane domains of the CRFR1 receptor are indicated (I, II, III, IV,V, VI, VII). NH2= N 
terminus and COOH= C-terminus of the receptor.  Adapted from: (Slominski et al, 2001). 
 
To date, eight human, three rat, four mouse and nine hamster CRFR1 mRNA 
transcripts have been identified, resulting from alternatively splicing of the CRFR1 
gene (Fekete and Zorrilla, 2007).  Of the eight CRFR1 human isoforms (CRFR1α, 
CRFR1β, CRFR1c, CRFR1d, CRFR1e, CRFR1f, CRFR1g and CRFR1h) shown in 
figure 1.9, only one, CRFR1α, is physiologically functional inducing signal 
transduction in its’ resident human tissues (Fekete and Zorrilla, 2007; Hauger et al, 
2006; Grammatopoulos and Chrousos, 2002).  Consequently, the CRFR1β, and 
CRFR1c-h splice variants, all of which appear to lack ligand binding and/or 
signalling properties, are currently regarded as non-functional and thus not 
classified by the International Union of Pharmacology Committee on Receptor 
Nomenclature and Drug Classification (NC-IUPHAR) as receptor splice variants 
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Figure 1.9: The eight human CRFR1 receptor variants. 
The diagram shows the schematic representation of the exon organisation and the structural 
differences of the potential protein structures of the human CRFR1 receptor variants following 
alternative splicing of the CRFR1 gene.  Adapted from:(Hillhouse and Grammatopoulos, 2006). 
  
example, progesterone alters the transcription of theCRH-R1
gene in such a way that the predominant transcript encodes
for CRH-R1!, thus enhancing tissue responsiveness to CRH,
an effect that is blocked by estrogen. Furthermore, some
variants of CRH-R1, such as the CRH-R1d, fully retain the
ability to bind agonist with high affinity although they are
deficient in signaling. These receptor variants might act as
“decoy receptors” capable of competing with the full-length
receptors for agonist binding and absorbing CRH and CRH-
like peptide bioactivity and therefore, change the efficiency
of hormonal stimulation. Interestingly, in other receptor sys-
tems, such as the CT-R system, similar splice variants con-
taining deletions in the 7 TMD, when coexpressed with the
fully active CT-R variant, act as dominant negative regula-
tors by forming heterooligomers within the cell. This process
inhibits normal receptor expression at the cell surface, lead-
ing to a reduction in the signaling response (98). Similar
interactions have been observed with the truncated forms of
CRH-R1, e and h, which are capable of binding CRH and
influencing tissue responsiveness to CRH. For example, in
coexpression experiments, CRH-R1e attenuated and CRH-
R1h amplified CRH-R1! signaling (99). These observations
provide tantalizing, although far from conclusive, evidence
suggesting that the regulation of transcription and splicing
of the CRH-R1 receptor gene might play a major role in
determining tissue responsiveness to CRH and UCNs. It
should be remembered, however, that there is no evidence
that these transcripts are translated into functional protein.
This might not be a prerequisite, however, because the dom-
inant expression of the aberrant transcripts at the expense of
the wild-type receptor at transcription would have the end
result of reducing levels of functional receptor.
With these caveats in mind, Pisarchik and Slominski (92)
have proposed a division of all potential CRH-R1 variants
into four groups according to their potential impact on ag-
onist signaling (Fig. 3):
a. Group 1. The first group includes variants with no frame-
shift (", c, d, g, and n) but with a variable number of TMDs
and intra- or extracellular C terminus (yet to be conclusively
demonstrated for some variants) that differ in their agonist
binding and G protein-coupling characteristics.
b. Group 2. The second group consists of mRNA variants
missing exons 1, 2, 3, and 4, which are important for agonist
binding and therefore appear functionally inert (R1e). Al-
though it is difficult to attribute any direct role to individual
members of this group, theymight have important functional
significance by modulating CRH-R1! activity.
c. Group 3.Members of the third group have conserved the
original reading frame of CRH-R1 up to the fifth exon, thus
retaining an intact CRH-binding domain but having no
TMDs. Two members of this group have been identified:
CRH-R1j and CRH-R1h. CRH-R1j has exon 5 deleted,
FIG. 1. Schematic representation of exon structure of human CRH-R1 variants and structural differences of potential protein products.
Hillhouse and Grammatopoulos • Regulation of Biological Activity of CRH-R Endocrine Reviews, May 2006, 27(3):260–286 265
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Despite the fact that the variants other than CRFR1α are likely to be non-
functional variants (as illustrated in figure 1.9), the predicted protein sequences for 
these results in receptor subtypes with varying agonist binding characteristics and 
signalling capabilities (Hillhouse and Grammatopoulos, 2006; Grammatopoulos 
and Chrousos, 2002).  However, there is arising evidence to suggest that some of 
these variants may be generated in response to a variety of factors such as UV 
irradiation and cAMP (Pisarchik and Slominski, 2001; Zmijewski and Slominski, 
2010). 
The CRFR1 receptor is extensively expressed in the Central Nervous system 
(CNS) including the hippocampus, anterior pituitary and cerebral cortex and 
olfactory bulbs (Grammatopoulos and Chrousos, 2002) and has also been 
identified at a variety of sites in the periphery including the ovaries, testes, lungs, 
skin, placenta, spleen, arterial smooth muscle and foetal membranes and immune 
cells (Slominski et al, 2001; Dautzenberg and Hauger, 2002; Chen et al, 2005). 
Whilst the mRNA expression of the isoforms has been widely demonstrated in the 
human periphery e.g. CRFR1α, CRFR1β, CRFR1c andCRFR1d in the pregnant 
myometrium (Slominski et al, 2001; Grammatopoulos et al, 1999) and CRFR1g in 
the skin, adrenal glands and pituitary (Pisarchik and Slominski, 2001), a lack of 
isoform specific antibodies for the non-functional variants means that their protein 
expression has yet to be confirmed.   
The sole functional CRFR1 variant, CRFR1α, contains 13 exons (following 
deletion of exon 6) producing a 415 amino acid protein.  Exon 6, encodes for a 29 
amino acid insert, which would normally be located in the first intracellular domain 
of the CRFR1 transcript (see figure 1.8,) but with the exception of CRFR1β, this 
exon is absent in all of the CRFR1 isoforms.  Consequently, as the CRFR1α 
receptor remains functional it appears that exon 6 is not essential for physiological 
function (Slominski et al, 2001; Hillhouse and Grammatopoulos, 2006; 
Grammatopoulos and Chrousos, 2002) interacting predominantly with the Gs 
protein pathway that stimulates adenylate cyclase activation (Zmijewski and 
Slominski, 2010). 
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Conversely, the CRFR1β receptor, contains all 14 exons (see figure 1.9), and 
generates a 444 amino acid protein isoform and as a result it is also regarded as 
pro-CRFR1.  The insertion of exon 6 renders this receptor non-functional resulting 
in an inability to bind ligands and impaired cAMP production (Hillhouse and 
Grammatopoulos, 2006; Zmijewski and Slominski, 2010).   
The CRFR1c variant is produced from splicing out of exons 3 and 6 (see figure 
1.9).  Therefore this receptor is composed of 12 exons with 375 amino acids.  
Though the CRFR1c contains all the exons that encode for the 7 transmembrane 
domains of the CRF receptor, the stability of the extracellular domain is 
compromised by deletion of exon 3; consequently, this receptor subtype is 
incapable of ligand binding.  In addition, experiments have also demonstrated that 
CRFR1c fails to stimulate signal transduction mechanisms (Grammatopoulos et al, 
1999; Zmijewski and Slominski, 2010). 
In addition to the deletion of exon 6, the further five CRFR1 isoforms (CRFR1d-h) 
have been predicted to contain alterations within their seventh transmembrane 
domain resulting in modification to the structure of the predicted protein products 
(see figure 1.9).  The CRFR1d receptor lacks exon 13, which encodes for the 
majority of the last transmembrane domain (see figure 1.8) resulting in this domain 
becoming shorter with a consequent distortion of the intracellular C-terminus and a 
failure to perform G-protein coupling and signal transduction (Grammatopoulos et 
al, 1999; Hillhouse and Grammatopoulos, 2006; Zmijewski and Slominski, 2010).  
CRFR1e is predicted to exist in two isoforms (see figure 1.9).  The first, designated 
CRFR1e1, is a truncated receptor devoid of transmembrane domains and is 
composed of 40 amino acids encoded by exons 1 and 2 and a further 154 amino 
acids derived from a coding sequence that has no homology to the other CRFR1 
isoforms or known proteins.  The second, designated CRFR1e2, is composed of 
240 amino acids with a sequence which begins in the third transmembrane 
domain and therefore has no ligand binding domain (Zmijewski and Slominski, 
2010; Grammatopoulos and Chrousos, 2002; Pisarchik and Slominski, 2001). 
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The CRFR1f and CRFR1h isoforms have no intracellular C-terminus domain due 
to a deletion of exons 12-14 and exons 5-14 respectively (see figure 1.9), which 
make their signal transduction capabilities questionable, although it is likely that 
both will retain the ability to bind ligands.   
Finally, although the CRFR1g transcript conserves the original CRFR1 reading 
frame and produces a C-terminus with the correct amino acid sequence, the 
deletion of exon 11 and partial deletion of exons 10 and 12 (see figure 1.9), would 
result in abnormal/ incomplete transmembrane domains and impaired signalling. It 
is likely however, that this variant would still retain ligand-binding properties 
(Zmijewski and Slominski, 2010; Grammatopoulos and Chrousos, 2002; Pisarchik 
and Slominski, 2001; Hillhouse and Grammatopoulos, 2006). 
Though CRFR1 is expressed both in the brain and periphery it appears to be 
predominantly involved in regulating the physiological functions of the nervous 
system (Dautzenberg and Hauger, 2002) whilst the CRFR2 receptor may be more 
important in mediating actions in the periphery.  Indeed, the CRFR2 receptor was 
first discovered following reports, which demonstrated that the effects of CRF may 
not be mediated via CRFR1 in the periphery (Dautzenberg and Hauger, 2002; 
Parkes and May, 2000). 
 
1.5.2 Corticotropin	  Releasing	  Factor	  Receptor	  2-­‐(CRFR2)	  
The human CRFR2, which spans about 50kb, was mapped to the short arm of 
chromosome 7(p21-p15) (Hillhouse and Grammatopoulos, 2006; Grammatopoulos 
et al, 1999).  The CRFR2 mRNA transcript is slightly larger than CRFR1 consisting 
of 15 exons (figure 1.10) and as a result of alternative splicing at the N terminus 
generates three human CRFR2 variants: CRFR2α, CRFR2β and CRFR2γ all of 
which are functional; whilst two isoforms have been identified in rat; CRFR2α, 
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The CRFR2α variant contains exons 4-15 encoding for a 411 amino acid protein, 
whilst the CRFR2β containing exons 1,2 and 5-15 resulting a 438 amino acid 
protein.  The CRFR2γ variant, the smallest of the three, contains exons 3 and 5-15 
is a 397 amino acid protein (Slominski et al, 2001; Grammatopoulos and Chrousos, 
2002).  The CRFR2α variant is widely expressed in the human CNS (e.g. septum, 
thalamus, hippocampus and hypothalamus) and is also the main variant 
expressed in human peripheral tissues (e.g. lungs, skeletal muscle, and colonic 
mucosa of the gastrointestinal tract (GI) (Chen et al, 2005; Kuizon et al, 2009; 
Muramatsu et al, 2000).  
CRFR2β is also found in the human CNS, particularly the septum, hippocampus 
and amygdala regions of the brain and it too is found in the periphery including the 
left atrium of the heart, and skeletal muscle, with lower levels in the GI tract 
(Slominski et al, 2001; Kostich et al, 1998; Kuizon et al, 2009; Muramatsu et al, 
2000).  The CRFR2β is the predominant isoform, which is expressed in the rat 
periphery, whilst the CRFR2α is the splice variant predominantly expressed in the 
rat brain (Chen et al, 2005).  To date however, CRFR2γ  expression has only been 
clearly identified in the human brain (predominantly in the Hippocampus and 
septum regions), although very low amounts of mRNA have been detected in the 
lungs (Slominski et al, 2001; Kostich et al, 1998) 
 
Figure 1.10: A diagrammatic representation of the CRFR2 receptor exon organisation 
containing all 15 exons. 
The 7 transmembrane domains of the CRFR2 receptor are indicated (I, II, III, IV, V, VI, VII). NH2= N 
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1.6 Other	  UCNI	  mediated	  cytoprotection	  mechanisms	  
Evidence from the cardiovascular system would suggest that UCNI may affect 
cellular protection by acting, at least partly, through ion channels.  Specifically, it 
has been suggested that UCNI may mediate its effects through two distinct types 
of ion channels, L-type calcium channels and inwardly rectifying potassium 
channels, both of which are involved in regulating intracellular cation 
concentrations and therefore resting membrane potential (Lawrence et al, 2002; 
Tao and Li, 2005a; Mobasheri et al, 2007). 
In the case of the L-type calcium channel, it has been suggested that UCNI 
binding to this cell membrane channel may protect cells by reducing/preventing 
intracellular calcium overload (Tao and Li, 2005a), whilst UCNI upregulation of the 
Kir6.1 subunit of inwardly rectifying potassium channels has been shown to be 
involved in the prevention of cardiac myocyte death in response to ischaemia/re-
perfusion injury (Lawrence et al, 2002).   
Lawrence et al, (2002) demonstrated that UCNI induces expression of the Kir6.1 
subunit in cardiac myocytes, potentially resulting in activation of the mitochondrial 
ATP sensitive potassium (mitoKATP) channels, the inhibition of which completely 
abrogated the cardioprotective effects of UCNI.  Further work in 2004, indicated 
that activation of mitoKATP channels prevents/reduces mitochondrial damage 
potentially helping to protect the cardiac myocytes from apoptosis (Lawrence et al, 
2004; Lawrence et al, 2002) via a CRFR dependent pathway. 
The effects of UCNI on these ion channels, particularly the KATP channels, may 
therefore represent a possible chondroprotective mechanism, especially given the 
observations of Intekhab-Alam (2006) and Petsa (2007) who noted that the UCNI 
peptide appears to be more effective against SNAP induced cell death, a potential 
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1.6.1 The	  ATP	  sensitive	  potassium	  channels	  (KATP	  channels)	  
The ATP sensitive potassium (KATP) channel, a member of the Inwardly Rectifying 
Potassium channel family (KIR), is a non-voltage dependent, potassium (K+) 
selective channel which is regulated by intracellular ATP and ADP concentrations; 
the activation of which occurs when intracellular levels of ATP decrease (Shi et al, 
2005; Mobasheri et al, 2007; Burke et al, 2008). 
The KATP channels are present in a variety of tissues these include: pancreatic islet 
cells, skeletal muscle, heart, brain and vascular smooth muscle (Seino and Miki, 
2003).  Two types of KATP channels have been identified so far: those situated at 
the plasma membrane/sarcolemma (sarcKATP or cellKATP) and those on the inner 
mitochondrial membrane (mitoKATP).  Though the structure of the mitoKATP remains 
uncertain, evidence from the sarcKATP channel suggests that KATP channels are 
hetero-octameric complex constituting of two protein subunits: a ~40kDa pore 
forming subunit, Kir6.x and a ~160kDa regulatory subunit, the sulfonylurea 
receptor (SURx).  The principal Kir6.x isoforms are: Kir6.1 and Kir6.2, and the 
SURx subunits existing in two main forms: SUR1, SUR2 (Burke et al, 2008; Shi et 
al, 2005; Moreau et al, 2005). 
The KIR6.x subunits: Kir6.1 and Kir6.2, are members of the Inwardly Rectifying K+ 
(KIR) channel family.  They are classified as inwardly rectifier K+ channels as the 
Kir6.x pore forming subunits are selective for K+ which favour the flow of K+ ions 
into the cell rather than out, favouring the maintenance of the resting membrane 
potential of the cell (Mobasheri et al, 2007; Bryan et al, 2007).  The human Kir6.1 
gene is designated KCNJ8, for potassium inwardly-rectifying channel, subfamily J, 
member 8.  It is approximately 9.7kb in length consisting of three exons and 
mapped to chromosome 12p11.23.  The resulting Kir6.1 subunit gene product 
composed of 424 amino acids, shares a 98% sequence homology at the amino 
acid level to the rat Kir6.1 (Inagaki et al, 1995; Aguilar-Bryan et al, 1998; Seino, 
1999).  The human Kir6.2 gene, KCNJ11, approximately 8.6kb is localised to 
chromosome 11p14.3 and produces a 390 amino acid protein.  The amino acid 
sequence homology between Kir6.1 and Kir6.2 is approximately 71%.  Each Kir6.x 
subunit is composed of a K+ selective pore loop flanked by two transmembrane  
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domains referred to as M1 and M2, the N and C-termini of which are located within 
the cell as cytoplasmic domains as illustrated in figure 1.11 (Aguilar-Bryan et al, 
1998; Seino, 1999). 
The SURx subunit is a member of the adenosine triphosphate (ATP) Binding 
Cassette (ABC) transporter family of proteins who utilise the energy released from 
ATP hydrolysis to adenosine diphosphate (ADP) to facilitate the transport of 
substances (e.g. ions and lipids) across membranes or regulate intracellular 
processes.  Consistent with such role, the SURx subunit functions as regulatory 
subunits modulating the activity of the KATP channels in response to intracellular 
ATP concentrations (Burke et al, 2008; Seino and Miki, 2003). 
The two predominant SURx isoforms: SUR1 and SUR2 are encoded for by 
separate genes, ABCC8 and ABCC9 respectively; interestingly both genes are 
located in close proximity to the Kir6.x genes.  The gene, which encodes for the 
SUR1, ABCC8 cloned in 1995, contains 39 exons and is localised to chromosome 
11(11p15.1) where the Kir6.2 gene is mapped approximately 4.5kb downstream 
(Bryan et al, 2007; Seino, 1999; Aguilar-Bryan et al, 1998).  Furthermore, the 
SUR2 gene, ABCC9, composed of 38 exons is on chromosome 12(12p11.12) and 
is separated from the Kir6.1 gene by approximately 26.2kb.  Consequently, it has 
been suggested that these genes were previously encoded for by a single gene 
(Seino, 1999; Aguilar-Bryan et al, 1998).  The SUR2 subunits exist in two major 
isoforms: SUR2A and SUR2B; though alternative splicing of each has been 
identified and characterised (Shi et al, 2005). 
Structurally, the SURx subunits are composed of three transmembrane domains 
(TMD) namely: TMDO (the N-terminus transmembrane domain), TMD1 and TMD2 
(the C-terminus transmembrane domain) with each domain consisting of five, six 
and six transmembrane spanning segments, respectively.  The TMD0 domain is 
linked to TMD1 by a cytoplasmic loop referred to as L0 and interaction of L0 with 
the N-terminus of Kir6.x is shown to modulate opening of the KATP channel.  The 
TMD1 and TMD2 domains also contain intracellular cytoplasmic loops named: 
Nucleotide binding domain 1 and 2 (NBD1 and NBD2) see figure 1.11; these 
NBD’s contain binding sites for ATP.  Upon hydrolysis of ATP to ADP, NBD2 binds 
ADP resulting in opening of the KATP channel.   
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Thus these domains are involved in regulating KATP channel opening (Burke et al, 
2008).  In addition to regulation by ATP concentrations, KATP channels can also be 
regulated by G-protein coupled receptors (Seino, 1999, Seino and Mikki, 2003).   
Typically, KATP channel consists of four KIR6.x (Kir6.1 or Kir6.2) and four SURx 
subunits each (SUR1 or SUR2) as shown in Figure1.11C (Shi et al, 2005; Moreau 




Figure 1.11: A schematic representation of the molecular structure of a KATP channel. 
A: typically a KATP channel consists of SUR and Kir6.x subunits as shown in the membrane 
structure.  The SUR has three transmembrane domains denoted: TMD0, TMD1, TMD2 each 
consisting of five, six and six membrane spanning regions respectively, whilst the Kir6.x subunits 
consist of two transmembrane domains M1 and M2. The SUR subunit cytoplasmic loops L0 and L1 
are also indicated along with the cytoplasmic nucleotide binding domains NBD1 and NBD2 with the 
Walker A, B and Linker L consensus sequences incorporated.  The ATP inhibitory binding site on 
the cytoplasmic domain of the Kir6.x subunit is also shown. B: the SUR and Kir6.x subunits exists 
in a 4:4 stoichiometry as shown here in the hetero-octamer complex to form a KATP channel which 
can function, C: assembly of the KATP channel hetero-octamer complex as represented in B.  
Adapted from: (Moreau et al, 2005; Seino and Miki, 2003). 
 
SUR1. The sulfonylurea receptor has been proposed to have three transmembrane domains,
TMD0, TMD1, and TMD2, each of which consists of five, five, and six membrane spanning
regions, respectively, based on studies with membrane-impermeable biotinylating reagent, biotin
maleimide (Conti et al., 2001) as well as the multi-sequence alignments of SUR1 and the
multidrug resistance-associated protein (MRP) family (Tusnady et al., 1997) (Fig. 2). The
sulfonylurea receptor has two nucleotide binding folds (NBF-1 and NBF-2) on the cytoplasmic
side (Conti et al., 2001). NBF-1 and NBF-2 are located in the loop between TMD1 and TMD2
and in the C-terminus, respectively. The SUR1 protein shows a high-affinity binding capacity to
the sulfonylurea glibenclamide, indicating that SUR1 confers sulfonylurea binding (Aguilar-
Bryan et al., 1995). The affinity of SUR2A for sulfonylureas is much lower than that of SUR1
(Inagaki et al., 1996). SUR2A cannot be photolabeled with [125I]-iodoglibenclamide under the
same conditions that photolabels SUR1 (Inagaki et al., 1996). SUR1 is expressed at high levels in
pancreatic islets and various clonal !-cells and moderate to low levels in brain. While SUR2A is
expressed predominantly in heart and skeletal muscle (Inagaki et al., 1996), SUR2B is
ubiquitously expressed, assessed by reverse transcription-polymerase chain reaction (RT-PCR)
assay (Isomoto et al., 1996). Other splice variants of SUR2 also have been identified (Chutkow
et al., 1996, 1999), and also of SUR1 (Sakura et al., 1999). Such variation might account in
part for the more subtle differences in the properties of the various KATP channels in native
tissues.
Fig. 2. Molecular structure of KATP channel. (a) Assembly of KATP channel. The KATP channel is a hetero-octamer
comprising two subunits: the pore-forming subunit Kir6.x (Kir6.1 or Kir6.2) and the regulatory subunit sulfonylurea
receptor SUR (SUR1 or SUR2). (b) Membrane topology of SUR and Kir6.x: The sulfonylurea receptor has been
proposed to have three transmembrane domains, TMD0, TMD1, and TMD2, each of which consists of five, five, and
six membrane spanning regions. Kir6.x has two transmembrane domains.
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Studies performed so far in other cell types indicate that the protective effects of 
UCNI may be mediated through any, or indeed all, of the mechanisms discussed.  
However, it is not yet known what upstream or downstream events of these 
pathways exist and whether the alternative mechanisms observed in cardiac 
myocytes play a significant role in UCNI mediated chondroprotection.  Thus, the 
research proposed here is aimed at determining which, if any, of these 
mechanisms exists in chondrocytes and thus if they offer a potential route for 
therapeutic intervention in OA.  With this in mind, the following aims detailed in 
section 1.7 have been developed. 
 
1.7 Aims	  
The aims of this present study are as follows:  
• To evaluate the paracrine/autocrine chondroprotective role of UCNI against 
NO induced apoptosis with the emphasis on mechanisms of action and 
effector systems.  
• To investigate the mRNA expression of CRF receptors (CRFR) by C-20/A4 
chondrocytes as potential cell surface targets for UCNI mediated 
chondroprotection 
•  To determine C-20/A4 chondrocyte mRNA expression of KATP channel 
subunits (Kir6.x and SURx) and their potential to constitute functional KATP 
channels that may act as downstream effectors involved in CRFR mediated 
chondroprotection.  
• To explore UCNI regulation of detected CRF receptor variant(s) and KATP 
channels subunits, by quantitative PCR studies, to determine the relative 
mRNA expression of CRF receptors and KATP channel subunits in NO and 
UCNI treated C-20/A4 chondrocytes  
• To examine the significance of KATP channels in the chondroprotective 
effects of UCNI by pharmacological manipulation with KATP channel 












Chapter	  2:	  Materials	  and	  Methods	  	  	  
	   42	  
	  
2 Materials	  and	  Methods	  
2.1 Materials:	  
2.1.1 Cells	  and	  Culture	  reagents:	  
2.1.1.1 The	  C-­‐20/A4	  Chondrocyte	  cell	  line	  
Prior to the development of stable human chondrocyte cell lines, the study of 
chondrocyte physiology and the mechanisms underlying degenerative joint 
pathologies was restricted principally, due to the lack of a reproducible source of 
human articular chondrocytes.  Obtaining an adequate number of primary 
chondrocytes is difficult but moreover, human articular cartilage samples vary in 
condition and age resulting in data with high variability between different 
preparations.  Furthermore, following expansion in primary cultures, adult human 
articular chondrocytes quickly become quiescent losing their cartilage specific 
phenotype altering their morphology and gene expression patterns (Goldring et al, 
1994; Finger et al, 2003).  As a consequence, immortalised chondrocyte cell lines 
have been established in an attempt to circumvent these issues.   
Chondrocytes isolated from primary cultures of juvenile (human or animal) or 
embryonic origins (Goldring et al, 1986; Gerstenfeld et al, 1990; Adams et al, 1991) 
are considered to be more advantageous for immortalisation, as the chondrocyte 
phenotype is maintained for a longer period (Goldring et al, 1994). Previous efforts 
were made to develop immortalised cell lines using chondrocytes from rabbit 
(Thenet et al, 1992), rat (Horton et al, 1988) and human chondrosarcomas 
(Takigawa et al, 1989; Block et al, 1991) but these did not express the unique 
cartilage-specific components and thus were not perceived as ideal 
representatives for investigating differentiated chondrocyte physiology (Goldring et 
al, 1994).  
The C-20/A4 is an immortalised human chondrocyte cell line, which was 
established in 1993 with chondrocytes from a specimen of rib cartilage discarded 
from surgical repair of pectus exacavatum.  These normal chondrocytes isolated 
from the costal cartilage ofa5 year old male, were immortalised by transfection 
with vectors containing origin-defective Simian virus 40 large T antigen (SV40Tag)  
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on day 10 of primary culture. Following continuous passage from a single focus, 
the resulting immortalised cell line was designated: C-20/A4.  
Following its’ establishment, investigations on the C-20/A4 cells demonstrated that 
these cells displayed the polygonal cobblestone morphology (figure 2.1) and the 
differentiated phenotype typical of human chondrocytes such as the expression of 
various cartilage specific molecules: collagen type II, IX and XI.  They were also 
capable of maintaining this morphology over continuous propagation for >80 
passages when cultured in monolayer in 10% serum containing medium.  Such a 
continuous proliferative capacity would imply a continuous supply of cells for 
experiments without a high risk of dedifferentiated cells (Goldring et al, 1994).  As 
a result, the C-20/A4 chondrocytes constitute a representative model system to 
investigate chondrocyte function and their environment.  However, this and other 
generated immortalised cell lines cannot replace primary chondrocytes entirely, as 
cell lines do have the capacity for dedifferentiation and so it is always 
recommended that experimental findings from immortalised culture systems be 
validated with primary chondrocyte cultures (Finger et al, 2003). 
The C-20/A4 cell line was used for all investigations documented in this thesis and 
was a kind gift from Professor Mary B, Goldring, Hospital for Special Surgery, New 
York, USA. 
 
Figure 2.1: Light microscopy image (x 100 magnifications) of the C-20/A4 human 
chondrocyte cell line in culture 
The C-20/A4 cell line displays the cobblestone morphology typical of human chondrocytes in 
primary culture.  The chondrocytes were cultured in DMEM supplemented with 10% FCS.  
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2.1.1.2 Cell	  Culture	  materials	  for	  C-­‐20/A4	  chondrocytes:	  
 
The following cell culture reagents were supplied by Lonza, Wokingham, UK: 
Dulbecco’s Modified Eagle’s Medium (DMEM) with sodium pyruvate, 4.5 g/L 
glucose and without L-glutamine, penicillin-streptomycin mixture (10,000 units/ml 
potassium penicillin G/10,000 units/ml streptomycin sulphate), 1x Dulbecco’s 
phosphate buffered saline (DPBS) without calcium (Ca2+) and magnesium (Mg2+), 
10x trypsin-ethylenediaminetetraacetic acid (EDTA) [5 g/L trypsin, 2 g/L EDTA] 
solution and L-glutamine (200 mM) solution.  Heat inactivated foetal calf serum 
(FCS) (South American origin) was purchased from Biosera Ltd, Ringmer, UK and 
dimethyl sulfoxide (DMSO) was from Sigma Aldrich, Poole, UK.  Cell culture flasks 
25 and 75 cm2, 96 well tissue culture plates, Millipore Millex GP PES 0.2 µm 
sterile syringe filters, 50 ml and 15 ml centrifuge tubes, 10 ml and 25 ml 
disposable pipettes were all supplied by Fisher Scientific, Loughborough, UK; 
while the 6 well tissue culture plates and 2 ml CRYO.S cell freezing vials were 
purchased from Greiner Bio-one, Stonehouse, UK. 
 
2.1.2 In	  vitro	  stimulation	  of	  C-­‐20/A4	  cells	  and	  Cell	  death	  Studies	  
 
S-nitroso-N-acetyl-L-penicillamine (SNAP) was from Ascent Scientific, Bristol, UK. 
Human UCNI, α helical Corticotropin Releasing Hormone (CRH) (9-41) [αhCRH(9-41)], 
Diazoxide and TOX-7 In Vitro Toxicology Lactate Dehydrogenase (LDH) assay kit, 
were from Sigma-Aldrich, Poole, UK.  Southern Biotech Aposcreen™ Annexin V- 
Fluorescein isothiocyanate (FITC) conjugate (200 µg/ml stock solution, supplied in 
1X binding buffer), Aposcreen™10X Annexin V binding buffer, Propidium iodide 
(100 µg/ml stock solution, supplied in PBS/sodium azide-NaN3) were all purchased 
from Cambridge Bioscience Ltd, Cambridge, UK. 
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2.1.3 Reagents	  for	  molecular	  biology	  studies	  
2.1.3.1 RNA	   extraction,	   agarose	   gel	   electrophoresis	   (AGE)	   and	  
sequence	  analysis	  
 
RNeasy® Mini kit, RNeasy® Plus Mini Kit, and Qiaquick® Gel Extraction kit were 
obtained from Qiagen Ltd, Crawley, UK.  Ethidium bromide (10 mg/ml) and 50X 
tris base acetic acid EDTA (TAE) buffer (composed of Tris Base/Trizma Base, 
glacial acetic acid and disodium EDTA) were purchased from Sigma-Aldrich, 
Poole, UK.  Molecular biology grade agarose, Hyperladder™ IV (100-1000 bp) 
DNA ladder and 5x sample loading buffer were from Bioline Ltd, London, UK.   
 
2.1.3.2 Reverse	   Transcriptase-­‐Polymerase	   chain	   Reaction	   (RT-­‐PCR)	  
and	  quantitative	  PCR	  (qPCR)	  
	  
Omniscript® Reverse Transcriptase (RT) kit, Qiagen® RNase inhibitor 7,500 units 
(30 units/µl), Taq Polymerase Chain Reaction (PCR) master mix and Qiagen® 
one-step RT-PCR kit, were all supplied by Qiagen, Crawley, UK.  Oligo-(dT)15 
primers (0.5 µg/µl) were from Promega Ltd, Southampton, UK.  All reverse 
transcriptase-quantitative PCR (RT-qPCR) experiments were conducted using the 
Rotor Gene ™ SYBR® Green one-step RT-qPCR kit purchased from Qiagen Ltd, 
Crawley, UK. 
The following forward and reverse primers used for PCR reactions were obtained 
from Sigma-Genosys, Poole, UK: GAPDH, SUR1 and SUR2, whilst the Kir6.1, 
Kir6.2, CRFR2α, CRFR2β and CRFR2γ primers were purchased from MWG 
Biotech London, UK and the UCNI, CRFR1, CRFR2 (generic), SUR2A, SUR2A-Δ-
14 and SUR2B were from Invitrogen, Fisher Scientific, Loughborough, UK. 
The primer sets employed in RT-PCR experiments are detailed in table 2.1 and for 
qPCR in table 2.2.  Where appropriate the primers were designed to span exonic 
splicing junctions to ensure that amplicon generation are from the mRNA avoiding 
amplification of genomic DNA (gDNA).   
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The following primer sets were designed using Primer 3 software version 0.4.0 
(URL http://fokker.wi.mit.edu/primer3/) and primer specificity for their human 
targets were verified by input of the sequences into the Basic Local Alignment 
Search Tool (BLAST) (URL http://blast.ncbi.nlm.nih.gov/Blast.cgi): Kir6.1, Kir6.2, 
SUR1, SUR2, and CRFR2 (generic) (see table 2.1).  Primers which were designed 
using the PrimerBlast software (URLhttp://www.ncbi.nlm.nih.gov/tools/primer-
blast/index.cgi) are as follows: GAPDH, CRFR1, SUR2A, SUR2A-Δ-14and SUR2B 
(see table 2.1.).  The CRFR2α, CRFR2β and CRFR2γ primer sets were previously 
designed by Petsa (Petsa, 2007); whilst the UCNI primers were from published 
data by Takahashi (Takahashi et al, 1998) (see table 2.1).  However sequences 
were verified for human specificity and expected amplicon sizes using the 
PrimerBlast Software. 
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2.2 Methods	  
2.2.1 C-­‐20/A4	  chondrocyte	  culture:	  
2.2.1.1 Recovery	  of	  C-­‐20/A4	  cells	  from	  frozen	  stocks	  
	  
C-20/A4 cell stocks in 2 ml CRYO.S vials were stored in liquid nitrogen at -196 °C 
in chondrocyte freezing medium composed of: 50% FCS, 20% DMSO and 30% 
Dulbecco’s Modified Eagle’s Medium (DMEM).  For the initiation of culture, a vial 
of C-20/A4 cells was recovered from liquid nitrogen, thawed, suspended in 10 ml 
of culture medium (see section 2.2.1.2) and centrifuged at 250 g for 10 min.  The 
culture medium was aspirated and the pellet was re-suspended again in culture 
medium and centrifugation repeated to ensure complete removal of DMSO.  The 
resulting pellet was then reconstituted in 7 ml of culture medium and incubated at 
37 °C, 5% CO2 in a 25 cm2 flasks.  The medium was replaced after approximately 
24 hrs to remove dead cells and the culture then grown to confluence.   
 
2.2.1.2 Continuous	  culture	  conditions	  for	  C-­‐20/A4	  cells	  
 
The C-20/A4 chondrocytes were cultured in DMEM supplemented with 10% FCS, 
1% L-glutamine and 1% penicillin/streptomycin.  Cell viability and confluence was 
observed by light microscopy and when fully confluent (normally achieved within 3 
- 4 days), the cell culture medium was aspirated and cells rinsed with 10 ml of Ca2+ 
and Mg2+ free dulbecco’s phosphate buffered saline (DPBS) followed by treatment 
with 5 ml of 1x trypsin-EDTA solution for 2 min to detach cells from tissue culture 
flasks.  Inactivation of trypsin-EDTA was achieved by adding an equal volume of 
fully supplemented culture DMEM (mentioned above) and the resulting cell 
suspension was centrifuged at 250 g, for 10 min, at room temperature.  Following 
aspiration of the supernatant, the obtained pellet was re-suspended in fresh 
culture medium and subcultured at a 1:2 split ratio.  
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Culturing was routinely performed in 75 cm2 tissue culture flasks in a total volume 
of 15 ml per vessel and subculture was conducted twice weekly.  The C-20/A4 
monolayer cultures were maintained at 37°C in the presence of 5% CO2 in a 
Galaxy S Carbon dioxide humidified incubator (Wolf Laboratories, York, UK).  All 
tissue culture was carried out in a BIOAIR Aura 2000 class II cabinet (Wolf 
Laboratories, York, UK) and cells were checked daily for morphology, bacterial or 
fungal infection by observation of media colour and microscopic examination.  
Cells were used between passages 5-30 for experiments after which cultures were 
terminated and fresh cultures initiated as before (see section 2.2.1.1).  C-20/A4 
cells used in either cell death experiments or total RNA preparations were 
harvested in the same manner. 
 
2.2.1.3 Preparation	  of	  cells	  for	  storage	  
	  
To ensure a continuous supply of cells for future use, C-20/A4 cells were routinely 
stored in liquid nitrogen as this ensures good viability of cells following long-term 
storage.  C-20/A4 chondrocytes were harvested as detailed in section 2.2.1.2 and 
following centrifugation, the pellet was re-suspended in 6 ml of freezing medium 
(composition: 50% FCS, 20% DMSO and 30% DMEM) and 2 ml aliquots placed in 
CYRO.S freezing vials.  The vials were then frozen at -80 °C in a “Mr Frosty” 
freezing chamber (Merck, Leicester, UK) containing 200 ml of isopropanol (to 
ensure a controlled rate of freezing) for a minimum of 24 hrs and subsequently 
transferred into liquid nitrogen storage. 
 
2.2.2 In	  vitro	  stimulation	  of	  C-­‐20/A4	  chondrocytes	  
	  
In vitro stimulation of cells for cell death assays (apoptosis and necrosis studies) 
and quantitative PCR, was performed on chondrocytes seeded into 6 well tissue 
culture plates at a density of 4.5 x105 cells/well to reach approximately 70-80% 
confluency (~5x105 cells/well).  The cells were then serum starved overnight prior 
to treatment, by replacing normal growth medium with medium containing 1% FCS.   
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Cells were then treated for 6hrs in culture medium supplemented with 1% FCS 
and the appropriate treatment: SNAP, UCNI, Diazoxide, α-helical CRH(9-41) 
alongside an untreated control.  The following treatment conditions for 
experimental assay were established: control (untreated), UCNI (10-8 M), SNAP 
(10-3 M), α-helical CRH(9-41) (10-8 M), Diazoxide (10-4 M), SNAP (10-3 M)+UCNI (10-8 
M), SNAP (10-3 M)+UCNI (10-8 M)+α-helical CRH(9-41) (10-8 M) and SNAP (10-3 
M)+Diazoxide (10-4 M).  The control cells (untreated) were supplemented with 
fresh 1% FCS culture medium for the duration of the treatment. 
Stock solutions for each reagent were prepared as follows: SNAP was 
reconstituted at a stock concentration of 10-1 M in ethanol, UCNI at a stock 
concentration of 10-4 M in DMEM, Diazoxide was dissolved at stock concentration 
of 10-1 M in 0.1 M Sodium Hydroxide (NaOH) and α-helical CRH(9-41) at stock 
concentration of 2.5 x 10-5 M in 1%(v/v) acetic acid (in distilled water).  The 
solutions were stored at -80 °C. 
Following treatment, C-20/A4 cells were harvested and prepared either for Flow 
cytometry analysis or total RNA extraction as detailed in sections 2.2.3.1, 2.2.3.2 
respectively.  An aliquot of treatment medium was removed and stored at -80 °C 
for LDH Release Assay (section 2.2.4). 
 
2.2.3 Cell	  death	  induction	  experiments	  
 
The assessment of apoptosis in C-20/A4 chondrocytes following treatment with 
various stimuli was determined by Annexin-V-FITC/Propidium iodide (PI) labelling 
in conjunction with flow cytometry.  The LDH release assay was performed on 
spent media to assess necrosis.  
The Annexin-V-FITC/PI labelling is based on the observation that during the early 
stages of apoptosis the phosphatidylserine (PS) phospholipids normally located on 
the inner leaflet of the plasma membrane become translocated to the outer 
surface of the membrane following loss of plasma membrane symmetry.  This 
externalisation of PS to the extracellular environment can be detected by the 
binding of Annexin V a calcium dependent phospholipid binding protein with a high  
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affinity for PS.  Visualisation of this binding of Annexin V to the PS residues can be 
achieved by conjugating Annexin V to a fluorochrome such as Fluorescein 
isothiocyanate (FITC) see figure 2.2.  In addition, following loss of membrane 
integrity that may occur in the latter stages of programmed cell death apoptotic 
cells may permeable to PI.  Consequently, based on the principle of Annexin-V-
FITC/PI labelling: viable cells (Annexin-V-FITC negative/PI negative), early 
apoptotic (Annexin-V-FITC positive/PI negative) and late apoptotic cells (Annexin-
V-FITC positive/PI positive) can be detected and visualised by flow cytometry 




Figure 2.2:  A schematic representation of Annexin-V-FITC conjugate calcium dependent 
binding to PS following its externalisation to the extracellular surface of plasma membrane.  
Adapted from: (www.abgab.com). 
 
The LDH release assay was developed by Wroblewski and Ladue in 1995 
(Wroblewski and Ladue, 1955) and since then, the assay has been routinely used 
as a method of assessing cell viability.  LDH is a cytosolic enzyme which is 
released from cells following loss of plasma membrane integrity and this release of 
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subsequently catalyses the conversion of a tetrazolium dye to a coloured 
compound, the absorbance of which may be measured spectrophotometrically at 
490 nm.  
Cell death experiments for apoptosis and necrosis determination were conducted 
on the following treatment conditions: control (untreated), UCNI (10-8 M), SNAP 
(10-3 M), α-helical CRH(9-41) (10-8 M), Diazoxide (10-4 M), SNAP (10-3 M)+UCNI (10-8 
M), vehicle control (1% ethanol), SNAP (10-3 M)+UCNI (10-8 M)+α-helical CRH(9-
41)(10-8 M) and SNAP (10-3 M)+Diazoxide (10-4 M).  The preparation of samples for 
flow cytometry and LDH assay analysis is detailed below. 
 
2.2.3.1 Detection	  of	  apoptosis	  in	  C-­‐20/A4	  chondrocytes	  byAnnexin-­‐
V-­‐FITC/PI	  labelling	  using	  Flow	  cytometry	  
 
Initial optimisation of flow cytometry protocol was performed by a 4-tube protocol: 
tube 1: unstained cells (cells in 500 µl of Aposcreen™ 1X Annexin V binding buffer 
without staining); tube 2: stained cells with Annexin-V-FITC only; tube 3: cells 
stained with PI only and tube 4: Annexin-V-FITC and PI labelled cells.  
Optimisation was required to establish the correct voltage for focusing the light 
emission from the flourochromes onto the photon detectors and to establish the 
fluorescence compensation on the flow cytometer used in post data analysis.    
Following protocol optimisation, apoptotic cell death in C-20/A4 chondrocytes was 
determined using the Southern Biotech Aposcreen™ Annexin-V-FITC apoptosis 
detection reagents.  Following appropriate treatment for 6 hr in 6 well tissue 
culture plates chondrocytes were harvested as follows: the supernatant 
(containing spent media and detached cells) was removed and the adherent cells 
were then rinsed with 1 ml DPBS all of which was collected.  Adherent cells were 
released by trypsinisation (see section 2.2.1.2) and both supernatants and the 
adherent cells were combined and centrifuged at 250 g for 10 min and there after 
the supernatant was carefully and completely aspirated.   
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The resulting pellet was re-suspended in 1 ml cold dulbecco’s phosphate buffered 
saline (DPBS) to remove any remnants of culture medium used to deactivate the 
trypsin and centrifuged at 4 °C, 250 g for 5 min.  Following centrifugation the 
DPBS was aspirated, cells were disaggregated by gently flicking the pellet and re-
suspended in 100 µl ofAposcreen™1X Annexin-V binding buffer.  The tubes were 
placed on ice and 5 µl of Aposcreen™ Annexin-V-FITC conjugate (0.5 µg/ml) 
added to each, mixed and incubated in the dark for 15 min.  A further 390 µl of 
Aposcreen™1X Annexin V binding buffer was then added to each tube followed by 
5 µl of Propidium iodide (1 µg/ml) and gently agitated.  Samples (500 µl total 
volume) were analysed immediately by flow cytometry on a Cyan™ ADP flow 
cytometer (Dako Cytomation, Ely, UK). 
Subsequent unstained samples were prepared following protocol optimisation for 
each experiment, and consisted of cells in 500 µl of Aposcreen™ 1X Annexin V 
binding buffer without Annexin-V-FITC and PI staining.  This cell population was 
required for the post-analysis of data to properly determine the quadrant regions 
used for estimating the viable, early and late apoptotic cell populations generated 
from the FITC and PI fluorescence channels.  A total of ~5.5x105 cells were 
prepared for each sample of which 10,000 cells/events were counted and 
analysed per experimental condition.  Cells were gated on forward scatter (FSC) 
and side scatter (SSC) dot plot histogram to exclude cellular debris.  Percentage 
apoptosis was determined from the 10,000 cells/events gated into four 
subpopulations/quadrants (viable cells, early apoptotic, late apoptotic and necrotic) 
and the number of events/cells in each quadrant represents the number of 
apoptotic or viable cells.  
Analysis of flow cytometry data was performed using Summit v4.3 software 
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2.2.3.2 LDH	  release	  assay	  for	  the	  assessment	  of	  necrosis	  in	  C-­‐20/A4	  
chondrocytes	  
	  
The levels of necrosis in chondrocytes following stimulation were determined using 
the TOX-7 In Vitro Toxicology Lactate Dehydrogenase (LDH) assay kit according 
to manufacturers’ protocol.  
Briefly, an aliquot of spent medium was removed following treatment and 
centrifuged at 250 g for 4 min to pellet any suspended cells.  The LDH assay 
mixture was then prepared by mixing equal volumes of LDH Assay substrate 
solution, LDH Assay Dye solution and 1x LDH Assay Cofactor Preparation.   
A volume of 50 µl of spent medium was added to the wells of 96 well plates and 
100 µl of the LDH assay mixture added to each sample.  The plate was incubated 
at room temp in the dark for 30 min and reaction subsequently terminated by 
adding 15 µl of 1 M Hydrochloric acid (HCl) to each well.  Cell culture medium 
containing 1% heat inactivated FCS was added to several wells on the 96 well 
plate to obtain a background absorbance reading.  
Absorbance of the samples was read spectrophotometrically at 490 nm using a 
THERMOmax plate reader ROM version 1.72 (Molecular Devices, Hampshire, UK) 
and a background absorbance was read at 690 nm.  LDH release (OD units) was 
calculated by subtracting the background absorbance at 690 nm from the initial 
490 nm measurement.  
 
2.2.4 Total	  RNA	  isolation	  from	  C-­‐20/A4	  chondrocytes	  
 
For Reverse Transcriptase-PCR (RT-PCR), total cellular RNA was extracted and 
purified from the C-20/A4 chondrocytes using the Qiagen RNeasy® Mini extraction 
kit according to the manufacturers’ protocol.  Extraction and purification of total 
cellular RNA for RT-qPCR experiments was conducted using the Qiagen RNeasy® 
Mini Plus kit, which includes a gDNA elimination step, according to manufacturers’ 
protocol.  In brief, cells were rinsed with DPBS and disassociated via trypsinisation 
as detailed in section 2.2.1.2 and following centrifugation the medium aspirated, 
the pellet disrupted by flicking the tube and the appropriate volume of lysis buffer 
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added from the Qiagen RNeasy® Mini or Mini Plus kit.  Subsequent addition of 
appropriate extraction reagents and centrifugation steps resulted in the elution of 
the total RNA from the spin column membrane into 30-50 µl of PCR grade water 
which was then stored at -80 °C. 
RNA purity and concentration (ng/µl) was determined by measuring the Optical 
Density (OD) of OD 260/280 using the Thermo Scientific NanoDrop™ 1000 v3.7.1 
(Fisher Scientific, Loughborough, UK) an OD 260/280 average absorption ratio 
typically between 1.8 and 2, generally suggests that the extracted RNA is largely 
undegraded, pure and of good quality free of protein interference (Fleige and Pfaffl, 
2006). 
RNA integrity was verified electrophoretically (on a 1% (w/v) agarose gel 
electrophoresis (AGE) in TAE) by ethidium bromide (200 ng/ml) staining and the 
18S and 28S ribosomal RNA bands visualised by a UV transilluminator (UViTec, 
Cambridge, UK).   
 
2.2.5 Reverse	  Transcriptase-­‐Polymerase	  Chain	  reaction	  (RT-­‐PCR)	  
 
RT-PCR was performed both as two-step RT-PCR and one step RT-PCR.  Initially, 
two-step PCR (where cDNA generation from mRNA was performed in a separate 
tube from the PCR reaction) was used to determine the optimum annealing 
temperature for designed primer sets.  This optimisation was conducted by 
gradient PCR where using an Eppendorf Mastercycler PCR machine generated 
PCR products from each tube given a different annealing temperature (55 °C±10).   
However, with the development of one-step RT-PCR kits by Qiagen Ltd (Crawley, 
UK), which enables reverse transcription, and PCR amplification to occur at a 
highly sensitive and specific rate with less need for reaction optimisation the 
method of PCR was changed from two-step RT-PCR to one-step RT-PCR.  The 
Qiagen one-step RT-PCR kit ensures efficient RT-PCR in a variety of ways, these 
include: firstly, the reverse transcriptase enzymes (Qiagen Ominiscript and 
Sensiscript) which has a high specificity for any RNA templates facilitating the 
transcription to cDNA even in the presence of secondary structures which would  
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otherwise cause lack efficient of cDNA synthesis.  Secondly, a Hotstart Taq DNA 
polymerase enquires which requires initial activation at 95 °C ensuring specific 
PCR amplification.  Thirdly, a RT-PCR buffer with a balanced combination of 
cations ensuring minimal PCR optimisation and Q solution which facilitates the 
amplification of RNA and cDNA templates which are otherwise difficult to amplify.  
 
2.2.5.1 Two-­‐step	  RT-­‐PCR	  
 
cDNA synthesis from C-20/A4 mRNA was performed using the Qiagen® 
Ominiscript® Reverse Transcriptase (RT) kit according to manufacturers’ protocol. 
In brief, 2 µg of total RNA was reverse transcribed into cDNA in a total reaction 
volume of 20 µl containing 2 µl of 10 µM oligo (dT)15 primer (0.5 µg/µl), 2 µl 10x 
Qiagen® RT buffer, 2 µl dNTP mix, 1 µl Qiagen RNase inhibitor (10 units/µl), 1 µl 
Omniscript RT enzyme and RNase free water (variable volume).  The oligo (dT) 
primers and RNA were initially incubated at 70 °C for 10 min to denature 
secondary RNA structures and allow annealing of primer to RNA template.  cDNA 
generation was performed for 1 hr at 37 °C with subsequent storage at -20 °C until 
required.  
Gradient PCR was conducted for GAPDH, Kir6.1, Kir6.2 and UCNI using the 
Qiagen® Taq Polymerase Chain Reaction (PCR) Master Mix according to 
manufacturers’ protocol.  Briefly, cDNA was amplified by PCR in a total reaction 
volume of 25µl containing 5 µl of cDNA (20 ng/µl), 12.5 µl 2X Qiagen Taq PCR 
master mix, 5.5 µl water and 1 µl each of forward and reverse gene specific 
primers (10 µM each).  A negative control was also prepared for each PCR 
reaction containing all the above reagents but replacing cDNA with water to detect 
any contamination of PCR reagents.   
PCR was performed using an initial denaturation of 94 °C for 3 min with 
amplification settings of 94 °C for 1 min, 55 °C ±10 (i.e. 45-65 °C) for 1 min (primer 
annealing), 72 °C for 1 min (for elongation) and a terminal elongation step of 72 °C 
for 10 min.  Products from PCR amplification were electrophoresed through a 2% 
(w/v) agarose gel (in 1x TAE buffer) containing ethidium bromide and visualised  
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under a UV transilluminator (UViTec, Cambridge, UK).  The number of PCR cycles 




The Qiagen® one-step RT-PCR kit was used for the PCR amplification of total 
RNA isolated from C-20/A4 chondrocytes and was performed according to 
manufacturers’ protocol in a total volume of 50 µl containing: 10 µl 5x Qiagen® 
one-step RT-PCR buffer, 2 µl dNTP mix (with 10 mM of each dNTP), 10 µl 5x Q-
Solution, 3 µl each of forward and reverse primer (10 µM each), 2 µl Qiagen® one-
step RT-PCR enzyme mix and RNase free water (volume variable).  An RNase 
inhibitor was not required in the reaction mixture as the one-step RT-PCR buffer 
contains RNase inhibitory components.  A negative control was also prepared for 
every RT-PCR experiment, the negative control contained all the above reagents 
but replacing RNA template with water to detect any contamination of PCR 
reagents. GAPDH (glyceraldehyde 3 phosphate dehydrogenase) was used as the 
reference gene. 
The PCR program for one-step RT-PCR consisted of 3 sections:(1) reverse 
transcription: 50 °C for 30 min (for cDNA synthesis from mRNA using gene 
specific primers), (2) 95 °C for 15 min (inactivation of RT enzymes, initial 
denaturation of cDNA template and activation of Hotstart Taq DNA Polymerase 
PCR enzyme), and (3) three-step PCR cycling: 94 °C for 1 min, primer annealing 
58 °C for 1 min, 72 °C for 1 min and a terminal elongation step of 72 °C for 10 min.  
Products from PCR amplification were electrophoresed through a 2% (w/v) 
agarose gel (in 1x TAE buffer) containing ethidium bromide and visualised under a 
UV transilluminator (UViTec, Cambridge, UK).  The number of PCR cycles for 
each gene is detailed in table 2.1. 
One-step RT-PCR was performed for the following mRNA targets: CRFR1, 
CRFR2, CRFR2α, CRFR2β, CRFR2γ, SUR1, SUR2, SUR2A, SUR2A-Δ-14 and 
SUR2B.  Details of the forward and reverse primers used for RT-PCR and their 
cycling conditions are detailed in table 2.1.   
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The CRFR1 forward and reverse primers were designed to distinguish between 
the two isoforms of this gene.  A 280 bp product denotes CRFR1α mRNA 
expression whilst a 367 bp product signifies CRFR1β.  All CRFR2 isoforms (α, β, 
& γ) primers share the same common reverse primer (see table 2.1). 
 
2.2.5.3 Preparation	  of	  PCR	  products	  for	  sequence	  analysis	  
 
The PCR products generated from one-step and two-step PCR amplification were 
excised from a 2% agarose gel and isolated using the Qiaquick® Gel Extraction kit 
according to manufacturers’ protocol.  The resulting PCR products were verified by 
sequence analysis conducted by GATC Biotech, London, UK in which PCR 
fragments were sequenced from both ends (forward and reverse) and homology to 
human their human targets verified by the input of sequences into BLAST 





Table 2.1: Sequences and conditions of primers sets employed in one-step and two-step RT-PCR experiments. 
Key: *= primers designed using Primer3 primer design software, **= primers designed using PrimerBlast software, §= primers previously designed by 






















       
GAPDH ** NM 002046 5’ GCCAAAAGGGTCATCATCTC 3’ 5’ GGTGCTAAGCAGTTGGTGGT 3’ 131 60 30 
Urocortin I *** NM 003353 5’ CAGGCGAGCGGCCGCG 3’ 5’CTTGCCCACCGAGTCGAAT 3’ 146 57 33 
Kir6.1* NM 004982 5’ GCTTTGTGTCCATTGTGACTG 3’ 5’ GCTGTCATGATTCCGATGTG 3’ 312 60 35 
Kir6.2* NM 000525 5’ ATGATCATCAGCGCCACCAT 3’ 5’ CACCACGCCTTCCAGGAT 3’  249 60 35 
SUR1* NM 000352 5’ CGATTTAACCTGGACCCTGA 3’ 5’ GGCTGTCATCACCACCTTTT 3’ 273 58 45 
SUR2* NM 005691 5’ TTCTGGATTGGTAGGCTTGG 3’ 5’ TTGATCTCCCCTTCTTGTGG 3’ 207 58 45 
SUR2A ** NM 005691 5’ CCGTGTCTCTTCTATTATGGATGCAGG 3’ 5’ GCCATTCTTGTGGGCGAGCAA 3’ 103 58 45 
SUR2A-Δ-14 ** NM 020298 5’ TCTCTTGAGTGATGAGATTGGTGACGA 3’ 5’ TCCATTTGTGACAACTCCAGTGTGCTT 3’ 100 58 45 
SUR2B ** NM 020297 5’ TGACGGCAGACCTGGTTATTGTGA 3’ 5’ TGTCTGCGCGAACAAAAGAAGC 3’ 114 58 45 
CRFR1 ** NM004382 5’ ACAAACAATGGCTACCGGGA 3’ 5’ GGACCACGAACCAGGTGGCG 3’ 280 or 367 58 45 
CRFR2* NM 001883 5’ AGCCCATTTTGGATGACAAG 3’ 5’ AGGTGGTGATGAGGTTCCAG 3’ 180 58 45 
CRFR2α  § NM 001883 5 ‘TCCACAGCCTGCTGGAGGCC 3’ 5’ CTCCAAGCATTCTCGATAGGC 3’ 239 58 45 
CRFR2β  § NM 
001202475 
5’ CCTCCTCTACGTCCCACACC 3’ 5’ CTCCAAGCATTCTCGATAGGC 3’ 310 58 45 
CRFR2γ  § NM 
001202481 
5’ TGGGAAGAGAGCCTTGGCC 3’  5’ CTCCAAGCATTCTCGATAGGC 3’ 212 58 45 
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2.2.6 Quantitative	  PCR	  (qPCR)	  studies	  
 
qPCR was conducted to determine any changes in expression of CRFR1, CRFR2, 
and Kir6.1m RNA following treatment of C-20/A4 chondrocytes with various stimuli 
and specifically to determine whether UCNI mediates cytoprotective effects in 
chondrocytes by altering expression of these genes.  For the qPCR experiments 
conducted herein, relative expression analysis was performed using the 
Comparative Cq (or 2-ΔΔCq) method which requires that PCR efficiencies of both 
target and reference genes are similar or within 10% of each other as this ensures 
reproducible results and the most accurate estimation of gene expression levels 
(Schmittgen and Livak, 2008).   
 
Therefore, to commence qPCR studies, standard curves were generated for the 
target and reference genes and the log of amount of RNA template (on the x-axis) 
plotted against the Cq values of the target and reference genes (on the y-axis).  
The PCR efficiency is the calculated where: E= 10(1/m)-1; where E=PCR efficiency, 
m=slope of the line.  If the slope of the resulting line is less than 0.1 or the PCR 
efficiencies are within 10% of each other; this demonstrates that the PCR 
efficiencies of the target and reference genes are comparable and so the 
Comparative Cq method can be used for the relative quantification of changes in 
gene expression (Schmittgen and Livak, 2008).  Alternatively, if the PCR 
efficiencies are not comparable, the Relative Expression Software Tool (REST) 
can be used as a method of analysis.  The REST mathematical model for relative 
quantification contains an efficiency-corrected calculation program which would 
provide a more accurate quantification of the relative expression of gene targets 
(Pfaffl, 2001).  However, REST, has been suggested to be more beneficial in 
analysing qPCR data with large quantities of samples and gene targets (Wong and 
Medrano, 2005). 
 
Standard curves for the target (CRFR1α, CRFR2, Kir6.1) and reference (GAPDH) 
genes was constructed using the Rotor Gene™ SYBR® Green one-step reverse 
transcriptase-quantitative PCR (RT-qPCR) kit (Qiagen Ltd, Crawley, UK) 
according to the manufacturers’ protocol.  This kit allows reverse transcription of 
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mRNA to cDNA and consequent amplification of this cDNA in a single tube using a 
combined primer annealing and extension time.  The one-step RT-qPCR reaction 
buffer contains the Q-bond additive, which strongly increases the affinity of the 
Taq DNA Polymerase to short single stranded DNA, and so primer and 
polymerase will bind together to the cDNA template immediately forming the 
ternary complex (primer/Taq DNA polymerase to template complex) in one step 
allowing primer extension to take place with high specificity.   
For the standard curves a final concentration of 100, 80, 60, 40 and 20 ng/reaction 
of total RNA was used. RT-qPCR was conducted in a total volume of 25 µl 
containing: 12.5 µl of 2x Rotor Gene SYBR green RT-PCR master mix, 1.25 µl of 
forward and reverse gene specific primer (10 µM each), 0.25 µl Rotor Gene RT 
mix, RNase free water (variable) and total RNA corresponding to the required final 
concentration of RNA mentioned above.  For the standard curve generation, each 
RNA concentration was performed in triplicates.  The PCR efficiency readings 
from the standard curves generated for GAPDH, Kir6.1, CRFR1 and CRFR2 were 
as follows: 99%, 95%, 99% and 97% respectively.  
RT-qPCR was performed using the following cycling conditions:(1) reverse 
transcription: 55 °C for 10 min (for cDNA synthesis from mRNA using gene 
specific primers), (2) 95 °C for 5 min (inactivation of RT enzymes, initial 
denaturation of cDNA template and activation of Hotstart Taq Plus DNA 
Polymerase), and (3) two-step PCR cycling: 95 °C for 5 sec, combined primer 
annealing and extension 60 °C for 10 sec (GAPDH) or 20 sec (Kir6.1, 
CRFR1α  and CRFR2β).  All Real Time PCR cycling was performed using the 
Rotor-Gene Q 2plex HRM System PCR machine (Qiagen Ltd, Crawley, UK).  A 
melt curve analysis of PCR amplicons was performed to determine specificity of 
primers.  Details of the forward and reverse primers used or RT-qPCR, their 
conditions and number of PCR cycles are detailed in table 2.2. 
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2.2.6.1 qPCR	  for	  the	  relative	  quantification	  of	  Gene	  expression	  
 
qPCR was conducted to determine changes in relative expression of Kir6.1, 
CRFR1 and CRFR2 mRNA in chondrocytes following treatment with UCNI, SNAP 
and SNAP+UCNI.  One-step RT-qPCR was conducted on 100 ng of total RNA 
using the Rotor Gene SYBR Green one-step RT-qPCR kit according to 
manufacturers’ protocol using the reagent volumes and RT-qPCR cycling 
mentioned above (section 2.2.6).  A negative control was also included in each 
experiment, which consisted of all the reagents except RNA and reverse 
transcriptase enzyme.  No DNA control was used in these experiments.  Each 
treatment condition was performed in triplicates of three experiments for each 
gene (CRFR1α, CRFR2β and Kir6.1). 
 
2.2.7 Statistical	  analysis	  
Results for cell death studies are presented as mean ± standard error of the mean 
(SEM).  The statistical analysis for differences between treatment groups was 
determined byone-way analysis of variance (ANOVA) with a post Hoc Bonfferoni’s 
correction test.  Values where p <0.05 were considered statistically significant. 
Data analysis was performed using Microsoft Excel2007 (Microsoft, USA) and 
graphs were plotted using Graphad Prism® v5 (Graphpad software, USA) and 
statistical analysis was performed using SPSS (version 18) software (IBM 
cooperation, USA). 
The Comparative Cq (or 2-ΔΔCq) method was used for analysing qPCR data for 
relative expression quantification.  Calculations for 2-ΔΔCq was performed using 
Microsoft Excel (Microsoft, USA) and the students unpaired T-test of the delta Cq 
(ΔCq) values determined the statistical significance of relative expression changes.  




































         
GAPDH NM 002046 5’ GCCAAAAGGGTCATCATCTC 3’ 
 
63 5’ GGTGCTAAGCAGTTGGTGGT 3’ 
 
64 60 30 131 
CRFR1α  NM 004382 5’ ACAAACAATGGCTACCGGGA 3’ 60 5’ GGACCACGAACCAGGTGGCG 3’ 68 60 45 280  
CRFR2 NM 001883 5’ AGCCCATTTTGGATGACAAG 3’ 58 5’ AGGTGGTGATGAGGTTCCAG 3’ 62 60 45 180 
Kir6.1 NM 004982 5’ GCTTTGTGTCCATTGTGACTG 3’ 63 5’ GCTGTCATGATTCCGATGTG 3’ 64 60 40 312 
 
Table 2.2: Sequences and conditions of primers sets used in one-step RT-qPCR experiments.  
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3 Results	  
Introduction	  
Several studies have reported NO to be an inducer of apoptosis in a variety of cell 
types (Blanco et al, 1995; Figueroa et al, 2006; Ushmorov et al, 1999; Maneiro et 
al, 2005) and there is evidence to demonstrate that NO produced spontaneously 
or via NO donors induces apoptosis in chondrocytes (Blanco et al, 1995; Goldring, 
2000; Lotz et al, 1999) which has been noted as a predominant event in the 
pathogenesis of OA (Blanco et al, 1998; Kim and Blanco, 2007).   
Research by Intekhab-Alam in 2006, in which C-20/A4 chondrocytes were 
stimulated with the pro-apoptotic stimuli: SNAP, TNFα and IL-1β has also 
documented that the predominant cell death resulting from these stimuli was 
apoptosis and not necrosis.  Furthermore, it was shown that the 40 amino acid 
peptide, UCNI, protected the stimulated chondrocytes from apoptotic cell death, 
with the chondroprotective action of UCNI being more evident against SNAP/NO 
induced apoptosis than that induced by TNFα  and IL-1β (Intekhab-Alam, 2006).   
Though UCNI mediated cytoprotection against apoptotic cell death in C-20/A4 
chondrocytes has been demonstrated, what still remains unclear is the underlying 
mechanisms by which the chondroprotective effects occur.  Possible intracellular 
signalling pathways have been identified by Western Blotting and pharmacological 
inhibition studies namely: Phosphatidyl inositol (PI) 3 Kinase, P38 Mitogen 
Activated Protein Kinase (MAPK) and P42/44 MAPK (Intekhab-Alam, 2006), 
although the cell surface targets (e.g. ion channels (L-type Calcium channels) or 
receptors (CRFR1 and CRFR2)) and full cell signalling pathways are yet to be 
elucidated.  Thus, the focus of this thesis is a continuation of the above work by 
Intekhab-Alam (2006), to establish the potential targets for UCNI mediated 
chondroprotection in the C-20/A4 chondrocyte cell line.  The mRNA expression of 
CRF receptors (CRFR1 and/or CRFR2) and KATP channel subunits were 
investigated as potential cell surface targets and downstream mediators for UCNI 
chondroprotection.  Furthermore, modulation of these CRF receptors and the 
Kir6.1 KATP channel subunit by UCNI using qPCR was determined to establish 
their role in the anti-apoptotic effects of UCNI.  In addition, activation of the 
mitoKATP channel in response SNAP, a mitochondrial pro-apoptotic stimulus, was 
examined.  The findings of these experiments are detailed in this chapter. 
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3.1 The	  effects	  of	  exogenous	  UCNI	  in	  C-­‐20/A4	  chondrocytes	  
To determine the effect of various stimuli on chondrocyte survival, the cells were 
cultured for in vitro stimulation studies as detailed in section 2.2.2.  Following 
treatment, flow cytometry analysis was performed according to the protocol in 
section 2.2.3.1 for the detection of apoptosis.  LDH release for the assessment of 
necrosis was conducted according the protocol of section 2.2.3.2.   
	  
3.1.1 Flow	  cytometric	  analysis	  of	  the	  effects	  of	  UCNI,	  SNAP	  and	  α-­‐hCRH(9-­‐41)	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Figure 3.1: A diagrammatic representation of a typical flow cytometric analysis of C-20/A4 
chondrocytes showing the effects of various treatments: (1) control (untreated), (2) UCNI, (3) 
SNAP, (4) SNAP+UCNI, (5) SNAP+UCNI+α-hCRH(9-41) and (6) α-hCRH(9-41)) on chondrocyte 
morphology and viability. Results presented here are from a representative experiment of at 
least three repeats performed.  A: Histogram for forward scatter (FSC) & side scatter (SSC); B: 
Histogram for Annexin-V-FITC vs PI fluorescence staining.  In the control histogram (histogram A), 
the arrow indicates the “viable region”.  A total of 10,000 cells/events were counted per sample.  
The number of cells in each quadrant (in histograms B) is equivalent of the percentage of viable or 
apoptotic cells of the 10,000 counted. 
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Figure 3.1 shows representative flow cytometric histograms (column A) and their 
corresponding Annexin-V-FITC and PI double labelled histograms (column B) for 
each set of experimental conditions.  The forward scatter (FSC) vs side scatter 
(SSC) histogram analysis (plotted on a linear scale) gives information regarding 
the size of the cells/events (FSC) and their granularity, refractiveness and internal 
complexity (SSC), hence allowing the distinction of cells from debris and other 
artefacts which may then be eliminated from the analysis.   
 
The double labelled histograms in column B however, are plotted on a logarithmic 
scale and demonstrate the Annexin-V-FITC and PI staining patterns obtained from 
the fluorescent channels (FL1: FITC fluorescence and FL3: PI/PE-Texas Red 
fluorescence).  During analysis, this data is divided into four quadrants enabling 
the differentiation of distinct cell populations.  Cells located in the lower left 
quadrant (designated R8) are both Annexin-V-FITC and PI negative representing 
the viable cells not undergoing measurable apoptosis whilst cells located in the 
lower right quadrant (R9) are positive for Annexin-V-FITC and negative for PI 
representing early apoptotic cells.  The upper right quadrant (R7) contains a 
population of cells, which are positive for both Annexin-V-FITC and PI, 
representing cells in the later stages of apoptosis whilst the upper left hand 
quadrant (R6) represents cells positive for PI only, indicative of a necrotic cell 
population. 
 
The histogram for the control sample of chondrocytes (histogram 1A) shows a 
large square “gate” which represents the population for analysis after the exclusion 
of debris and artefacts, which appear below and to the left of the gate.  Within that 
gate is a large population of cells, which have a low SSC, and high FSC (indicated 
by a black arrow), which represents live cells and is described as the “viable 
region”.  Situated to the left of this viable region, but inside the main gate, is a 
smaller collection of cells, which have a low FSC and high SSC characteristic of 
apoptotic cells.  Similarly, the Annexin-V-FITC and PI binding shown in the 
fluorescence (histogram 1B) for the control sample, shows that most of the cells 
are alive (R8, 92.16%) with low levels of apoptosis occurring (R9, 2.54% and R7, 
5.03% representing early and late apoptosis).   
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The same is true for the cells treated with UCNI (histogram 2B), where most cells 
are viable (R8, 88.87%) and not undergoing measurable apoptosis. However, it 
can be observed that following stimulation of cells with SNAP, the cell population 
in the FSC/SSC histogram (histogram 3A) is shifted to the left when compared to 
the control (histogram 1A); a consequence of an increase in the size of the 
population of cells undergoing apoptosis displaying a low FSC and high SSC, 
coupled with a loss of a distinctive viable region as seen in histogram 1A.  A higher 
percentage of Annexin-V-FITC/PI positive (late apoptotic), cells may also be 
observed in the upper right quadrant (R7, 23.95%) of the fluorescence histogram,  
(histogram 3B) after SNAP treatment. 
Subsequent treatment of cells with SNAP+UCNI (histograms 4A and 4B), it can be 
seen that a considerably higher percentage of cells remaining in the viable region 
(histogram 4A: high FSC/low SSC) with a smaller population of cells located to the 
left of the viable region that are apoptotic with high SSC and low FSC.  Thus, in 
comparison to the chondrocytes treated with SNAP only (see histogram 3B), it is 
evident that SNAP+UCNI co-treatment causes a reduction in the percentage of 
Annexin-V-FITC positive/PI negative (R9, 5.53%, early apoptotic) and Annexin-V-
FITC/PI positive (R7, 9.59%, late apoptotic) chondrocytes (see histogram 4B).   
Concurrent treatment of cells with SNAP+UCNI+α−helical CRH(9-41) (histograms 
5A and 5B), shows that most cells also remain in the viable region and the flow 
cytometric plots are similar to those seen for SNAP+UCNI (see histograms 4A and 
4B).  Analysis of data indicates that the percentage of Annexin-V-FITC positive/PI 
negative (early apoptotic) and Annexin-V-FITC/PI positive (late apoptotic) cells in 
the fluorescence histogram for SNAP+UCNI+α−helical CRH(9-41) treatment 
(histogram 5B), had remained largely unchanged (R9, 3%; R7, 15%), suggesting 
that additional treatment with α−helical CRH(9-41) had no observable effect on cell 
viability when compared to the SNAP+UCNI treatment (histogram 4B: R9, 5.53%; 
R7, 9.59%). In addition, treatment of cells with α−helical CRH(9-41) alone give a 
similar cell viability pattern (see histogram 6B: R8, 90.30%; R9, 4.64% and R7, 
4.35%) to that observed in the control (see histogram 1B: R8, 92.16%; R9, 2.54% 
and R7, 5.03%) and UCNI (see histogram 2B: R8, 88.87%; R9, 3.42% and R7, 
7.29%) fluorescence histogram cell populations suggesting that treatment 
α−helical CRH(9-41) does not significantly affect cell morphology or viability.  
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3.1.2 The	   effects	   of	   various	   stimuli	   on	   the	   levels	   of	   apoptosis	   and	  
necrosis	  in	  C-­‐20/A4	  cultured	  chondrocytes	  
 
Following optimisation of the flow cytometry protocol as documented in section 
2.2.3.1.  Studies were performed to investigate the chondroprotective properties of 
UCNI in cells exposed to the Nitric Oxide (NO) donor, SNAP. 
The effects of UCNI, SNAP and αhelical CRH(9-41) treatment on chondroycte survival
















































Figure 3.2: The cytoprotective effects of exogenous UCNI (10-8M) when administered 
concurrently with the pro-apoptotic stimulus of SNAP (10-3M) in the presence or absence of 
α-helical CRH(9-41) (ahCRH) (10-8M).  Annexin-V-FITC only represents percentage of early 
apoptosis and Annexin-V-FITC/PI indicates late apoptotic percentage of apoptosis. Necrosis was 
measured by LDH released from C-20/A4 cells from stimulated and unstimulated cells.  Data 
presented as mean values (±SEM), n=3 of a minimum of three different experiments performed in 
triplicates. *P<0.05 
 
Figure 3.2 shows the assessment of apoptosis in C-20/A4 cells by flow cytometry 
in which cells were labelled with Annexin-V-FITC and PI prior to analysis. The data 
indicate that stimulation of cells with the pro-apoptotic stimulus SNAP, causes a 
significant increase in apoptotic cell death (p<0.05) compared to the control which 
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Co-treatment of chondrocytes with SNAP+UCNI+α-helical CRH(9-41) partially 
revoked the protective effects of UCNI causing minimal increase in apoptosis; 
however, this was not statistically significant (p>0.05).  UCNI alone appears to 
induce some chondrocyte apoptosis but again this increase was not of statistical 
significance when compared to the control.  
Necrotic cell death, as measured by LDH release, was not observed to be 
significantly different from the control in any of the experiments performed (p>0.05), 




3.1.3 SNAP:	  an	  inducer	  of	  apoptosis	  in	  C-­‐20/A4	  chondrocytes	  
 
The nitric oxide donor, SNAP, was reconstituted in ethanol prior to use for cell 
death experiments (see section 3.1.2).  Given that ethanol can have toxic effects 
on a number of cell types (Fernandez-Sola et al, 2007), it was therefore necessary 
to determine if the vehicle used (ethanol) was contributing to the apoptosis 
observed in the chondrocytes stimulated with SNAP.  For this purpose, 
chondrocytes were stimulated with 1% ethanol (final concentration) or 10-3M SNAP 
in 1% ethanol to establish their effect on chondrocyte viability.   
Apoptosis was determined by Annexin-V-FITC/PI labelling by flow cytomtery and 
necrosis by assessing LDH release in treatment medium.  Results of these 
experiments are shown in figure 3.3.  
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Figure: 3.3: The effects of Ethanol (1%) and SNAP (10-3M) treatment on the levels of 
apoptosis in C-20/A4 cells.  Data presented as mean values (±SEM), n=3 of three different 
experiments.  Annexin-V-FITC only represents percentage of early apoptosis and Annexin-V-
FITC/PI indicates late apoptotic percentage of apoptosis. Necrosis was measures by LDH released 
from C-20/A4 cells from stimulation and unstimulated cells.  *P<0.05 
 
The data presented in figure 3.3, shows a significant increase in apoptosis (p<0.05) 
when the chondrocytes were stimulated with 10-3M SNAP in 1% ethanol.  The 
graph also demonstrates that treatment of chondrocytes with 1% ethanol alone 
(the vehicle for SNAP) does not significantly increase apoptosis (p>0.05).  
Therefore, the apoptotic cell death observed following SNAP treatment of 
chondrocytes is attributable to the SNAP and not the vehicle used to dissolve it.  
 
  
The Effect of SNAP and Ethanol treatment  on the levels of Apoptosis in C-20/A4 cells
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3.2 The	  endogenous	  mRNA	  expression	  of	  UCNI	  and	  GAPDH	  genes	  by	  
C-­‐20/A4	  chondrocytes	  
	  
Studies in other cell types have indicated that UCNI exerts cytoprotective effects 
against apoptosis (Tao et al, 2004; Brar et al, 1999; Lawrence et al, 2002). These 
findings are comparable to our data in chondrocytes, which demonstrate that 
UCNI exerts a chondroprotective effect in C-20/A4 cells.  Further to such findings, 
the possible mechanisms by which these anti-apoptotic effects in C-20/A4 
chondrocytes are mediated, remains to be identified and so will be the objective of 
the work detailed in this thesis.  To commence the investigation of potential 
mechanisms for UCNI protection, RT-PCR was performed to confirm the 
endogenous expression of UCNI mRNA in the C-20/A4 chondrocyte cell line.  RT-
PCR studies were also performed for the expression of a reference gene 
(GAPDH).  A negative control was included in all RT-PCR experiments and 
showed no amplification of products (data not shown).  Sequence analysis on the 
generated PCR products was performed by GATC Biotech, London, UK and 
sequence homology to the human gene targets at the nucleotide level was 
conducted by input of sequences into BLAST human sequence resources. 
3.2.1 The	  mRNA	  expression	  of	  UCNI	  by	  C-­‐20/A4	  chondrocytes	  
	  
	  
Figure 3.4: Expression of UCNI by C-20/A4 chondrocytes on a 2% (w/v) agarose gel stained 
with ethidium bromide. 
Gradient PCR for the mRNA expression of UCNI was conducted using a range of annealing 
temperatures 55 ± 10˚C. M= hyperladder IV marker (1Kb ladder), lanes 1-11 UCNI gradient PCR 
product.  Annealing temperatures for each lane are as follows: lane 1= 45 °C, lane 2= 46 °C, lane 
3= 47 °C, lane 4= 49 °C, lane 5= 52 °C, lane 6= 54 °C, lane 7=57 °C, lane 8= 60 °C, lane 9= 62 °C, 
lane 10= 64 °C and lane 11= 65 °C. 
 






600bp UCNI PCR product 	  
(146bp)	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Figure 3.4, demonstrates the gradient PCR conducted for the mRNA expression of 
UCNI in untreatedC-20/A4 cells, to establish an optimum annealing temperature 
for the UCNI forward and reverse primers.   
The expected 146bp product observed in figure 3.4, demonstrates that the C-
20/A4 chondrocytes do indeed express the mRNA for the UCNI peptide 
endogenously. Furthermore, the PCR products in the gel image also suggest that 
in order for an efficient amplification of the UCNI mRNA, annealing temperatures 
of 57°C (lane 7), 60°C (lane 8) or 62°C (lane 9) could be used.  However, if 
several PCR runs of different targets were to be performed simultaneously, an 
annealing temperature of 57°C is more appropriate for the UCNI primer pair 
allowing many PCR assays to be conducted using the same PCR cycling 
conditions.  The mRNA expression of UCNI was also previously detected using 
RT-PCR by Intekhab-Alam (2006), in which the identification of the generated 
PCR amplicon was also confirmed by sequence analysis as the mRNA for the 
human UCNI (Intekhab-Alam, 2006). 
 





Figure 3.5: Expression of GAPDH by C-20/A4 chondrocytes on a 2% (w/v) agarose gel 
stained with ethidium bromide. 
Gradient PCR was conducted with annealing temperatures 55 ± 10 ˚C. M= hyperladder IV marker 
(1Kb ladder), lanes 1-11 GAPDH gradient PCR products. Lane 1= 45 °C, lane 2= 46 °C, lane 3= 
47 °C, lane 4= 49 °C, lane 5= 52 °C, lane 6= 54 °C, lane 7=57 °C, lane 8= 60 °C, lane 9= 62 °C, 
lane 10= 64 °C and lane 11= 65 °C 
 
 






GAPDHPCR product 	  
(131	  bp)	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GAPDH was selected as the reference gene for RT-PCR and RT-qPCR studies. 
Following Gradient PCR using the designed primers detailed in table 2.1 (see 
chapter 2), an expected PCR product size of 131 bp was visualised on a 2% gel 
stained with ethidium bromide.  Subsequent sequence analysis of the generated 
PCR product further confirmed the resulting product as the human GAPDH mRNA. 
Details of the results for the sequence analysis of the GAPDH PCR product are in 
section 3.2.3.  
It is evident from the gel image above that a specific product for GAPDH can be 
obtained with these primers using a range of optimum annealing temperatures: 
from 45 °C to 62 °C (lanes 1 to 9).  However, given that the melting temperatures 
of the GAPDH forward and reverse primers is ≤ 63 °C (see table 2.2), annealing 
temperatures above 64 °C would not appear to be favourable for amplification of 
this mRNA as a smaller amount of product is generated compared to the 
amplicons generated at lower temperatures. A temperature of 60 °C was used to 
allow for greater operational flexibility. 
 
3.2.3 Sequence	  analysis	  data	  for	  the	  human	  GAPDH	  mRNA	  
	  
Human GAPDH mRNA sequence:  NM 002046  
• GAPDH mRNA forward sequence: 
TGAGAAGTATGACAACAGCCTCAAGATCATCAGCAATGCCTCCTGCACCACC
AACT 
Length of sequence=56 nucleotides  
Identities =56/56 (100%) 
Sequence location on human GAPDH mRNA: nucleotides 513-568 
 
• GAPDH mRNA reverse sequence: 
TTCTCATGGTTCACACCCATGACGAACATGGGGGCATCAGCAGAGGGGGCA
GAGATGATGA 
Length of sequence =61 nucleotides  
Identities =61/61 (100%) 
Sequence location on human GAPDH mRNA: 518-458 nucleotides  
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3.3 The	  mRNA	   expression	   of	   potential	  UCNI	  receptors	   on	   C-­‐20/A4	  
chondrocytes	  
	  
UCNI and other members of the Corticotropin Releasing Factor family of peptides 
may be expected to predominantly mediate their physiological functions by initial 
ligation to the G-protein coupled receptors known as Corticotropin Releasing 
Factor Receptors (CRFRs) (Grammatopoulos and Chrousos, 2002; Brar et al, 
2000).   
The identification of potential endogenous expression of UCNI receptors (CRFR1 
and CRFR2 variants) and KATP channel subunits (Kir6.x and SURx) at the mRNA 
level (which could function as putative targets for UCNI mediated 
chondroprotection) were identified by employing reverse transcriptase-PCR (RT-
PCR) studies.   
Following C-20/A4 culture as detailed in section 2.2.1.2, total RNA was extracted 
and quantified from the cells according to protocol 2.2.4.  The RT-PCR 
experiments for the mRNA expression of GAPDH, UCNI and Kir6.1 and 6.2 
subunits were performed by two-step RT-PCR using protocol 2.2.5.1.  In addition, 
the expression of CRF receptor and SURs subunit genes were detected by 
performing one-step RT-PCR as detailed in protocol 2.2.5.2.Sequence analysis on 
the generated PCR products were performed by GATC Biotech, London, UK and 
sequence homology to the human gene targets at the nucleotide level was 
conducted by input of sequences into BLAST human sequence resources. 
 
3.3.1 The	   endogenous	  mRNA	   expression	   of	  Corticotropin	  Releasing	  
Factor	  Receptors	  (CRFRs)	  by	  the	  C-­‐20/A4	  chondrocytes	  
 
Initial RT-PCR experiments were performed with two primers pairs designed to 
amplify any functional CRFR mRNA, regardless of the isoforms.  The CRFR1 
primers were designed to generate PCR fragment sizes of 280bp (CRFR1α) or 
367bp (CRFR1β), whilst the CRFR2 primers were designed to amplify a generic 
band of 180bp to indicate mRNA expression of anyCRFR2 variants (CRFR2α, 
CRFR2β or CRFR2γ).  
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Figure 3.6: The mRNA expression of CRFR1αand CRFR2 by C-20/A4 chondrocytes on a 2% 
(w/v) agarose gel stained with ethidium bromide. 
M= hyperladder IV marker (1Kb ladder).  Lanes 1-2= CRFR1α  PCR products, lane 3= 
CRFR1α  negative control; lanes 4-5= CRFR2 PCR products, lane 6= CRFR2 negative control; 
lanes 7-8= GAPDH PCR products, lane 9= GAPDH negative control. 
 
The RT-PCR products displayed in figure 3.6 indicate that the C-20/A4 
chondrocytes express mRNA for both CRFR1 and CRFR2 receptors.  The 
observed product size of 280bp for the CRFR1 primers (lanes 1-2) indicates 
chondrocyte expression of mRNA for the functional CRFR1α  receptor.  The gel 
image also indicates the expression of a CRFR2 receptor by the C-20/A4 
chondrocytes (lanes 4 and 5, 180 bp).  Identification of the observed CRFR1 and 
CRFR2 PCR amplicons in figure 3.6 were subjected to sequencing and both PCR 
products confirmed by subsequent sequence analysis as the mRNA for the human 
CRFR1α and a CRFR2 gene.  The sequence analysis data for the CRFR1α and 
CRFR2 mRNA is detailed is section 3.3.1.1 and 3.3.1.2 respectively. 
Further RT-PCR experiments were then conducted to establish the specific mRNA 
isoform (CRFR2α, CRFR2β or CRFR2γ) of the CRFR2 receptor present, the 
results of which are documented in section 3.3.2.  The PCR products in lanes 7 
and 8 of the gel image are for the reference gene, GAPDH, the sequence data for 
which was shown previously (see pg 75). 







600 bp CRFR1α  product 
 ( 280 bp) CRFR2  PCR 
product (180 bp)	   GAPDH PCR 
products (131 bp)	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3.3.1.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  CRFR1αhuman	  variant	  in	  
C-­‐20/A4	  chondrocytes	  
	  
Human CRFR1α mRNA: NM004382 






Length of sequence= 228 nucleotides  
Identities= 227/228 (99%) 
Sequence location on human CRFR1α mRNA: nucleotides 553-780 
 






Length of sequence= 216 nucleotides  
Identities= 216/216 (100%) 
Sequence location on human CRFR1α mRNA: nucleotides 720-505 
 





Length of consensus sequence= 163 nucleotides  
Identities= 163/163 (100%) 
Sequence location on human CRFR1α mRNA: nucleotides 558-720 
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3.3.1.2 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  human	  CRFR2	  in	  C-­‐20/A4	  
chondrocytes	  
	  
Human CRFR2 mRNA sequence:  NM 001883 
 
• CRFR2 mRNA forward sequence: 
GGGCCACTGCGTATCTGTGGCAGCCCTGGTGGCCGCCTTCCTGCTTTTCCTG
GCCCTGCGGAGCATTCGCTGTCTGCGGAATGTGATTCACTGGAACCTCAT 
Length of sequence= 102 nucleotides  
Identities= 102/102 (100%) 
Sequence location on human CRFR2 mRNA: nucleotides 611-712 
 
 




Length of sequence= 109 nucleotides  
Identities= 109/109 (100%) 
Sequence location on human CRFR2 mRNA: nucleotides 654-546 
 
 
• CRFR2 mRNA sequence consensus: 
GGGCCACTGCGTATCTGTGGCAGCCCTGGTGGCCGCCTTCCTGC 
 
Length of consensus sequence= 44 nucleotides  
Identities= 44/44 (100%) 
Sequence location on human CRFR2 mRNA: nucleotides 611-654 
 
	  
	   	  
Chapter	  3:	  Results	  
	  
	   80	  
3.3.2 The	  mRNA	  expression	  of	  the	  CRFR2	  receptor	  variant:	  CRFR2β 	  




Figure 3.7: A 2% (w/v) agarose gel stained with ethidium bromide showing the mRNA 
expression of CRFR2β  isoform by C-20/A4 chondrocytes.	  
M = hyperladder IV marker (1Kb ladder), Lanes 1-2= CRFR2α  PCR product, lane 3= 
CRFR2α  negative control; lanes 4-5= CRFR2β PCR product, lane 6= CRFR2β negative control, 
lanes 7-8= CRFR2γ  PCR product, lane 9= CRFR2γ  negative control. 
 
RT-PCR experiments were conducted to establish the CRFR2 variant following the 
initial RT-PCR data in figure 3.6, which indicated the expression ofCRFR2 
receptor mRNA in the C-20/A4 chondrocytes. As a result, forward primers were 
designed towards the N terminus of the CRFR2 mRNA transcript to generate 
specific products for the three splice variants of the CRFR2 receptor (CRFR2α, 
CRFR2β or CRFR2γ) based on the alternative splicing which occurs at the N 
terminus of the receptor(Grammatopoulos and Chrousos, 2002). Thus, 239bp, 
310bp and 212bp products would indicate CRFR2α, CRFR2β or 
CRFR2γexpression, respectively.   
Results from the RT-PCR experiments, which were electrophoresed on a 2% 
agarose gel (figure 3.7) indicated the presence of a 310bp product, which, 
suggests that theCRFR2β variant of the CRFR2 receptor is expressed by C-20/A4 
chondrocytes. No specific PCR products of 239 bp and 212bp were visible which 
would have indicated the mRNA expression of CRFR2α and CRFR2γ variants, 
respectively.  Subsequent sequence analysis of the 310 bp observed PCR 







600 bp CRFR2α (239bp) 
CRFR2β  (310 bp) 
CRFR2γ  (212bp) 
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amplicon (see section 3.3.2.1), confirmed the PCR product as the human CRFR2β 
mRNA. 
3.3.2.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  CRFR2β  in	  C-­‐20/A4	  
chondrocytes	  
	  
Human CRFR2β isoform mRNA sequence:  NM 001202475 






Length of sequence= 256 nucleotides  
Identities= 255/256 (100%) 
Sequence location on human CRFR2β mRNA: nucleotides 148-403 
 






Length of sequence= 227 nucleotides  
Identities= 227/227 (100%) 
Sequence location on human CRFR2β mRNA: nucleotides 326-100 
 






Length of consensus sequence= 170 nucleotides  
Identities= 170/170 (100%) 
Sequence location on human CRFR2β mRNA: nucleotides 157-326 
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3.4 Investigation	  of	  the	  mRNA	  expression	  of	  KATP	  channel	  subunits:	  
Kir6.x	  and	  SURx	  by	  C-­‐20/A4	  chondrocytes	  
	  
Studies by Lawrence et al in 2004, have suggested a role for KATP channels, in 
particular the mitochondrial KATP channel (mitoKATP) with pore forming subunit, 
Kir6.1, in UCNI mediated prevention of cell death.  Their findings documented that 
UCNI reduced cell death by activation of the mitoKATP channel and subsequent 
prevention of damage to the cells mitochondria (Lawrence et al, 2004). 
 
To determine if these KATP channels may be involved the chondroprotective effects 
of UCNI in the C-20/A4 chondrocytes, the existence of the mRNA and protein 
expression of the subunits (Kir6.x and SURx), which constitute functional KATP 
channels, firstly needs to be confirmed in the chondrocytes. Consequently, RT-
PCR studies were performed to optimise the detection of the mRNA expression of 
the mitochondrial KATP channel subunits in C-20/A4 cells.   
 
All RT-PCR products generated from these studies were confirmed by sequence 
analysis.  Sequence analysis was performed by GATC Biotech, London, UK and 
sequence homology to the human gene targets at the nucleotide level was 
conducted by input of sequences into BLAST human sequence resources.  A 
negative control was included in all RT-PCR experiments and showed no 
amplification of products (data not shown). 
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3.4.1 The	  endogenous	  mRNA	  expression	  of	   the	  Kir6.1	  KATP	   channel	  
subunit	  by	  C-­‐20/A	  4	  chondrocytes	  
	  
Result for the investigation of the mRNA expression of the KATP channel pore 




Figure 3.8: The mRNA expression of Kir6.1 by C-20/A4 cells on a 2% (w/v) agarose gel 
stained with ethidium bromide. 
Gradient PCR for Kir6.1 mRNA expression was conducted with annealing temperatures 55±10 ˚C. 
M= hyperladder IV marker (1Kb ladder).  Annealing temperature for each lane are as follows: lane 
1= 45 °C, lane 2= 46 °C, lane 3= 47 °C, lane 4= 49 °C, lane 5= 52 °C, lane 6= 54 °C, lane 7=57 °C, 
lane 8= 60 °C, lane 9= 62 °C, lane 10= 64 °C and lane 11= 65 °C. 
 
Figure 3.8 shows the results of the gradient PCR for the KATP channel pore forming 
subunit, Kir6.1.The result indicates the expression of mRNA for this mitochondrial 
subunit-Kir6.1, by C-20/A4 chondrocytes.  The gel image also illustrates that a 
range of annealing temperature exists for amplification, however for operational 
flexibility, the annealing temperature of 60 °C (lane 8) was considered favourable 
for the optimum amplification of Kir6.1 mRNA.  The 312bp generated PCR product 
in figure 3.8, was confirmed as the human Kir6.1 subunit by sequence analysis 
(see section 3.4.1.1).   
 
 







Kir6.1 PCR product 
(312 bp) 
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3.4.1.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  Kir6.1	  in	  C-­‐20/A4	  
chondrocytes	  
	  
Human Kir6.1 mRNA sequence: NM 004982 







Length of sequence= 244 nucleotides  
Identities= 243/244 (99%) 
Sequence location on human mRNA: nucleotides 1362-1605 
 







Length of sequence= 236 nucleotides  
Identities= 236/236 (100%) 
Sequence location on human mRNA: nucleotides 1543-1308 
 





Length of consensus sequence=175 nucleotides  
Identities= 175/175(100%) 
Sequence location on human mRNA: nucleotides 1369-1543 
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3.4.2 The	  mRNA	  expression	  of	  theKir6.2	  KATP	  channel	  subunit	  by	  the	  
C-­‐20/A4	  chondrocytes	  
	  
RT-PCR was also conducted to determine C-20/A4 expression of the second KATP 





Figure 3.9:  The mRNA expression of Kir6.2 by C-20/A4 chondrocytes on a 2% (w/v) agarose 
gel stained with ethidium bromide. 
The gradient PCR for the mRNA expression of Kir6.2 was conducted using a range of annealing 
temperatures 55±10˚C. M = hyperladder IV marker (1Kb ladder).  Lanes 1-11= Kir6.2 PCR product.  
Annealing temperature for each lane are as follows: lane 1= 45 °C, lane 2= 46 °C, lane 3= 47 °C, 
lane 4= 49 °C, lane 5= 52 °C, lane 6= 54 °C, lane 7=57 °C, lane 8= 60 °C, lane 9= 62 °C, lane 10= 
64 °C and lane 11= 65 °C.  
 
Results from the gradient PCR (figure 3.9) and sequencing analysis (section 
3.4.2.1), confirmed the expression of mRNA at 249 bp for the Kir6.2 KATP channel 
subunit by C-20/A4 chondrocytes.  Moreover, it is evident from the PCR amplicons 
generated from the different annealing temperatures in figure 3.9, that for future 
PCR studies an annealing temperature of 60 °C (lane 8) would yield optimum 
amplification of the Kir6.2 subunit.  
  







Kir6.2 PCR product 
(249 bp) 
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3.4.2.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  Kir6.2	  in	  C-­‐20/A4	  
chondrocytes	  
	  
Human Kir6.2 mRNA sequence:  NM 000525 
 





Length of sequence= 193 nucleotides  
Identities= 193/193 (100%) 
Sequence location on human mRNA: nucleotides 1247-1439 
 





Length of sequence= 165 nucleotides  
Identities= 165/165 (100%) 
Sequence location on human mRNA: nucleotides 1365-1201 
 




Length of consensus sequence= 119 nucleotides  
Identities= 119/119 (100%) 
Sequence location on human mRNA: nucleotides 1247-1365 
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3.4.3 The	  mRNA	  expression	  of	  KATP	  channels	  Sulfonyl	  Urea	  Receptor	  
(SUR)	  regulatory	  subunits	  by	  C-­‐20/A4	  Chondrocytes	  
	  
Typically, Kir6.x subunits associate with SURx subunits and so existence of the 
latter are essential for the formation of functional KATP channels.  The SURs are 
the regulatory components and so will modulate the activation and closure of the 
pore (Kir6.x) subunit of the channel.  To confirm the possibility that C-20/A4 
chondrocytes may express functional KATP channels, RT-PCR was conducted for 
the expression of mRNA for the KATP channels regulatory subunits (SUR) of which 




Figure 3.10: The mRNA expression of SUR1 andSUR2 regulatory subunits by the C-20/A4 
cells demonstrated on a 2% (w/v) agarose gel stained with ethidium bromide. 
M= hyperladder IV marker (1Kb ladder), lanes1-2= SUR1 PCR products, lane 3= SUR1 negative 
control, lanes 4-5= SUR2 PCR products, lane 6= SUR2 negative control. 
 
The PCR products in figure 3.10 demonstrate that the C-20/A4 chondrocytes 
express products corresponding to SUR1 (lanes 1 and 2, 273bp) and also SUR2 
(lanes 4 and 5, 207bp) mRNA.  Sequence analysis (see section 3.4.3.1) of these 
PCR products confirmed the amplicons generated as SUR1 and SUR2 subunits.  
SUR2 subunits however, exist in two predominant isoforms: SUR2A and SUR2B.   
Further RT-PCR studies were performed to establish which functional SUR2 
receptor subunit was present in these chondrocytes.  
 







SUR1 PCR product 
(273 bp) SUR2 PCR product 
(207 bp) 
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3.4.3.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  KATP	  channel	  SUR1	  and	  
SUR2	  subunitsin	  C-­‐20/A4	  chondrocytes	  
 
3.4.3.1.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  the	  KATP	  channel	  
subunit:	  SUR1	  
	  
Human SUR1 sequence:  NM 000352 
 





Length of sequence= 190 nucleotides  
Identities= 190/190 (100%) 
Sequence location on human mRNA: nucleotides 4506-4695 
 






Length of sequence= 215 nucleotides  
Identities= 215/215 (100%) 
Sequence location on human mRNA: nucleotides 4649-4435 
 




Length of consensus sequence=144 nucleotides  
Identities= 144/144 (100%) 
Sequence location on human mRNA: nucleotides 4506-4649 
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3.4.3.1.2 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  the	  KATP	  channel	  
subunit:	  SUR2	  
	  
Human SUR2 mRNA sequence:  NM 005691 
 




Length of sequence= 149 nucleotides  
Identities= 148/149 (99%) 
Sequence location on human mRNA: nucleotides 3808-3956 
 




Length of sequence= 140 nucleotides  
Identities= 140/140 (100%) 
Sequence location on human mRNA: nucleotides 3895-3756 
 
• SUR2 mRNA consensus sequence: 
TTGGCTGACCTGGAGGTCCAGATGGGTGCAGTGAAGAAGGTGAACAGTTTCC
TGACTATGGAGTCAGAGAA 
Length of consensus sequence= 71 nucleotides  
Identities= 71/71 (100%) 
Sequence location on human mRNA: nucleotides 3825-3895 
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3.4.4 The	  mRNA	  expression	  of	  KATP	  channel	  SUR2	  isoform	  subunits	  
by	  the	  C-­‐20/A4	  Chondrocytes	  
 
Investigation into the specific SURx (SUR1 or SUR2) isoform expressed at the 
mRNA level by the C-20/A4 chondrocytes demonstrated that they express both 
SUR1 and SUR2subunits (figure 3.10).  Consequently, the mRNA of the 
specificSUR2 isoform(s) expressed by the C-20/A4 chondrocytes was investigated 
(figure 3.11).  
 
 
Figure 3.11: The mRNA expression of the SUR2 isoforms present in C-20/A4 chondrocytes 
electrophoresed a 2% (w/v) agarose gel stained with ethidium bromide. 
 M= hyperladder IV marker (1Kb ladder), lanes 1-2= SUR2A PCR products, lane 3= SUR2A 
negative control, lanes 4-5= SUR2A-delta-14 PCR products, lane 6= SUR2A-delta-14 negative 
control, lanes 7-8= SUR2B PCR products, lane 9= SUR2B negative control. 
 
The gel image in figure 3.11 illustrates the findings from further RT-PCR 
experiments that were conducted to establish which SUR2 subunit is expressed by 
the C-20/A4 cells.  The PCR products of figure 3.11 indicate that the chondrocytes 
express a SUR2A (lanes 1 and 2) and SUR2B (lanes 7 and 8) regulatory subunits.  
SUR2A can exist both as a functional and non-functional splice variant(Shi et al, 
2005).  The amplification of a product in lanes 4 and 5 indicate that the SUR2A 
isoform expressed by the C-20/A4 chondrocytes is the isoform denoted SUR2A-
delta-14 [SUR2A-Δ-14], a non-functional variant(Chutkow et al, 1999).  Thus the 
functional SUR2 subunit that is expressed by the chondrocytes is SUR2B. 
Sequence analysis data of the generated SUR2 isoforms (SUR2A, SUR2A-Δ-14 
and SUR2B) PCR products in figure 3.11, are demonstrated in section 3.4.4.1. 
 








product  (103 bp) 
SUR2A-delta-14 
PCR product  
(100 bp) 
SUR2B PCR 
product  (114 bp) 
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3.4.4.1 Sequence	  analysis	  for	  the	  mRNA	  expression	  of	  the	  KATP	  
channel	  SUR2	  isoforms	  subunits:	  SUR2A,	  SUR2A-­‐Δ-­‐14	  and	  
SUR2B	  in	  C-­‐20/A4	  chondrocytes	  
 
3.4.4.1.1 Sequence	  analysis	  for	  SUR2A	  isoform	  mRNA	  expression	  	  
	  
Human SUR2A isoform sequence: NM 005691 
 
• SUR2A isoform mRNA forward sequence: 
TTAGTGGAGTGTGATACTGTCCCAATTTGCTCGCCCACAAGAATGGC 
 
Length of sequence= 48 nucleotides  
Identities= 47/48 (98%) 
Sequence location on human mRNA: nucleotides 4590-4637 
 
• SUR2A isoform mRNA reverse sequence  
AAAGACTAAAACAAGGCCTGCATCCATAATAGAAGAGACA 
Length of sequence= 40 nucleotides  
Identities = 40/40 (100%) 
Sequence location on human mRNA: nucleotides 4577-4538 
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3.4.4.1.2 Sequence	  analysis	  for	  SUR2A-­‐Δ-­‐14	  mRNA	  expression	  	  
	  
Human SUR2A delta 14 isoform sequence: NM 020298 
• SUR2A delta 14 isoform mRNA forward sequence: 
TTTTGATCCTGTAAGAAGCACACTGGAGTTGTCACAAATGG 
Length of sequence= 41 nucleotides  
Identities = 24/24 (100%) 
Sequence location on human mRNA: nucleotides 1908-1931 
• SUR2A delta 14 isoform mRNA reverse sequence: 
GTCACCAATCTCATCACTCAAGAG 
Length of sequence= 24nucleotides  
Identities= 24/24 (100%) 
Sequence location on human mRNA: nucleotides 1868-1845 
	  
3.4.4.1.3 Sequence	  analysis	  for	  SUR2B	  isoform	  mRNA	  expression	  	  
 
Human SUR2B isoform sequence: NM 020297 
• SUR2B isoform mRNA forward sequence:  
GCTCAGGAAAATGGAGTATTTGCTTCTT 
Length of sequence= 28 nucleotides  
Identities= 28/28 (100%) 
Sequence location on human mRNA: nucleotides 4623-4650 
• SUR2B isoform mRNA reverse sequence: 
TTTCTGGAGTGTCATATTCTAAAATATTTCCTCGCTTCATCACAATAACCAGGT
CTGCCGT 
Length of sequence= 61 nucleotides  
Identities= 61/61 (100%) 
Sequence location on human mRNA: nucleotides 4614-4554 
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3.5 qPCR	   studies	   for	   analysis	   of	   the	   relative	   expression	   of	  CRFR1,	  
CRFR2	  and	  Kir6.1	  by	  the	  2-­‐ΔΔCq	  method	  
 
This section aims to investigate the relative expression of CRFR1, CRFR2 and 
Kir6.1 by qPCR to determine their relative abundance following treatment and 
determine whether their expression is modulated by UCNI.  The cell death studies 
in section 3.1.2 showed that UCNI is a cytoprotective agent in chondrocytes 
against SNAP induced apoptosis.  Furthermore, RT-PCR experiments further 
demonstrated that previously described receptors and intracellular targets, for 
UCNI mediated protection exist in the C-20/A4 chondrocytes.  
For the qPCR studies, chondrocytes were treated with UCNI, SNAP and 
SNAP+UCNI; total RNA extracted from these treated samples and an untreated 
control were subjected to qPCR experiments to determine the effects of treatment 
on the relative expression of CRFR1, CRFR2 and Kir6.1 mRNA.  Chondrocytes 
were subjected to SNAP and UCNI treatment as detailed in 2.2.2 protocol and 
total cellular RNA extracted and quantified according to 2.2.4.  qPCR experiments 
were conducted using one-step RT-qPCR as detailed in 2.2.6 and the relative 
quantification of these genes (CRFR1α, CRFR2β and Kir6.1) was performed using 
the Comparative Cq (or 2-ΔΔCq) method of analysis where expression changes are 
expressed as fold change relative to the calibrator (Livak and Schmittgen, 2001).  
Three different experiments (n=3) were performed for the reference gene (GAPDH) 
and each gene of interest (CRFR1α, CRFR2β, and Kir6.1).  For each experiment 
(n=1), RT-qPCR on the control and treated samples were performed in triplicates 
and three different control and treated RNA preparations were used.  
Relative Expression using the 2-ΔΔCq method is calculated in three steps using the 
following equations: 
(Step A): 
Equation 1: ΔCq =average Cq (Gene of interest) – average Cq (reference gene) 
 
(Step B): 
Equation 4: ΔΔCq= ΔCq (sample of interest) – ΔCq (calibrator) 
 
(Step C): 
Equation 5: Fold change= 2-ΔΔCq 
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In general, if the calculated value for the ΔΔCq is positive, this results in a 2-ΔΔCq 
value that is negative indicating a reduction in expression levels.  Conversely, a 
negative ΔΔCq value generates a positive 2-ΔΔCq value signifying an increase in 
expression of the target gene due to treatment (Schmittgen and Livak, 2008).  The 
calculations for the relative expression by 2-ΔΔCq was performed using Microsoft 
Excel, 2007 (Microsoft,USA). 
The results for the relative quantification of CRFR1α, CRFR2β and Kir6.1 following 
treatment are illustrated in the following sections (3.5.1-3.5.3).  An unpaired T-test 
was performed on the ΔCq values to determine the level of significance of the 
changes in the relative expression of the genes of interest following treatment and 
significance was at p<0.05 (Yuan et al, 2006). 
 
3.5.1 Determination	  of	  the	  relative	  expression	  of	  CRFR1α  in	  C-­‐
20/A4	  cells	  following	  stimulation	  with	  UCNI	  and	  SNAP	  
 
qPCR experiments assessed the effect of treatment on the relative expression of 
the CRFR1α receptor,  a potential UCNI receptor for mediating UCNI 
chondroprotection.  Tables 3.1-3.3 shows the calculations employed for 
determining the fold changes in gene expression levels for each of three 
experiments performed and the average fold change from these three experiments 
is illustrated in table 3.4.  
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Treatments	  




Cq	   ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   25.3	   7.46	   	  	   	  	   	  	  
	  	   24.46	   7.67	   	  	   	  	   	  	  
	  	   25.59	   7.75	   	  	   	  	   	  	  
Average	  Cq	   25.12	   7.63	   17.49	   0	   1	  
SD	   ±0.59	   ±0.15	   ±0.74	   ±0.74	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   26.18	   7.68	   	  	   	  	   	  	  
	  	   24.68	   7.7	   	  	   	  	   	  	  
	  	   24.73	   7.71	   	  	   	  	   	  	  
Average	  Cq	   25.20	   7.70	   17.5	   0.01	   1.01	  
SD	   ±0.85	   ±0.02	   ±0.87	   ±0.87	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   26.39	   8.1	   	  	   	  	   	  	  
	  	   25.6	   8.25	   	  	   	  	   	  	  
	  	   26.12	   8.17	   	  	   	  	   	  	  
Average	  Cq	   26.04	   8.17	   17.86	   0.37	   1.30	  
SD	   ±0.40	   ±0.04	   ±0.44	   ±0.44	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   26.12	   8.36	   	  	   	  	   	  	  
	  	   26.04	   8.35	   	  	   	  	   	  	  
	  	   26.48	   8.35	   	  	   	  	   	  	  
Average	  Cq	   26.21	   8.35	   17.86	   0.37	   1.29	  
SD	   ±0.23	   ±0.01	   ±0.24	   ±0.24	   	  	  
 
Table 3.1:The Cq values from experiment one and calculation of the expression levels of 
CRFR1α  mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cqvalues are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  N= 3 of three different experiments, in which each control, UCNI, SNAP and 
SNAP+UCNI treatment was performed in triplicates.	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Cq	    ΔCq	  
 ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   24.91	   9.27	   	  	   	  	   	  	  
	  	   26.94	   9.32	   	  	   	  	   	  	  
	  	   25.42	   9.3	   	  	   	  	   	  	  
Average	  Cq	   25.76	   9.30	   16.46	   0	   1	  
SD	   ±1.06	   ±0.03	   ±1.08	   ±1.08	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   25.36	   9.13	   	  	   	  	   	  	  
	  	   25.76	   9.09	   	  	   	  	   	  	  
	  	   25.32	   9.27	   	  	   	  	   	  	  
Average	  Cq	   25.48	   9.16	   16.32	   -­‐0.14	   1.10	  
SD	   ±0.24	   ±0.09	   ±0.34	   ±0.34	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   27.66	   9.71	   	  	   	  	   	  	  
	  	   27.47	   9.8	   	  	   	  	   	  	  
	  	   27.39	   9.74	   	  	   	  	   	  	  
Average	  Cq	   27.51	   9.75	   17.76	   1.30	   -­‐2.46	  
SD	   ±0.14	   ±0.05	   ±0.18	   ±0.18	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   27.22	   9.78	   	  	   	  	   	  	  
	  	   27.93	   9.76	   	  	   	  	   	  	  
	  	   28.17	   9.81	   	  	   	  	   	  	  
Average	  Cq	   27.77	   9.78	   17.99	   1.53	   -­‐2.89	  
SD	   ±0.49	   ±0.03	   ±0.52	   ±0.52	   	  	  
 
Table 3.2:The Cq values from experiment two and calculation of the expression levels of 
CRFR1α  mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cq values are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  N= 3 of three different experiments, in which each control, UCNI, SNAP and 
SNAP+UCNI treatment was performed in triplicates.	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Cq	     ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   24.18	   8.25	   	  	   	  	   	  	  
	  	   25.59	   7.13	   	  	   	  	   	  	  
	  	   25.42	   7.53	   	  	   	  	   	  	  
Average	  Cq	   25.06	   7.64	   17.43	   0	   1	  
SD	   ±0.77	   ±0.57	   ±1.34	   ±1.34	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   26.71	   7.62	   	  	   	  	   	  	  
	  	   25.62	   7.09	   	  	   	  	   	  	  
	  	   25.54	   7.38	   	  	   	  	   	  	  
Average	  Cq	   25.96	   7.36	   18.59	   1.17	   -­‐2.24	  
SD	   ±0.65	   ±0.27	   ±0.92	   ±0.92	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   25.47	   7.99	   	  	   	  	   	  	  
	  	   25.94	   8.25	   	  	   	  	   	  	  
	  	   25.66	   8.3	   	  	   	  	   	  	  
Average	  Cq	   25.69	   8.18	   17.51	   0.08	   -­‐1.06	  
SD	   ±0.24	   ±0.17	   ±0.40	   ±0.4	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   24.96	   8.63	   	  	   	  	   	  	  
	  	   25.35	   8.77	   	  	   	  	   	  	  
	  	   25.22	   8.13	   	  	   	  	   	  	  
Average	  Cq	   25.18	   8.51	   16.67	   -­‐0.76	   1.69	  
SD	   ±0.20	   ±0.34	   ±0.54	   ±0.54	   	  	  
 
Table 3.3: The Cq values from experiment three and calculation of the expression levels of 
CRFR1α  mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cq values are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  N= 3 of three different experiments, in which each control, UCNI, SNAP and 
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Table 3.4: Calculation of the expression levels of CRFR1α  mRNA following stimulation of 
chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours using the Comparative Cq method 
for relative quantification.  The Cq values represented as mean±SEM of three different experiments 
performed and 2-ΔΔCq presented as fold change with range: E.g. -1.28 fold decrease with range –
(0.9-1.8). GOI= Gene of interest, ΔCq = delta Cq, ΔΔCq= Delta Delta Cq.  N= 3 of three different 
experiments, in which each control, UCNI, SNAP and SNAP+UCNI treatment was performed in 
triplicates. 
 
Analysis of the qPCR experiments for the relative expression of the 
CRFR1α receptor following treatment was determined using the comparative Cq 
method and the calculations for such are displayed in tables 3.1-3.4.   The data 
shown in tables 3.1-3.3 are the Cq values obtained for the target gene (CRFR1α) 
and the reference gene (GAPDH) from three independent experiments.  The data 
in table 3.4 is an average of the three experiments performed.  
The student unpaired T-test was used for statistical analysis of the qPCR data 
shown in table 3.4, for the relative expression of CRFR1α mRNA following 
treatment of chondrocytes with UCNI, SNAP and SNAP+UCNI.  The statistical 
analysis of the ΔCq values as described in section 3.5 suggested that 
chondrocytes subjected to treatment with UCNI, SNAP and SNAP+UCNI showed 



















	   	   	   	   	   	  
Control	   25.31	  ±	  0.26	   8.19	  ±	  0.29	   17.12	  ±	  0.56	   0	  ±	  0.56	   1	  (0.7-­‐1.5)	  
UCNI	   25.54	  ±	  0.21	   8.07	  ±	  0.28	   17.47	  ±	  0.49	   0.35	  ±	  0.49	   -­‐1.28	  (0.9-­‐1.8)	  
SNAP	   26.41	  ±	  0.29	   8.70	  ±	  0.26	   17.71	  ±	  0.55	   0.59	  ±	  0.55	   -­‐1.50	  (1.0-­‐2.2)	  
SNAP+UCNI	   26.39	  ±	  0.39	   8.88	  ±	  0.23	   17.51	  ±	  0.62	   0.39	  ±	  0.62	   -­‐1.31	  (0.9-­‐2.0)	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3.5.2 Determination	  of	  the	  relative	  expression	  of	  CRFR2β  in	  C-­‐
20/A4	  cells	  following	  stimulation	  with	  UCNI	  and	  SNAP	  
 
Analysis of the qPCR experiments for the relative expression of the 
CRFR2β receptor (another potential UCNI receptor for mediating UCNI 
chondroprotection) following treatment was determined.  Similarly, employing the 
equations described in section 3.5, the calculations for determining the fold 
changes in gene expression levels for CRFR2β are detailed in tables 3.5-3.8.  
Treatments	  
(a)	  CRFR2β   
Cq	  
(b)	  GAPDH	  
Cq	   ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   25.04	   7.46	   	  	   	  	   	  	  
	  	   24.9	   7.67	   	  	   	  	   	  	  
	  	   25.05	   7.75	   	  	   	  	   	  	  
Average	  Cq	   25.00	   7.63	   17.37	   0	   1	  
SD	   ±0.08	   ±0.15	   ±0.23	   ±0.23	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   25.25	   7.68	   	  	   	  	   	  	  
	  	   25.37	   7.7	   	  	   	  	   	  	  
	  	   24.76	   7.71	   	  	   	  	   	  	  
Average	  Cq	   25.13	   7.70	   17.43	   0.06	   -­‐1.04	  
SD	   ±0.32	   ±0.02	   ±0.34	   ±0.34	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   25.7	   8.1	   	  	   	  	   	  	  
	  	   26.35	   8.25	   	  	   	  	   	  	  
	  	   25.99	   8.17	   	  	   	  	   	  	  
Average	  Cq	   26.01	   8.17	   17.84	   0.47	   -­‐1.39	  
SD	   ±0.33	   ±0.08	   ±0.40	   ±0.4	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   26.47	   8.36	   	  	   	  	   	  	  
	  	   25.28	   8.35	   	  	   	  	   	  	  
	  	   26.84	   8.35	   	  	   	  	   	  	  
Average	  Cq	   26.20	   8.35	   17.84	   0.47	   -­‐1.39	  
SD	   ±0.82	   ±0.01	   ±0.82	   ±0.82	   	  	  
	   	   	   	   	   	  Table 3.5: The Cq values from experiment one and calculation of the expression levels of 
CRFR2β mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cq values are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates.	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gene	  Cq	   ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   24.05	   9.27	   	  	   	  	   	  	  
	  	   24.64	   9.32	   	  	   	  	   	  	  
	  	   25.25	   9.3	   	  	   	  	   	  	  
Average	  Cq	   24.65	   9.30	   15.35	   0	   1	  
SD	   ±0.60	   ±0.03	   ±0.63	   ±0.63	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   24.15	   9.13	   	  	   	  	   	  	  
	  	   24.83	   9.09	   	  	   	  	   	  	  
	  	   25.51	   9.27	   	  	   	  	   	  	  
Average	  Cq	   24.83	   9.16	   15.67	   0.32	   -­‐1.25	  
SD	   ±0.68	   ±0.09	   ±0.77	   ±0.77	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   25.22	   9.71	   	  	   	  	   	  	  
	  	   25.5	   9.8	   	  	   	  	   	  	  
	  	   25.93	   9.74	   	  	   	  	   	  	  
Average	  Cq	   25.55	   9.75	   15.8	   0.45	   -­‐1.37	  
SD	   ±0.36	   ±0.05	   ±0.40	   ±0.4	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   25.62	   9.78	   	  	   	  	   	  	  
	  	   25.08	   9.76	   	  	   	  	   	  	  
	  	   26.8	   9.81	   	  	   	  	   	  	  
Average	  Cq	   25.83	   9.78	   16.05	   0.7	   -­‐1.62	  
SD	   ±0.88	   ±0.03	   ±0.90	   ±0.9	   	  	  
	  
Table 3.6: The Cq values from experiment two and calculation of the expression levels of 
CRFR2β mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cq values are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates.	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Treatments	  




gene	  Cq	   ΔCq	  
 ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   24.53	   8.25	   	  	   	  	   	  	  
	  	   25.4	   7.13	   	  	   	  	   	  	  
	  	   24.81	   7.53	   	  	   	  	   	  	  
Average	  Cq	   24.91	   7.64	   17.28	   0	   1	  
SD	   ±0.44	   ±0.57	   ±1.01	   ±1.01	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   25.32	   7.62	   	  	   	  	   	  	  
	  	   25.26	   7.09	   	  	   	  	   	  	  
	  	   25.12	   7.38	   	  	   	  	   	  	  
Average	  Cq	   25.23	   7.36	   17.87	   0.59	   -­‐1.51	  
SD	   ±0.10	   ±0.27	   ±0.37	   ±0.37	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   26.17	   7.99	   	  	   	  	   	  	  
	  	   25.49	   8.25	   	  	   	  	   	  	  
	  	   27	   8.3	   	  	   	  	   	  	  
Average	  Cq	   26.22	   8.18	   18.04	   0.76	   -­‐1.70	  
SD	   ±0.76	   ±0.17	   ±0.92	   ±0.92	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   26.62	   8.63	   	  	   	  	   	  	  
	  	   25.85	   8.77	   	  	   	  	   	  	  
	  	   27.17	   8.13	   	  	   	  	   	  	  
Average	  Cq	   26.55	   8.51	   18.04	   0.76	   -­‐1.69	  
SD	   ±0.66	   ±0.34	   ±1.00	   ±1.00	   	  	  
 
Table 3.7: The Cq values from experiment three and calculation of the expression levels of 
CRFR2β mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 
hours using the Comparative Cq method for relative quantification.  The Cq values are represented 
as mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= 
Delta Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates.	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control	   24.85	  ±	  0.14	   8.19	  ±	  0.29	   16.66	  ±	  0.43	   0	  ±	  0.43	   1	  (0.7-­‐1.3)	  
UCNI	   25.06	  ±	  0.14	   8.07	  ±	  0.28	   16.99	  ±	  0.42	   0.33	  ±	  0.42	   -­‐1.26	  (0.9-­‐1.7)	  
SNAP	   25.93	  ±	  0.18	   8.70	  ±	  0.26	   17.23	  ±	  0.44	   0.57±	  0.44	   -­‐1.48	  (1.1-­‐2.0)	  
SNAP+UCNI	   26.19	  ±	  0.25	   8.88	  ±	  0.23	   17.31	  ±0.48	   0.65	  ±0.48	   -­‐1.57	  (1.1-­‐2.2)	  
 
 
Table 3.8: Calculation of the expression levels of CRFR2β mRNA following stimulation of 
chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours using the Comparative Cq method 
for relative quantification.  The Cq values represented as mean± SEM and 2-ΔΔCq presented as fold 
change with range.  GOI= Gene of interest, ΔCq = delta Cq, ΔΔCq= Delta Delta Cq.  N=3 of the 
three different experiments performed of which raw data is shown in tables 3.5-3.7. 
 
The relative quantification of CRFR2β mRNA for each experiment indicated in the 
calculation in table 3.5-3.7 demonstrates the fold change in CRFR2β  due to 
treatment of cells with UCNI, SNAP and SNAP+UCNI relative to the calibrator.  In 
addition, the average fold change for CRFR2β mRNA expression from the three 
independent experiments (shown in tables 3.5-3.7) are summarised in table 3.8.   
It can be deduced from all of the above data that stimulation of cells with UCNI, 
SNAP, and SNAP+UCNI resulted in no statistical significant change (p>0.05) in 
CRFR2β mRNA expression when compared to the calibrator.  Statistical 
significance of the relative expression of CRFR2β mRNA expression was 
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3.5.3 Determination	  of	  the	  relative	  expression	  of	  Kir6.1	  in	  C-­‐20/A4	  
cells	  following	  UCNI	  and	  SNAP	  treatment	  
	  
The Kir6.1 was considered a potential target for UCNI inhibition of apoptosis in 
chondrocytes based on the work by Lawrence et al, which showed that UCNI 
mediated its cardioprotective effects partially via inducing expression of the KIr6.1 
subunit localised to the mtioKATP channel in the cardiac myocytes (Lawrence et al, 
2004).  The calculations for determining the changes in mRNA expression levels 





gene	  Cq	   ΔCq	  
 ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   28.13	   7.46	   	  	   	  	   	  	  
	  	   27.65	   7.67	   	  	   	  	   	  	  
	  	   28.51	   7.75	   	  	   	  	   	  	  
Average	  Cq	   28.10	   7.63	   20.47	   0	   1	  
SD	   ±0.43	   ±0.15	   ±0.58	   ±0.58	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   28.23	   7.68	   	  	   	  	   	  	  
	  	   28.81	   7.7	   	  	   	  	   	  	  
	  	   29	   7.71	   	  	   	  	   	  	  
Average	  Cq	   28.68	   7.70	   20.98	   0.51	   -­‐1.43	  
SD	   ±0.40	   ±0.02	   ±0.42	   ±0.42	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   26.89	   8.1	   	  	   	  	   	  	  
	  	   27.32	   8.25	   	  	   	  	   	  	  
	  	   26.3	   8.17	   	  	   	  	   	  	  
Average	  Cq	   26.84	   8.17	   18.66	   -­‐1.81	   3.50	  
SD	   ±0.51	   ±0.08	   ±0.59	   ±0.59	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   26.08	   8.36	   	  	   	  	   	  	  
	  	   26.12	   8.35	   	  	   	  	   	  	  
	  	   26.35	   8.35	   	  	   	  	   	  	  
Average	  Cq	   26.18	   8.35	   17.83	   -­‐2.64	   6.23	  
SD	   ±0.15	   ±0.01	   ±0.15	   ±0.15	   	  	  
 
Table 3.9:The Cq values from experiment one and calculation of the expression levels of Kir6.1 
mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours using 
the Comparative Cq method for relative quantification.  The Cq values are represented as 
mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= Delta 
Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates. 
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gene	  Cq	   ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   28.5	   9.27	   	  	   	  	   	  	  
	  	   27.77	   9.32	   	  	   	  	   	  	  
	  	   29.01	   9.3	   	  	   	  	   	  	  
Average	  Cq	   28.43	   9.30	   19.13	   0	   1	  
SD	   ±0.62	   ±0.03	   ±0.65	   ±0.65	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
UCNI	   26.91	   9.13	   	  	   	  	   	  	  
	  	   28.43	   9.09	   	  	   	  	   	  	  
	  	   28.76	   9.27	   	  	   	  	   	  	  
Average	  Cq	   28.03	   9.16	   18.87	   -­‐0.26	   1.20	  
SD	   ±0.99	   ±0.09	   ±1.08	   ±1.08	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   28.71	   9.71	   	  	   	  	   	  	  
	  	   28.02	   9.8	   	  	   	  	   	  	  
	  	   28.84	   9.74	   	  	   	  	   	  	  
Average	  Cq	   28.52	   9.75	   18.77	   -­‐0.36	   1.28	  
SD	   ±0.44	   ±0.05	   ±0.49	   ±0.49	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   28.07	   9.78	   	  	   	  	   	  	  
	  	   29.82	   9.76	   	  	   	  	   	  	  
	  	   24.06	   9.81	   	  	   	  	   	  	  
Average	  Cq	   27.32	   9.78	   17.53	   -­‐1.60	   3.02	  
SD	   ±2.95	   ±0.03	   ±2.98	   ±2.98	   	  	  
	  
Table 3.10:The Cq values from experiment two and calculation of the expression levels of Kir6.1 
mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours using 
the Comparative Cq method for relative quantification.  The Cq values are represented as 
mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= Delta 
Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates.	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gene	  Cq	   ΔCq	  
ΔΔCq	  =	  
ΔCq(a)-­‐ΔCq(b)	   2-­‐ΔΔCq	  
	  	   	  	   	  	   	  	   	  	   	  	  
control	   30.32	   8.25	   	  	   	  	   	  	  
	  	   28.78	   7.13	   	  	   	  	   	  	  
	  	   30.14	   7.53	   	  	   	  	   	  	  
Average	  Cq	   29.75	   7.64	   22.11	   0	   1	  
SD	   ±0.84	   ±0.57	   ±1.41	   ±1.41	   	  	  
	  	   	  	   7.62	   	  	   	  	   	  	  
UCNI	   30.78	   7.09	   	  	   	  	   	  	  
	  	   30.24	   7.38	   	  	   	  	   	  	  
	  	   30.44	   	  	   	  	   	  	   	  	  
Average	  Cq	   30.49	   7.36	   23.12	   1.01	   -­‐2.02	  
SD	   ±0.27	   ±0.27	   ±0.54	   ±0.54	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP	   30.53	   7.99	   	  	   	  	   	  	  
	  	   31.23	   8.25	   	  	   	  	   	  	  
	  	   31.76	   8.3	   	  	   	  	   	  	  
Average	  Cq	   31.17	   8.18	   22.99	   0.88	   -­‐1.84	  
SD	   ±0.62	   ±0.17	   ±0.78	   ±0.78	   	  	  
	  	   	  	   	  	   	  	   	  	   	  	  
SNAP+UCNI	   30.34	   8.63	   	  	   	  	   	  	  
	  	   30.84	   8.77	   	  	   	  	   	  	  
	  	   32	   8.13	   	  	   	  	   	  	  
Average	  Cq	   31.06	   8.51	   22.55	   0.44	   -­‐1.36	  
SD	   ±0.85	   ±0.34	   ±1.19	   ±1.19	   	  	  
 
Table 3.11:The Cq values from experiment three and calculation of the expression levels of 
Kir6.1 mRNA following stimulation of chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours 
using the Comparative Cq method for relative quantification.  The Cq values are represented as 
mean±standard deviation (SD) and 2-ΔΔCq presented as fold change.  ΔCq = delta Cq, ΔΔCq= Delta 
Delta Cq.  Each control, UCNI, SNAP and SNAP+UCNI treatment was performed in triplicates. 
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control	   28.76	  ±0.31	   8.19	  ±	  0.29	   20.57	  ±	  0.61	   0	  ±	  0.61	   1	  (0.7-­‐1.5)	  
UCNI	   29.07	  ±	  0.41	   8.07	  ±	  0.28	   21.00	  ±	  0.69	   0.43	  ±	  0.69	   -­‐1.35	  (0.8-­‐2.2)	  
SNAP	   28.29	  ±0.87	   8.70	  ±	  0.26	   19.59	  ±1.13	   -­‐0.98	  ±1.13	   1.97	  (1.1-­‐4.3)	  
SNAP+UCNI	   28.19	  ±	  0.90	   8.88	  ±	  0.23	   19.31	  ±	  1.13	   -­‐1.26±	  1.13	   2.39	  (1.1-­‐5.2)	  
 
 
Table 3.12: Calculation of the expression levels of Kir6.1 mRNA following stimulation of 
chondrocytes with: UCNI, SNAP and SNAP+UCNI for 6 hours using the Comparative Cq method for 
relative quantification.  The Cq values represented as mean± SEM and 2-ΔΔCq presented as fold 
change with range.  GOI= Gene of interest, ΔCq = delta Cq, ΔΔCq= Delta Delta Cq.  N= 3 of three 
different experiments, in which each control, UCNI, SNAP and SNAP+UCNI treatment was 
performed in triplicates. 
 
 
The data in tables 3.9-3.11 which shows the Cq values and fold change 
calculation for three independent experiments indicates a varying in Kir6.1 mRNA 
expression following stimulation of the C-20/A4 chondrocytes with UCNI, SNAP 
and SNAP+UCNI.  An average fold change calculation for these three experiments 
in shown in table 3.12.  The qPCR analysis in the latter table indicates that 
following treatment of chondrocytes with UCNI demonstrated a 1.35 fold decrease 
in Kir6.1 mRNA expression.  Treatment with SNAP resulted in Kir6.1 being 
upregulated 1.97 fold; indicating that the Kir6.1 gene is 1.97x more abundant in 
SNAP treated C-20/A4 cells than untreated cells.  In addition, a fold increase of 
2.39 fold was also observed following concurrent treatment of the cells with both 
SNAP+UCNI.  Statistical analysis of the calculated ΔCq values in table 3.12 implies 
that none of the observed changes in Kir6.1 mRNA expression appears to be 
significant at the level p<0.05 according to unpaired T-test. 
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3.6 The	  effect	  of	  Diazoxide	  and	  SNAP	  treatment	  on	  C-­‐20/A4	  cells	  
 
In relation to the findings from earlier work by Lawrence et al, in 2004, and the 
relative quantification studies in table 3.12 of section 3.5.3 which demonstrated 
that stimulation of C-20/A4 cells with SNAP and SNAP+UCNI resulted in increased 
expression levels of Kir6.1 (although this change was not statistically significant, 
p>0.05) , experiments were performed to assess involvement of this KATP channel 
in preventing apoptosis, emulating a proposed mechanism of action for UCNI. 
In this section, cell death following treatment of chondrocytes with SNAP, and a 
pharmacological KATP channel opening agent, Diazoxide, was assessed by flow 
cytometry (apoptosis) and LDH release (necrosis).  Chondrocytes were cultured 
for in vitro stimulation studies as detailed in section 2.2.2.  Following treatment, 
flow cytometry analysis was performed according to the protocol in section 2.2.3.1 
for the detection of apoptosis.  LDH release for the assessment of necrosis was 
conducted according the protocol of section 2.2.3.2.   
 
The Effect of SNAP,UCNI and Diazoxide treatments on C-20/A4 cells apoptosis levels



































Figure 3.12: The effects of SNAP, UCNI and Diazoxide (Dz) treatment on cell death by 
apoptosis in C-20/A4 chondrocytes. 
Data values are presented as means (± SEM), n=3, triplicates of a minimum of three different 
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The flow cytometry data of figure 3.18 demonstrates results for treatment of 
chondrocytes with Diazoxide and SNAP singly and in combination.  As previously 
observed, SNAP alone caused a significant increase in apoptotic cell death 
(p<0.05).   
These preliminary data also demonstrate that Diazoxide appears to ameliorate 
SNAP induced apoptotic cell death, similar to UCNI, when cells are stimulated 
concurrently with SNAP+Diazoxide.  However, these preliminary experiments 
need to be repeated to establish whether the reduction in apoptotic cell death 
observed following treatment of C-20/A4 chondrocytes with SNAP+Diazoxide is 
statistically significant; but these initial findings are encouraging.  
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4 Discussion	  
4.1 Introduction:	  
The principal aim of this thesis was to investigate the potential mechanism(s) of 
UCNI mediated protection in chondrocytes against SNAP/NO induced apoptosis.  
This aim was established following previous research by Intekhab-Alam, in 2006, 
which reported that (1) UCNI is a cytoprotective agent against apoptosis in C-
20/A4 chondrocytes stimulated with the pro-apoptotic stimuli: TNFα, IL-1β and 
SNAP (a NO donor) and (2) UCNI exerted greater protection against apoptosis 
induced SNAP/NO than that induced by the death receptor ligands (TNFα and IL-
1β) (Intekhab-Alam, 2006).   
This 40 amino acid peptide, UCNI, has been shown to exert anti-apoptotic effects 
not only in C-20/A4 chondrocytes but also in other cell types including cardiac 
myocytes, where it has been reported to potentially mediate these properties via 
CRF receptors (CRFR2β) and KATP channels (particularly the mitoKATP channel) 
(Brar et al, 1999; Lawrence et al, 2002; Brar et al, 2000). Given the lack of data 
with regards to the targets for UCNI mediated protection in chondrocytes, it was 
therefore necessary to elucidate which, if any, of these potential signalling 
pathways exist in the C-20/A4 cells and whether they play a role in UCNI mediated 
chondroprotection.  Towards this end, a number of experiments have been 
conducted to ascertain the potential contribution of CRFR’s and ion channels to 
this observed chondroprotection following SNAP/NO stimulation. 
 
4.2 	  The	  effects	  of	  exogenous	  UCNI	  in	  C-­‐20/A4	  chondrocytes:	  
The protective effects of exogenous UCNI against NO induced cell death, initially 
demonstrated by Intekhab-Alam 2006,were revisited.  These initial studies used 
fluorescence microscopy based Annexin V-FITC/PI and TUNEL assays to quantify 
chondrocyte apoptosis which, whilst valid, can be very subjective and are highly 
dependent on the interpretation, and, indeed, experience of the operator.  Herein, 
apoptotic chondrocyte death andthe cytoprotective effects of UCNI were assessed 
by a flow cytometry method following labelling of untreated and stimulated cells 
with Annexin- V-FITC and Propidium Iodide (PI) fluorochromes as shown figure 
3.1.   
Chapter	  4:	  Discussion	  
	  
	   111	  
Many studies investigating aspects of chondrocyte structure and physiology such 
as chondrocyte viability, proliferation and cell cycle phenotype have employed flow 
cytometry as method of analysis (Bell et al, 1988; Lopez-Armada et al, 2006; 
Takacs-Buia et al, 2008; Wang et al, 2001; Matsuki et al, 2008; Thuong-Guyot et 
al, 1994)as it is regarded as a multi-parametric and constant method for analysis 
of cells in culture which is less subjective.  A variety of parameters (non-
fluorescent and fluorescent) of single cells can be assayed rapidly and analysed 
by dedicated computer software generating histograms relating morphology and 
fluorescence of the cells as shown in figure 3.1 (Loo and Rillema, 1998; Wang et 
al, 2001).  Flow cytometry analysis is typically performed on cell counts of 10,000 
or more per sample in contrast to fluorescence microscopy based techniques 
where Annexin V/TUNEL positivity is determined by microscopy, typically based 
on counting 100 cells in 3 different, randomly selected, fields of view.  Thus flow 
cytometry represents a much less subjective technique based on a much larger 
sample of the cell population.  Other methods for apoptosis detection include: 
agarose gel electrophoresis and DNA fragmentation ELISA assays, caspase 
cleavage and activity assays and electron microscopy (Kim and Blanco, 2007; 
Kuhn et al, 2004; Schultz and Harrington, 2003).  
In the assay developed here, assessment of cell death was performed by 
individual interrogation of 10,000 cells per sample with a 488 and 635nm laser.  
The flow cytometer then characterises and enumerates the counted C-20/A4 cells 
based on cell size, internal complexity and fluorescence intensity which, when 
analysed by dedicated software, allows the quantification of apoptosis dividing the 
cells into four distinct cell populations (i.e. viable, early apoptotic, late apoptosis 
and necrotic).  The information regarding the cell size and internal structure of the 
C-20/A4 cells is generated from the non-fluorescent parameters: the Forward 
Scatter (FSC) and Side Scatter (SSC) respectively, whilst relative fluorescence 
intensity is produced from fluorescent labelled cells undergoing measurable cell 
death.  Diagrammatic representations of FSC/SSC and fluorescence (FL1/FL2) 
histograms are shown in section 3.1.1, which documents representative data 
generated in this assay. 
 
Chapter	  4:	  Discussion	  
	  
	   112	  
The flow cytometer generates FSC (i.e. cell size) and SSC (internal complexity/ 
granularity) data from the light scattering channels.  The forward scatter is 
diffracted light which scattered in a forward direction and thus correlates with the 
relative cell size.  Conversely, light which is detected at right angles to the laser 
beam is refracted and reflected light (SSC) and so correlates with granularity and 
internal structures which reflect the light.  Accordingly, these two parameters 
provide vital information about the state of cells as analysis of scattered light can 
allow differentiation between cells undergoing measurable apoptosis from the 
viable cells.  For instance, in the flow cytometric histogram of figure 3.1 column A, 
it is evident that the apoptotic cells have a decreased FSC and increased SSC (for 
e.g. histogram 3A: SNAP treatment).  The observed decrease in FSC occurs as a 
result of cell shrinkage; a characteristic morphological feature of apoptotic cells 
(Takacs-Buia et al, 2008; Kim and Blanco, 2007), which correlates with a decrease 
in the intensity of the diffracted light and thus a low FSC.  Furthermore, an 
increase in SSC results from an increase in refracted and reflected light, which is 
scattered at a right angle to the laser beam by the condensed chromatin and 
fragmented nuclei of apoptotic cells (Takacs-Buia et al, 2008). 
In addition, FSC and SSC, cell death was also determined by Annexin-V-FITC/PI 
labelling, detected by the fluorescence channels within the flow cytometer.  This 
was achieved as these fluorochromes (FITC and PI) absorb the light energy from 
the laser (at their excitation wavelenght) and emit this energy at a longer 
wavelength (the emission wavelength).  On the fluorescence histogram (figure 3.1 
column B), the data represented on the logarithmic scale demonstrates the 
emitted fluorescence intensity, which correlates with the binding sites of the 
fluorochromes on the cells (Takacs-Buia et al, 2008).  Therefore, observing the 
fluorescence histograms of figure 3 .1, it is evident that the cells located further 
along the abscissa (towards 104) have more binding of Annexin-V-FITC, 
suggesting that a greater proportion of phosphotidylserine (PS) phospholipids are 
externalised on the plasma membrane of these C-20/A4 cells undergoing 
measurable apoptosis.  PI fluorescence is conversely recorded on the ordinate 
giving a distinct location for an individual cell depending on the relative binding of 
the two fluorochromes.   
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Although flow cytometry is a more objective technique than fluorescence 
microscopy, the possibility of false positives results cannot be ruled out.  User 
defined compensation is applied to minimise fluorochrome “bleed over” between 
channels so that the existence of false positives are reduced; hence the term 
“FITC log Comp” and PE-Texas Red Log Comp” when compensation is applied to 
data obtained from the fluorescence histograms. 
In relation to the cell death studies documented in section 3.1.2, the detection of 
apoptosis as determined by flow cytometry illustrates in figure 3.2 that UCNI 
significantly reduces apoptotic cell death induced by the SNAP (p<0.05), a NO 
donor.  In addition, section 3.2.1 demonstrates the exndogenous expression of 
UCNI mRNA.  These findings agree with observations by Intekhab-Alam, 2006 
which demonstrated that exogenous UCNI exerted protection against SNAP 
induced apoptosis.  Furthermore Intekhab-Alam (2006) also demonstrated by 
qPCR that treatment of C-20/A4 cells with SNAP/NO resulted in a significant 
increase in UCNI mRNA expression compared to the control (p>0.01).  Therefore 
this demonstrates that UCNI is a cytoprotective agent in C-20/A4 chondrocytes as 
it reduces SNAP/NO induced apoptosis in these cells.  This observed protection 
against apoptotic cell death may occur as addition of exogenous UCNI would 
increase the amount of UCNI peptide, which was present in the medium to confer 
protection possibly through a CRFR dependent (or non-dependent) mechanism.  
Similarly, an increase in UCNI mRNA expression in cardiac myocytes has also 
been observed in following thermal injury and exogenous UCNI was protective 
against hypoxia (Okosi et al, 1998) and similar results were obtained for primary 
cultures of cardiac myocytes following cell death induced by ischemia (Brar et al, 
1999) where a cardioprotective role of UCNI was implicated.  Moreover, the result 
that apoptosis and not necrosis is the predominant form of cell death occurring in 
C-20/A4 cells is also in broad agreement with work by Intekhab-Alam, 2006 and 
Pesta, 2007.  
Additionally, the data in figure 3.3 demonstrates that the observed apoptosis in the 
C-20/A4 chondrcoytes is a result of SNAP and not ethanol the vehicle for SNAP.  
Other in vitro studies have also documented chondrocyte death induction by NO 
donors (Blanco et al, 1995; Notoya et al, 2000; Maneiro et al, 2005; Kim et al, 
2005).  Furthermore, NO is considered a catabolic factor which induces apoptosis 
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and cartilage degeneration in OA (Abramson, 2008; Blanco et al, 1998; Martel-
Pelletier et al, 2008; Goggs et al, 2003).  Work by Hashimoto et al, in 1998, 
showed that chondrocyte apoptosis and NO production correlates with the severity 
of matrix degradation in OA cartilage (Hashimoto et al, 1998).  Consequently, the 
implication of NO production with regards to OA pathogenesis is that NO 
generation may result in chondrocyte apoptosis which is related to cartilage 
degeneration (Lotz et al, 1999).  In addition, previous studies by Kim et al in 2000, 
in which they assessed the occurrence of apoptosis in human osteoarthritic 
cartilage demonstrated that chondrocyte apoptosis is a predominant feature in 
Osteoarthritis (OA) and OA lesional cartilage compared to normal and non-OA 
lesional cartilage respectively (Kim et al, 2000). 
Previous studies have shown that SNAP induces apoptosis via the intrinsic 
mitochondrial pathway (Figueroa et al, 2006; Tamatani et al, 1998). Moreover, 
Intekhab-Alam (2006) has also shown activation of caspase-9 and -3, but not 
caspase-8 in C-20/A4 chondrocytes.  SNAP induces apoptosis via promoting DNA 
damage with consequent elevation of p53 levels, activation of caspase 9 and 3, 
inhibition of activity of the Mitochondrial respiratory transport chain (in particular 
complex IV), breakdown of the mitochondrial membrane potential, up-regulation of 
the pro-apoptotic Bcl-2 protein Bax and mitochondrial pore opening accompanied 
by cytochrome c release (Tamatani et al, 1998; Maneiro et al, 2005; Figueroa et al, 
2006).  Consequently, based on the above evidence, it can be suggested that the 
NO donor, SNAP, may induce apoptosis through the intrinsic (mitochondrial) 
pathway in C-20/A4 chondrocytes. 
Given that UCNI protected the chondrocytes from apoptotic cell death, as 
members of the CRF family predominantly, but not exclusively, mediate their 
autocrine/paracrine effects through CRF receptors (CRFR1 or CRFR2), 
(Grammatopoulos and Chrousos, 2002)the assumption could be made that this 
cytoprotection would be achieved through a CRF receptor mediated pathway.  
Indeed, there is evidence from other cell types to show that UCNI effects are 
blocked following the addition of the receptor antagonist α-helical CRH(9-
41)(Lawrence et al, 2005; Terui et al, 2001; Tu et al, 2007) and preliminary studies 
by Intekhab-Alam (2006) has suggested similar results in the C-20/A4 chondrocyte 
cell line (Intekhab-Alam, 2006).Despite these reports, the data, documented in 
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figure 3.2 showed that treatment of chondrocytes with the CRF receptor antagonist: 
α-helical CRH(9-41) in isolation did not induce chondrocyte apoptosis, neither was 
the protective effect of UCNI significantly inhibited following co-treatment of C-
20/A4 cells with SNAP+UCNI+α-helical CRH(9-41).  A diagrammatic representation 
of the data in figure 3.2 is illustrated in the flow cytometry histograms of figure 3.1, 
which shows a range of flow cytometry analysis of C-20/A4 cells following various 
treatments from a typical experiment.  In the latter figure, it can be observed that 
treatment of C-20/A4 chondrocytes with SNAP resulted in ~32% apoptosis (R7, 
7.82%; R9, 23.95%); and SNAP+UCNI resulted in ~15% (R7, 9.59%; R9, 5.53%) 
apoptotic cell death; whilst treatment of chondrocytes with SNAP+UCNI+α-helical 
CRH(9-41) resulted in ~ 18% (R7, 15%; R9, 3%) apoptosis.  This data shows that 
UCNI reduces apoptosis previously induced by SNAP/NO; however the protective 
effects was not revoked when α-helical CRH(9-41) was added in conjunction with 
SNAP+UCNI.  In addition, treatment of chondrocytes with α-helical CRH(9-41) alone 
did not induce apoptosis ~9% (R7, 4.35%; R9,4.64%) when compared to the 
control (untreated) chondrocytes ~ 8% (R7, 5.03%; R9, 2.54%).  This would 
suggest that the chondroprotective effects of UCNI may be mediated through a 
non-CRFR dependent pathway possibly involving L-type calcium channels as 
previously demonstrated by Tao et al.  The studies by Tao et al, showed that UCNI 
inhibits L-type calcium channels in ventricular cells which may have a 
consequence of preventing calcium overload by reducing intracellular calcium ions; 
a mechanism which has been implicated in the cardioprotective effects of UCNI.  
This inhibition of L-type calcium channels by UCNI was in a CRF receptor 
independent manner, which could occur via binding of UCNI to L-type calcium 
channels inhibiting activation, to reduce the entry of calcium into the cell that 
consequently, reduce calcium overload (Tao and Li, 2005a; Tao et al, 2004; Tao 
and Li, 2005b).  Therefore, the findings in this study that the CRF receptor 
antagonist: α-helical CRH(9-41) , did not induce apoptosis in the C-20/A4 
chondrocytes, based on the findings from Tao et al, would suggests that UCNI 
may be acting through ion channels and consequently, α-helical CRH(9-41) would 
have no effect. 
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Alternatively, it is possible that the α-helical CRH(9-41) has lost its efficacy from long 
term storage.  This discrepancy can be resolved by repeating these inhibition 
experiments with a fresh supply of α-helical CRH(9-41); however due to financial 
and time constraints these experiments could not be repeated. 
4.3 UCNI	  mRNA	  in	  C-­‐20/A4	  chondrocytes	  
Following, the data in section 3.1 which demonstrated the anti-apoptotic effects of 
UCNI in vitro, experiments were also performed to confirm the endogenous 
expression of UCNI mRNA in C-20/A4 chondrocytes under basal conditions and to 
determine the nature of UCNI expression in human chondrocytes.  The UCNI 
forward and reverse primers used for the detection of UCNI mRNA (see table 2. 1) 
were those used by Takahashi et al, 1998 for the detection of UCNI mRNA in the 
human brain.  The sequence for the human UCNI mRNA transcript (GenBank 
accession no. NM_003353), comprises a nucleotide sequence which encodes for 
the UCNI pro-peptide (nucleotide 192-488, (296bp)) which is processed into a 
mature protein (nucleotide 363-482, (119bp)).  The UCNI primer set used in this 
study includes a forward primer located at nucleotide 343-358 and a reverse at 
470-488, generating the 146 bp product observed in figure 3.4.  This RT-PCR 
amplicon therefore confirms that UCNI is synthesised by C-20/A4 chondrocytes as 
a precursor protein, and this pro-peptide is cleaved proteolytically by convertases 
to yield the 40 amino acid mature peptide.  This is in keeping with the proposed 
synthesis of UCNI in other tissues including regions of the human brain (e.g. in the 
hypothalamus, cerebral cortex, pons, thalamus and cerebellum), foetal 
membranes and placenta (Takahashi et al, 1998; Petraglia et al, 1996). 
Given the endogenous mRNA expression of the UCNI pro-peptide and other 
members of the Urocortin family (Stresscopin Related peptide (UCNII) and 
Stresscopin (UCNIII)) which have also been shown to be chondroprotective albeit 
less effectively than UCNI, the results from the studies with α-helical CRH(9-41) are 
even more curious.  The endogenous mRNA expression of members of the CRF 
family of peptides (UCNI, SRP and SCP) in the C-20/A4 chondrocytes suggests a 
possible function of these peptides within chondrocyte.  One such role is their 
cytoprotective effects against apoptosis as shown in figure 3.2 of this thesis and 
also previous work in the C-20/A4 chondrocytes (Pesta, 2007; Intekhab-Alam, 
2006). 
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Consequently, one would expect the expression of CRF receptors to which these 
peptides could bind and mediate their functions.  RT-PCR studies were 
consequently performed for all known functional forms of human CRFR and other 
postulated targets for UCNI.   
4.4 Urocortin	  I	  receptor/target	  expression:	  
In keeping with CRF receptor mediated pathways for UCNI chondroprotection, 
reverse transcriptase-PCR (RT-PCR) studies were performed to identify potential 
CRF receptors and KATP channel subunits based on reports from Brar et al 1999, 
Brar et al 2000 and Lawrence et al 2002; which showed that UCNI protection 
against ischaemia is achieved by activation of such targets in cardiac myocytes.  
In relation to CRF receptor mRNA expression in the C-20/A4 chondrocytes, the 
RT-PCR data in figure 3.6, demonstrates that the C-20/A4 chondrocytes express 
the mRNA for the only functional CRFR1 isoform: CRFR1α (Zmijewski and 
Slominski, 2010) and a CRFR2 receptor which was verified by further RT-PCR 
and sequence analysis as CRFR2β (figure 3.7), the largest of the CRFR2 isoforms 
containing 438 amino acids; although the predominant CRFR2 isoform expressed 
in the human peripheral tissues is CRFR2α (Chen et al, 2005; Dautzenberg and 
Hauger, 2002).  The sequence analysis data for the mRNA expression of CRFR1α 
is detailed in section 3.3.1.1, CRFR2 in section 3.3.1.2 and CRFR2β in section 
3.3.2.1.  Interestingly, the CRFR2β isoform mRNA has also been found in 
osteoclasts (personal communication with Lawrence, 2011). While no PCR 
products were generated for the CRFR2α (239 bp) and CRFR2γ (212 bp) in figure 
3.7 suggesting the mRNA expression of such CRFR2 isoforms in the C-20/A4 
chondrocytes, the RT-PCR for CRFR2γ mRNA expression requires further 
optimization to confirm that only CRFR2β mRNA is expressed.  This is due to the 
presence non-specific PCR products which are visible on the gel image of figure 
3.7 for CRFR2γ.  As previously mentioned, the CRFR1α contains 13 exons 
following alternative splicing of exon 6, which forms the first intracellular loop (see 
figure 1.8) (Grammatopoulos and Chrousos, 2002).  The CRFR2β contains exons 
1,2, 5-15 (see figure 3.8).  Although, the CRFR2 isoforms vary in their N-terminus 
(due to alternative splicing) and tissue distribution, no pharmacological differences 
in ligand binding exists between the CRFR2 variants (Dautzenberg and Hauger, 
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2002), however, in adenylate cyclase activation studies, UCNI and other CRF 
related peptides preferentially activate CRFR2β than either CRFR2α or 
CRFR2γ (Grammatopoulos and Chrousos, 2002; Parkes et al, 2001).  
Consequently, it is thought that the exons 1 and 2 which are absent in both 
CRFR2α or CRFR2γ are important in ligand –receptor recognition and interaction 
(Grammatopoulos and Chrousos, 2002).  To the best of our knowledge, the 
chondrocytes are the only known cell type which express both CRFR1 and CRFR2 
mRNA simultaneously. 
Indeed, the observation in C-20/A4 chondroctyes that UCNI exerted greater 
protection than UCNII and UCNIII against apoptotic cell death (Pesta, 2007) could 
be attributed to the fact that UCNI can bind and activate both CRFR1 and CRFR2 
receptors (Grammatopoulos and Chrousos, 2002), whilst UCNII and UCNIII are 
exclusive ligands for CRFR2 (Grammatopoulos and Chrousos, 2002; Koob and 
Heinrichs, 1999).  Therefore, this would suggest that the chondroprotective effects 
of UCNI may be mediated through both CRFR1 and CRFR2 receptors, whilst 
UCNII and UCNIII employ CRFR2 only.  However, as UCNI has a higher affinity 
for CRFR2 than CRFR1 receptors (Dautzenberg and Hauger, 2002) it can be 
postulated that the CRFR2 receptor may play a greater role in UCNI mediated 
chondroprotection. 
Figure.3.8 and 3.9 illustrates the products obtained from amplification for the pore 
forming Kir6.1 and Kir6.2 subunits of the KATP channels.  The expected product 
sizes of 312 bp and 249 bp respectively and sequence analysis data (sections 
3.4.1.1 and 3.4.2.1, respectively) confirms the mRNA expression of both the Kir6.1 
and Kir6.2 subunits by C-20/A4 chondrocytes.  Although the Kir6.x pore forming 
subunits, 6.1 and 6.2 are ubiquitously expressed in many tissue types, the Kir6.1 
subunit, is showed to be predominantly expressed in the inner mitochondrial 
membrane, thus constituting the mitoKATP channel (Seino and Miki, 2003; Seino, 
1999).  Conversely, knockout mice studies of the KATP channel subunits indicates 
that the Kir6.2 is largely the Kir6.x pore forming subunit composing the 
sacrcolemmal KATP channels (Seino and Miki, 2003; Burke et al, 2008; Tao and Li, 
2005b). In relation to the potential formation of functional KATP channels by the C-
20/A4 chondrocyte cell line, the mRNA expression of the regulatory subunit, the 
Sulfonyl Urea Receptor (SUR) for these Kir channels were also investigated by 
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RT-PCR.  The data in figure 3.10 and sequence analysis data in sections 
3.4.3.1.1and 3.4.3.1.2 shows the initial experiments for SUR1 and SUR2 mRNA 
expression by the C-20/A4 cell line; and indicates that both a SUR1 and SUR2 
regulatory sub unit is expressed by these chondrocytes.   
As previously mentioned, the SUR2 regulatory subunit exists in two predominant 
isoforms resulting from alternative splicing; SUR2A and SUR2B, which share a 97% 
amino acid homology differing only at the C-terminal exon, exon 38 (Yokoshiki et 
al, 1998) which encodes for 42 amino acids.  As a consequence, the SUR2A 
mRNA has a C-terminus exon denoted 38A whilst the SUR2B employs the 
alternatively spliced exon 38B (Shi et al, 2005; Seino and Miki, 2003).  Previous 
RT-PCR studies have indicated that the SUR2A gene found primarily in the heart 
and skeletal muscle whereas the SUR2B variant is ubiquitously expressed (Seino 
and Miki, 2003; Seino, 1999).   
In considering the exon composition of SUR2A and SUR2B, primer pairs were 
designed towards the non-identical exons of these receptors (38A and 38B) and 
further RT-PCR studies performed in an aim to establish the specific isoforms 
being expressed in the C-20/A4 cell line.  The results for these experiments are 
shown in figure 3.11 with sequencing data in sections 3.4.4.1.1 to 3.4.4.1.3.  
Interestingly, the latter figure demonstrates that the chondrocytes expressed 
mRNA for SUR2A and SUR2B, lanes 1-2 and lanes 7-8 respectively.  Further 
alternative splicing of the SUR2A isoforms is known to exist resulting in two such 
transcript variants which have been identified and characterised human tissues 
namely: SUR2A delta 14 (SUR2-A-Δ-14) and SUR2A delta 17 (SUR2A-Δ-17) 
which are generated from deletion of exon 14 and 17 respectively (Shi et al, 2005; 
Chutkow et al, 1999; Aguilar-Bryan et al, 1998).  Subsequent assessment of the 
SUR2A transcript variant expressed by C-20/A4 chondrocytes shown also in figure 
3.11, reveals that the SUR2A-Δ-14 variant (lanes 4-5) exists at the mRNA level.  
Presently, this variant has only been detected in the heart tissue in mouse 
(Chutkow et al, 1999; Burke et al, 2008). 
Additionally, work by Chutkow et al in 1999, also showed that KATP channel re-
constituted with the SUR2A-Δ-14 subunit failed to generate currents in 
electrophysiological studies thus deeming this subunit not functional.  Although, 
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they were unclear as to why this KATP channel was non-functional, these studies 
indicated that exon 14 is essential for the formation of functional KATP channels as 
it is constitutes a segment of amino acid sequence for the cytoplasmic NBD1 
domain of the SUR subunit (see figure 1.11) (Chutkow et al, 1999) which is 
involved in regulating KATP channel activity (Burke et al, 2008) .  Based on these 
findings, it can be confirmed that the functional SUR2 regulatory subunit that is 
expressed at the mRNA by the C20/A4 chondrocytes is SUR2B.  Having 
established that the C-20/A4 chondrocytes express the mRNA for Kir6.1, Kir6.2, 
SUR1, andSUR2B subunits it is suggested that these cells are capable of 
expressing functional KATP channels.  The mRNA expression of Kir6.1 subunit by 
the C-20/A4 human chondrocyte cell line is comparable to research findings which 
demonstrated that the chondrocytes from normal and OA cartilage expressed the 
pore forming subunit, Kir6.1 and functional KATP channels.  The protein for the 
Kir6.1 subunit was identified in all four layers of normal articular cartilage (see 
figure 1.1) but predominantly in the superficial and middle layer, whilst Kir6.1 
expression was altered in OA cartilage where it was only detected in the 
superficial layer (Mobasheri et al, 2007).     
Accordingly, in an attempt to investigate UCNI regulation ofthe CRF receptors and 
KATP channels subunits, C-20/A4 chondrocytes was treated with SNAP and 
exogenous UCNI to determine their effect on the expression levels of some of the 
potential targets (CRFR1α, CRFR2β and Kir6.1) for UCNI.  qPCR studies were 
conducted and the relative quantification of gene expression analysed by the 
Comparative Cq (2-ΔΔCq) method to establish if their expression is regulated by 
UCNI.  The Comparative Cq method quantifies changes in gene expression as a 
relative fold change in expression levels between the treated and calibrator 
sample.  The calibrator is the reference sample to which all other samples are 
compared and is given a value of 1 which denotes “no change”; in most instances 
the untreated sample is the calibrator (Wong and Medrano, 2005); herein the 
control (untreated) samples for CRFR1α, CRFR2β and Kir6.1 were used as the 
calibrator samples.  The calculations for the determination of changes in gene 
expression by this method were detailed in section 3.5.  The statistical approach 
for the analysis of the qPCR data was to subject the ΔCq of the control and treated 
samples to an students unpaired T-test to determine the significant of the changes 
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in gene expression (Yuan et al, 2006), and values where p<0.05 was considered 
statistically significant.  qPCR was conducted using one-step RT-qPCR and a total 
of three independent experiments (the minimum number of repeats required in 
order to scientifically determine the statistical significance of data) was performed 
for each gene (GAPDH, CRFR1α, CRFR2β and Kir6.1).   
Within each experiment conducted the control, UCNI, SNAP and SNAP+UCNI 
samples were performed in triplicates.  The reference gene used as an internal 
control for normalising mRNA for qPCR studies was GAPDH.  This was based on 
previous work by Petsa (2007), which demonstrated that the mRNA expression of 
GAPDH was stable in C-20/A4 chondrocytes and does not vary under 
experimental conditions.  Additionally, studies on the human chondrocyte cell line, 
C-28/I2, an immortalised chondrocyte cell line derived from a mature cartilage 
sample (a 15 yr old donor), recommended GAPDH as suitable reference gene in 
their investigation of chondroprotective agents by qPCR (Toegel et al, 2007).  
However, the qPCR data generated in tables 3.1-3.12 demonstrates that the 
mRNA synthesis of GAPDH varied under experimental conditions.  Though qPCR 
is a very robust technique, it is also very sensitive and minor variations in PCR 
components and cycling conditions can affect the amount of PCR product 
produced.  The quantification of mRNA in this thesis was performed using one-
step RT-qPCR; and although it is suggested that the one-step RT-qPCR method 
may minimise experimental variation since both the reverse transcription and 
qPCR occurs in the same tube, the fact the starting material which is mRNA rather 
than cDNA degrades rapidly, can affect the RNA concentration.  Additionally, the 
structure of the RNA can cause variation in qPCR as RNA secondary structures 
may interfere with the PCR reaction (Wong and Medrano, 2005; Bustin et al, 2009).  
For the reasons mentioned above a two-step qPCR system would have been 
more advantageous for qPCR studies since it is suggested to be more sensitive 
and reproducible than one-step RT-qPCR (Wong and Medrano, 2005). 
Statistical analysis of the qPCR data shows that treatment of C-20/A4 
chondrocytes with UCNI only, SNAP only and SNAP+UCNI all resulted statistically 
significant (p>0.05) change in the mRNA expression of CRFR1α (section 3.5.1), 
CRFR2β (section 3.5.2) when compared to the calibrator (control CRFR1α and 
CRFR2β samples respectively); as determined by the students unpaired T-test.  
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This therefore suggests that UCNI regulation of CRF receptors in the C-20/A4 
chondrocytes does not require de novo mRNA synthesis of the CRF receptors and 
thus the peptide may be utilising the receptors present to mediate its anti-apoptotic 
effects.  Several studies have also documented down-regulation of CRF receptors 
in vivo and in vitro.  Findings by Heldwein et al, demonstrated in vivo that 
administration of the bacterial endotoxin lipopolysaccharide (LPS) resulted in a 
down-regulation of CRFR2β mRNA expression in the rat heart.  This down-
regulation is potentially mediated via NO generation following the release of 
inflammatory cytokines (e.g. TNFα and IL-1β) from LPS exposure (Heldwein et al, 
1997; Finkel et al, 1992).  To test their hypothesis of proinflammatory mediators’ 
regulation of CRFR2β, they conducted studies on the effects of IL-1α, TNFα and 
UCNI administration on CRFR2β mRNA expression in mouse heart.  The results 
demonstrated that these cytokines and UCNI which were administered singly and 
not in combination, down-regulated CRFR2β expression. Based on their findings 
they suggested that cytokines, endotoxins and other inflammatory mediators 
regulate CRFR2 mRNA expression indirectly by enhancing UCNI mRNA 
expression and release in vivo which then down-regulates CRFR2β expression 
(Coste et al, 2001).  Studies by Kageyama group in 2000 and 2005, is also in 
broad agreement as they also demonstrated that UCNI decreased CRFR2β 
expression in the aortic smooth muscle cells (Kageyama et al, 2005; Kageyama et 
al, 2000).  
It may postulated that the down-regulation of CRFR2 mRNA expression will result 
in a reduced amount of ligand binding sites and mediated activity that may serve 
to limit the time course of CRFR2 agonists (such as UCNI) during prolonged stress 
in order to restore tissue homeostasis (Kageyama et al, 2000).  A decrease of 
CRFR1 mRNA expression has also been documented following treatment of rat 
anterior pituitary cells with CRF (Moriyama et al, 2005; Dautzenberg and Hauger, 
2002) and this down-regulation of the CRFR mRNA may occur via internalisation 
and receptor degradation and suppression of further receptor synthesis (via 
inhibition of mRNA translation) (Moriyama et al, 2005; Kageyama et al, 2000; 
Dautzenberg and Hauger, 2002). 
In keeping with UCNI regulation of receptor and KATP channel targets, the qPCR 
data in section 3.5.3 for the relative expression of Kir6.1 mRNA indicates that 
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treatment of C-20/A4 chondrocytes with UCNI, SNAP and SNAP+UCNI resulted in 
no statistically significant (p>0.05) change in Kir6.1 mRNA expression levels when 
compared to the calibrator.  The KATP channels have been previously implicated in 
the cardioprotective mechanisms of UCNI against cell death (Lawrence et al, 2002; 
Lawrence et al, 2004).  However, the observation that stimulation of chondrocytes 
with UCNI resulted in no significant change in Kir6.1mRNA expression is in 
contrast to findings by Lawrence et al in 2002, which showed that cardiac 
myocytes exposed to exogenous UCNI resulted in an increased expression 
ofKir6.1 mRNA and protein (Lawrence et al, 2002).  Lawrence et al, (2002) also 
demonstrated enhanced expression of Kir6.1in the intact heart during 
ischaemia/reperfusion.  Furthermore, they showed that ischaemia/reperfusion 
injury causes damage to the cardiac myocyte mitochondrial membrane and that 
the cardioprotective mechanism of UCNI against ischaemia/reperfusion injury may 
be a result of preventing mitochondrial damage and therefore cell death.  This was 
partly achieved by opening of mitochondrial Kir6.1 KATP channels, inhibition of a 
calcium independent phospholipase A2 and its’ metabolite, 
Lysophosphatidylcholine- LPC, and Protein Kinase C epsilon (PKCε) activation all 
localised to the cardiac myocyte mitochondria (Lawrence et al, 2004; Lawrence et 
al, 2003; Kuizon et al, 2009).  Again, similar to the CRF receptor qPCR findings of 
sections 3.5.1 and 3.5.2, the qPCR data for the relative expression of Kir6.1 
mRNA expression following SNAP and SNAP+UCNI treatment would suggest that 
de novo synthesis of this potential UCNI target is not required for mediating the 
chondroprotective effects against apoptosis.   
Additionally, as previously mentioned, it is believed that the activity of KATP 
channels can be regulated by G-protein coupled receptors directly or via Protein 
Kinase A or C stimulation.  The SUR regulatory subunit is said to be the target for 
direct stimulation of the Gα subunit of the GPCR and thus suggests that the SUR 
regulatory subunits could be directly activated by the binding of UCNI to its’ 
receptor.  Moreover, the Kir6.1 protein is said to contain two PKA phosphorylation 
sites and seven for PKC.  Conversely, the Kir6.2 contains two and five 
phosphorylation sites for PKA and PKC respectively.  Protein Kinase A and C 
dependent phosphorylation sites also exist on the SUR regulatory subunits; for 
instance SUR1 contains four sites for PKA and multiple sites have been identified 
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for PKC in humans (Seino, 1999; Seino and Miki, 2003).  In the heart, as 
mentioned, where UCNI has been shown to activate the epsilon isoform of PKC 
and this is at least partially responsible for its cardioprotective effects, although it is 
unknown whether this particular isoform can phosphorylate Kir6.1 or 
SURs(Lawrence et al, 2004). However, PKC activation by UCNI may be another 
mechanism by which UCNI modulates KATP channel activity in C-20/A4 cells 
possibly by phosphorylation of Kir6.1 or SURs considering that phosphorylation 
sites exits in these KATP channel subunits.  
In an attempt to determine the possible functional involvement of KATP channels in 
UCNI chondroprotection as previously implicated in cardiac myocytes (Lawrence 
et al, 2004), chondrocytes were treated with a pharmacological KATP channel 
opener, Diazoxide.  The pharmacological agent, Diazoxide is a KATP channel 
opener with a high affinity for the mitochondrial KATP channels (Suzuki et al, 2003).  
It is well established that the site of action of KATP channel openers and blockers 
(KCO’s and KCB’s respectively) are via interaction with the SURx regulatory 
subunits of the KATP channels (Shi et al, 2005; Moreau et al, 2005).  Diazoxide has 
been implicated to activate KATP channels via interaction with the transmembrane 
segments TM6-11 of TMD1 and the NBD1 of the SUR subunit (see figure 1.11A) 
(Shi et al, 2005).   
The preliminary flow cytometry data shown in figure 3.12 indicates that concurrent 
treatment of chondrocytes with SNAP and Diazoxide reduces apoptosis induced 
by SNAP.  This may occur as a result of activation of the mitoKATP channels and 
subsequent prevention of calcium overload and mitochondrial damage (Lawrence 
et al, 2003; Tao and Li, 2005a; Jahangir and Terzic, 2005).  Whilst the data 
requires further confirmation, it does suggest that the KATP channels may be 
involved in UCNI reduction of apoptosis in chondrocytes as in the heart.  Although 
the existence of Kir6.x and SURx subunits that can form functional KATP channels 
in the C-20/A4 chondrocyte cell line was demonstrated by RT-PCR and sequence 
analysis of the generated PCR amplicons, the exact molecular formation of KATP 
channels in these C-20/A4 chondrocytes were not inferred.  It is believed that 
Diazoxide activates KATP channels by interacting with SUR1 and SUR2B but not 
SUR2A regulatory subunits (Shi et al, 2005; Isomoto et al, 1996).  Additionally, the 
Kir6.1 pore forming subunit has been shown to be activated by SUR1and SUR2B 
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and not SUR2A (Aguilar-Bryan et al, 1998).  Therefore, if the Kir6.x and SURx 
subunits are expressed at the protein level in the C-20/A4 chondrocytes, then the 
Kir6.1 pore forming subunit could preferentially associate with SUR1 or SUR2B 




Figure 4.1: The potential mechanisms of UCNI’s chondroprotective effects against apoptosis in the 
C-20/A4 chondrocytes. 
UCNI may mediate their effects through ligation to CRF receptors or by inhibiting L-type calcium 
channels.  Activation of the CRF receptors may result in PKC activation and subsequent P42/P44 
MAPK and KATP channels mediated pathways.  The UCNI mediated protection via P42/44 MAPK 
may involve induced protein expression of heat shock protein (hsp) 90, whilst activation of the 
mitoKATP channels prevents mitochondrial damage through maintenance of the mitochondrial 
membrane potential.  UCNI inhibition of L-type calcium channels may reduce calcium entry into the 
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4.5 Conclusions	  and	  Future	  Work	  
Having confirmed the cytoprotective effects of UCNI against SNAP induced 
apoptosis in the C-20/A4 chondrocyte cell line by flow cytometry, the research in 
this thesis has gone to further identify possible receptors and/or target molecules 
involved in the chondroprotective mechanism. 
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) studies indicated 
that UCNI, CRFR1α and CRFR2β  mRNA is endogenously expressed by the C-
20/A4 chondrocyte cell line providing a viable cell surface receptor dependant 
pathway for UCNI mediated chondroprotection.  This suggests that, in C-20/A4 
cells, UCNI may act in an autocrine/paracrine manner through either CRFR. 
Indeed, Intekhab-Alam (2006) has shown that treatment with a CRFR antagonist 
resulted in cell death, suggesting that UCNI also acts as a growth factor for C-
20/A4 cells. In both animal models of cardiac ischaemia/reperfusion and in the 
human heart exposed to the I/R that accompanies bypass surgery, UCNI 
expression is increased, and UCNI expressing cells, unlike UCNI negative cells, 
are viable (Knight et al, 2008; Scarabelli et al, 2004).   
Furthermore, the increased expression of endogenous UCNI mRNA following 
SNAP treatment suggests an autocrine/paracrine mode of action for this 
cytoprotective peptide in chondrocytes although the importance of this mechanism 
may be called in question based upon the lack of inhibition of the cytoprotective 
effect following αhCRH(9-41) treatment.  For reason discussed earlier however, this 
work requires further confirmation.   
qPCR studies demonstrated that stimulation of chondrocytes with SNAP/NO and 
UCNI alone and in combination resulted in no statistically significant change 
(p>0.05) in CRFR1 and CRFR2 mRNA expression.  This suggests thatinC-20/A4 
chondrocytes, UCNI regulation of the CRF receptor expression does not require 
de novo mRNA and protein synthesis.  Additionally, RT-PCR also demonstrated 
the mRNA expression of KATP channel subunits (Kir6.1, Kir6.2, SUR1 and SUR2B) 
that can constitute functional KATP channels in the C-20/A4 chondrocytes.  
Our preliminary experiments also indicated that the Kir6.1 channel opener, 
Diaxoxide, is also cytoprotective, though further studies with both channel openers 
and inhibitors are required to confirm this.  However, based on these preliminary 
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pharmacological studies performed, it is possible that the Kir6.1 mitoKATP channels 
may also comprise a mechanism by which UCNI may exert its effects, perhaps by 
preventing mitochondrial damage; although the mRNA and protein expression of 
the Kir6.1 subunit to the mitochondria remains controversial (Lawrence et al, 2002).  
Nevertheless, if the Kir6.1 subunit is located at the inner mitochondrial membrane 
to constitute a mitoKATP and SNAP/NO induces apoptosis via the mitochondrial 
pathway then opening of the Kir6.1 mitoKATP channel following SNAP and UCNI 
alone and in combination further supports the hypothesis that the Kir6.1 mitoKATP 
channel represents a possible protective mechanism in chondroprotection. 
Other signalling mechanisms for UCNI chondroprotection may also exist in the C-
20/A4 chondrocyte cell line.  Indeed, previous studies have indicated that the 
P42/P44 MAP Kinase pathways may be involved in mediating UCNI protection as 
there was a significant increase in P42/P44 MAP Kinase following exposure to 
exogenous UCNI (Intekhab-Alam, 2006).  In cardiac myocytes the P42/44 MAP 
Kinases were suggested to mediate UCNI cardioprotection possibly by inducing 
the protein expression of heat shock protein (hsp) 90, therefore hsp 90 may also 
be implicated in UCNI chondroprotection (see figure 4.1) (Brar et al, 2002).   
Another alternative mechanism for UCNI chondroprotection may be via L-type 
calcium channels as discussed earlier.  Therefore further work to be undertaken 
includes: further investigation in the effects of Diazoxide and pharmacological 
inhibitors (e.g. the mitochondrial KATP channel blocker 5-Hdroydecanoate; 5-HD) 
on the levels of apoptosis in chondrocytes and the significance of the KATP 
channels (in particular the Kir6.1 mitoKATP channel) in preventing cell death.  
Additionally, western blot studies could be performed on subcellular fractions to 
confirm the localisation of Kir6.1 protein expression to the mitochondria in C-20/A4 
chondrocytes.  
Following qPCR experiments that indicated UCNI regulation of CRF receptor and 
Kir6.1 subunit at the mRNA level, further studies can be conducted to determine 
whether the mRNA is translated into protein since not all mRNA which is detected 
is translated to functional protein (Bustin et al, 2009). The changes in protein 
expression of the CRF receptors and KATP channels subunits could also be 
investigated following treatment with SNAP/NO and UCNI alone and in 
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combination to determine any change in protein expression following exposure to 
these treatments.   
The regulation of the SUR regulatory subunits (SUR1 and SUR2B) by UCNI could 
also be investigated by qPCR to determine any changes in their mRNA expression 
following treatment of chondrocytes with SNAP/NO and UCNI.  The existence of 
the protein expression for the SUR subunits detected at the mRNA level could also 
be examined by performing western blot analysis.  The identification of Kir6.x and 
SURx proteins in the C-20/A4 chondrocytes would thus indicate that functional 
KATP channels would exist in this cell line.  Furthermore, changes in protein 
expression of the SUR subunits following SNAP/NO and UCNI treatment can then 
be determined.  
 
Since both SNAP/NO and UCNI act at the mitochondrial level, it would also be of 
interest to investigate the effects of UCNI on the anti and pro-apoptotic members 
of the Bcl2 family, a mechanism that has not been studied in other models of UCNI 
mediated cytoprotection.  As shown in the heart, the phosphorylation of protein 
kinase C in the prevention of chondrocyte apoptotic cell death could also be 
investigated.  These studies would indicate the possible G-protein and CRF 
receptor signalling pathway activated (see figure 1.7) to mediate UCNI 
chondroprotection.  The investigation of L-type calcium channels in C-20/A4 
chondrocytes by Reverse transcriptase PCR (RT-PCR) and inhibition studies 
could be performed to confirm the existence of a non-CRF receptor mediated 
UCNI protection in chondrocytes.   
Consequently, if UCNI serves as a possible protective mechanism against NO 
induced apoptosis, identifying the exact intracellular effectors molecules which 
underlying this chondroprotection could provide avenues for the development of 
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